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ABSTRACT 
Bradley Gordon Hammill: The Use of Propensity Score Methods to  
Address Confounding by Provider 
(Under the direction of Amy H. Herring) 
For research questions regarding the real-world effectiveness and safety of medical 
therapies and devices, researchers must often rely on observational data.  Unlike controlled 
clinical trials, the assignment of treatment to patients in routine medical practice is not 
randomized.  One class of methods used extensively by researchers to address this selection 
problem is propensity score methods.  The role of the healthcare provider has not typically 
been accounted for when propensity score methods are employed, despite the fact that 
provider, by imparting an effect on both patient-level treatment assignment and patient-level 
outcomes, is a potential confounding factor.
When a healthcare provider has measurable impacts on both a patient’s treatment 
assignment and their downstream outcomes, simulation results demonstrated that not 
accounting for these provider effects could lead to biased estimates of treatment effect when 
using propensity score methods. This was true specifically when a provider’s direct effect on 
treatment was correlated with their effect on outcome; a situation that occurs when providers 
having better patient outcomes use therapies at higher (or lower) rates than other providers.  
Propensity score methods that incorporated provider were able to control this error. 
Even when provider effects on treatment and outcome were uncorrelated, it was still 
important to account for provider in the propensity score treatment model.  Failure to do so 
iv
resulted in confidence intervals around the estimated treatment effect that were either 
substantially too wide or too narrow, depending on the estimation methods used. 
A criticism of typical 1:1 propensity score matching, whether stratified by provider or 
not, is that the data from many patients are not utilized in the outcomes analysis.  Full 
matching addresses this issue by optimally assigning all treated patients and all comparison 
patients into variably-sized matched sets.  The result is closer matches between study groups 
than those obtained by other matching methods.  Full matching is not currently utilized 
frequently because it is difficult to implement.  A macro to perform full matching by 
leveraging SAS optimization procedures is presented. 
vTo my wife, Azot, and son, Sebastian,  
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
Background
For research questions regarding the real-world effectiveness and safety of medical 
therapies and devices, researchers must often rely on observational data.  Unlike controlled 
clinical trials, the assignment of treatment to patients in real world settings is not randomized.  
This differential selection of patients to treatment leaves analyses susceptible to confounding, 
which can result in biased effect estimates unless properly addressed. 
One class of methods used extensively by researchers to address this treatment 
selection problem is propensity score methods (Austin, 2008; Sturmer et al., 2006).  The goal 
of propensity score methods, in short, is to balance confounding factors between the treated 
and comparison groups (Rosenbaum & Rubin, 1983).  Assuming all confounding factors are 
measured, this balance leads to consistent estimates for the effect of the treatment on the 
response.   
The role of the healthcare provider has not typically been accounted for in clinical 
research when propensity score methods are employed.  This despite the fact that provider, 
by imparting an effect on both patient-level treatment assignment and patient-level outcome, 
is a potential confounding factor.  In analyses that utilize propensity score methods for data 
scenarios where providers act as confounder factors, important questions remain about how 
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best to incorporate provider into the analysis and about the costs of ignoring provider in the 
analysis.   
In this chapter, we review the theoretical basis of propensity scores and describe how 
they are typically used in analyses.  We discuss the issues surrounding providers in 
healthcare research and possible extensions of propensity score methods to address the 
problem of confounding by provider.  And we will examine prior research that has addressed 
similar ideas about clustered data within propensity score analyses.   
 
Propensity Score Methods  
Theory
The theoretical justification for propensity score methods is based on the Rubin 
causal model (Rubin, 1974).  In this model, it is supposed that every experimental unit has 
multiple potential outcomes, one for each experimental condition.  Suppose A represents a 
point exposure, with 9 : . when the subject is exposed to the experimental treatment of 
interest (“treatment”) and 9 : - when the patient is not exposed to the experimental 
treatment (“comparison”).  Whether the comparison group is simply unexposed to the 
experimental treatment or exposed to an alternative treatment is not a critical distinction, 
theoretically.  For each subject, there is an outcome associated with each condition.  We let 
Y1 denote the outcome the subject would have experienced if they received treatment and Y0 
denote the outcome the subject would have experience if they did not receive treatment.  The 
outcome, Y, we actually observe for each subject corresponds to one of these potential 
outcomes.  For subjects in the treatment group, ; : ;<and for subjects in the comparison 
group, ; : ;=.  Even though we can only observe one of these outcomes per subject, we rely 
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on the existence of the other unobserved outcome, the counterfactual, to draw conclusions 
about causation. 
If it were possible for all subjects in the population to belong to both the treatment 
and comparison groups, the population average treatment effect, , would be easily estimated 
as the average of each subject’s individual treatment effect, as >?;< @ ;=A : >?;<A @
>?;=A : B< @ B= : C, where B= and B< are population outcomes for the comparison and 
treatment conditions.  Instead, what is estimable is dependent on the treatment actually 
received, or >?;<D9 : .A @ >?;=D9 : -A which typically does not equal  due to 
confounding.  Meaning, if subjects have known values for covariates X that affect outcomes, 
and treatment is assigned with respect to those covariates, then >E>?;<D9 : .F GAH I >?;<A. 
Randomized trials are able to properly estimate the average treatment effect by assigning 
treatment independent of a subject’s covariates, and therefore, potential outcomes.  Formally, 
in these cases, ?;<F ;=A J 9DG, where J indicates independence.
Rosenbaum and Rubin (1983) introduced the propensity score as a balancing score 
which would lead to this same conditional independence when formal randomization was not 
present.  The propensity score K?GA : L?9 : .DGA is the probability of receiving treatment 
for a particular set of covariate values.  Use of the propensity score requires sufficient 
conditions. First, assuming X includes all confounders, then ?;<F ;=A J 9DK?GA, meaning all 
potential responses are conditionally independent of the treatment given the measured 
variables.  This is the condition of no unmeasured confounding.  Second, there must be a 
non-deterministic probability of receiving each treatment at all values of the measured 
variables, or - M LN9 : ODK?GAP M ..  When these both hold, then >?;<D9 : .F K?GAA :
>?;<DK?GAA and >?;=D9 : -F K?GAA : >?;=DK?GAA which allows unbiased estimation of the 
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treatment effect.  Different propensity score methods achieve this in slightly different ways, 
as will be discussed below. 
 
Estimation and Application of Propensity Scores 
The propensity score is a subject-specific probability of treatment.  It is usually 
estimated with a logistic regression model having treatment as the dependent variable and 
other measured factors as the independent variables.  Prior research has demonstrated that the 
most important factors to include in this treatment model are those that confound the 
relationship between treatment and outcome.  If important confounders are not included, the 
eventual estimate of the treatment effect will be biased (Austin, Grootendorst, & Anderson, 
2007; Brookhart et al., 2006).  Inclusion of other factors, those related only to the treatment 
or only to the outcome, may be helpful, but can lead to fewer matches being made, if 
propensity score matching is used, and may result in a treatment effect estimate with reduced 
efficiency (Austin et al., 2007; Brookhart et al., 2006; Bhattacharya & Vogt, 2007). 
A number of methods have been proposed for utilizing propensity scores in ways that 
induce the covariate balance between treatment groups that is so critical.  Three were 
proposed by Rosenbaum and Rubin (1983) in their manuscript that initially described the 
basis and use of propensity scores.  These methods are stratification (or subclassification), 
model-based adjustment, and matching.  The newest application of propensity scores is 
inverse probability of treatment weighting, proposed by Robins, Hernán, and Brumback 
(2000) and Hirano and Imbens (2001).  Propensity score matching and inverse probability of 
treatment weighting are the two methods most commonly applied in clinical research today 
and will be discussed in more detail than the other two methods. 
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Stratification, or subclassification, on the propensity score is done by first creating 
equally sized strata of subjects based on quantiles of the estimated propensity score 
distribution, then estimating the treatment effect within each stratum (Rosenbaum & Rubin, 
1984).  These individual stratum-specific estimates may be combined using Mantel-Haenszel 
methods to arrive at an overall treatment effect estimate.  Quintiles are often used to define 
the group, because Cochran (1968) showed that five groups is often adequate to reduce 90% 
of the bias for many distributions.  For stratification to yield accurate treatment effect 
estimates, there needs to be balance on the covariates between treated and comparison groups 
within each stratum.  This should happen because propensity scores should be similar 
between the treated and comparison groups within each of these strata.  Stratification has the 
advantage of utilizing all subjects in the data.  It is also very easy to implement and balance 
between study groups within the strata is easy to assess.  In practice, however, it has been 
demonstrated that in the extreme strata, containing the highest and lowest propensity score 
estimates, there is often residual imbalance between study groups that results in poor 
performance of the resulting effect estimates (Austin et al., 2007).   
Model-based adjustment involves simply replacing the covariates in a traditional 
regression model with the estimated propensity score or some function of the estimated 
propensity score, such as the linear predictor from the treatment model.  While this method is 
simple to implement and uses data from all available study subjects, it does not allow for 
evaluation of covariate balance between study groups.  It is also the method with the weakest 
theoretical basis.  Rosenbaum and Rubin (1983), themselves, urge caution using this method 
and list several scenarios common within observational data analysis where it may perform 
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poorly. For example, if the covariance matrices, for the observed covariates, are not equal 
between the study groups then this method can lead to bias in estimates of treatment effect.   
Propensity score matching seeks to create covariate balance between the treated and 
comparison groups more directly than stratification, by matching individual patients from 
each group to each other.  The goal of any matching scheme is to identify appropriate 
comparison patients for all treated patients such that the only difference between the group of 
treated patients and comparison patients, after matching, is the treatment itself.  This 
independence between treatment assignment and potential outcomes is required for the 
causal model presented earlier to be valid, as: 
>Q>N;<D9 : .F K?GAP @ >N;=D9 : -F K?GAPR : >Q>N;<DK?GAP @ >N;=DK?GAPR
: >?;< @ ;=A 
If it were possible to find exact matches for all treated patients on all covariates, that would 
be ideal.  However, given the number of covariates typically used in clinical research, that 
goal is often unattainable.  Matching on the propensity score, or some function of the 
propensity score, instead of on individual covariates allows for multivariate matching 
through the use of a scalar balancing score.   
The goal listed above contain a few, sometimes competing ideas.  First, the distance 
between covariates for individual sets of matched patients should be as minimal as possible.  
Second, the total distance between covariates for the matched groups should be as minimal as 
possible.  And third, all treated patients should be matched.  Regarding the first two, there are 
many ways to specify how propensity score matching is accomplished (Rosenbaum & Rubin, 
1985a), some that prioritize patient-level distance and some that prioritize group-level 
distance.  These will be discussed below.  But the third idea is also important.  Incomplete 
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matching occurs when there are treated patients without suitable matches from the 
comparison group.  Rosenbaum and Rubin (1985) demonstrated that incomplete matching 
opens the door for bias in the resulting effect estimates, especially if the response curves for 
each study group are not parallel across all levels of the propensity score. 
The most commonly used matching method is greedy matching.  To perform a greedy 
match, patients in the treatment group are matched, one by one, to the closest matching 
patient in the comparison group.  Once a match is made, both patients are removed from the 
pool of eligible patients used for matching and there is no reconsideration of the complete 
matches.  An alternative to greedy matching is optimal matching.  Instead of prioritizing 
close matches at the patient-level, optimal matching methods seek to minimize the total 
distance between the treated and comparison groups among the matched patients.  This 
process is more intensive computationally in that it is iterative and does not often have a 
closed-form solution.  Research has found some advantage of using optimal matches to 
achieve balance, although greedy matching has been found to balance study groups 
adequately (Gu & Rosenbaum, 1993; Rosenbaum, 1989).   
Other issues related to the mechanics of matching include the use of calipers 
(D’Agostino, 1998) and the number of treated and comparison patients in the matched sets.  
Using calipers when matching means that two patients whose propensity scores are farther 
apart than the set caliper size cannot be matched.  There is some evidence to indicate that this 
may be beneficial for balance when any of the covariates to be matched are continuous 
(Austin, 2011), although this usually means that some treated patients will not have any 
eligible comparison patients for matching.  And while most matched sets include one treated 
and one comparison patient, matching multiple comparison patients to a single treated patient 
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in a fixed m:1 ratio has shown mixed results.  Austin (2010) found that matching multiple 
patients from the comparison group to each treated patient, if sample size allows, may lead to 
better efficiency of the treatment effect estimate.  Hansen (2004), on the other hand, has 
shown that the use of multiple comparison patients per treated patients can actually introduce 
substantial imbalance on covariates between the matched sets.  As a more flexible option, Gu 
and Rosenbaum (1993) showed that “full” matching—using all records in the data and 
allowing for unequal sized matching sets—may be an even better strategy. 
Once a matched sample has been created, the outcomes analysis proceeds using usual 
methods.  Analysis with unequally sized matched sets, resulting from methods like “full” 
matching, require conditional statistical methods, accounting for the matched sets.  In fact, 
some insist that conditional statistical methods should be used in all cases (Austin, 2008), 
while others disagree that it is essential for 1:1 or 1:m matching (Hill, 2008).  Advantages of 
propensity score matching include ease of implementation and analysis.  As usually 
performed, disadvantages include reduced sample size that is representative of the treated 
population, not the overall population.  Estimates generated from this method are not the 
average treatment effect of the population, but the average treatment effect among the 
treated, which can be a different quantity.  
Propensity score weighting is more appropriately called inverse probability of 
treatment weighting (IPTW).  Each patient is weighted by the inverse of the estimated 
probability that they would have, based on their covariate, received the treatment they were 
assigned.  For treated patients, this weight is just the inverse of the estimated propensity 
score.  For comparison patients, this weight is the inverse of 1 minus the propensity score, as: 
ST : .U?9T : .AKVW?GA X U?9T : -A?. @ KVW?GAA 
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This weighting creates pseudo-populations in which the covariates are no longer associated 
with the outcome.  There is a direct relationship between these weights and post-stratification 
weights based on Horvitz-Thompson estimators in the survey sampling literature (Horvitz & 
Thompson, 1952).  The weight above is based on a point exposure.  IPTW methods can be 
extended for exposures that vary over time.  If appropriate time-varying covariates are also 
available, the marginal structural model (Robins et al., 2000) is one such extension that 
entails re-estimation of the propensity score and reweighting at multiple time points during a 
follow-up period. 
Once weights are assigned, they can be used within usual analytic methods.  Because 
the weights are based on estimated propensity scores that have their own variance, however, 
standard errors should be estimated appropriately, using bootstrapping or derived formulas 
(for example, Lunceford & Davidian, 2004).  An advantage of IPTW is that it utilizes all 
study subjects.  Unlike matching, this means the estimand associated with IPTW is the 
average treatment effect, so the results are generalizable back to the source population that 
generated the treated and comparison patients.  Of course, because all patients are utilized, 
problems can arise if there are values of the propensity score for which no treated (or 
comparison) patients can be found, as this violates one of the basic assumptions of propensity 
score analysis.  A disadvantage of IPTW is that results are subject to extreme weights, which 
occur when patients who are very likely to be treated are not treated and vice versa.  
Stabilized versions of the weight may alleviate some of these problems, by rescaling all 
weights around 1.0 to prevent very large weights from affecting the calculations and results. 
10 
Assessing Covariate Balance 
For valid inference, all propensity score methods aim to make the treatment 
conditionally independent of the potential outcomes given measured covariates.  One way to 
check the success of the propensity score method chosen is to measure the covariate balance 
between the treatment and comparison groups after matching on the propensity score (or on 
some function of the propensity score) or after weighting by the inverse probability of 
treatment.   
The measure most frequently recommended for balance is the standardized 
difference, (Rosenbaum & Rubin, 1985a).  The standardized difference is a metric for 
determining the distance between two samples for a given covariate free of the effects of 
sample size.  For continuous variables, the standardized difference, d, is defined as: 
Y : ?Z[\ @ Z[]A^_\` X _]`,
 
Note that this difference depends only on the sample means and a pooled estimate of 
standard deviation.  The analogous measure for dichotomous variables (Austin 2009) is often 
given as: 
Y : ?a\ @ a]A^a\?. @ a\A X a]?. @ a]A,
 
Variables are usually assessed one at a time and said to be balanced if the standardized 
difference is less than 0.10 between groups.  It is often helpful to show the standardized 
difference in both the original sample and the matched or weighted sample, to demonstrate 
the reduction in imbalance that resulted from the specific propensity score methods being 
utilized.  Standard hypothesis testing is not recommended for the assessment of balance since 
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the sample size in the matched cohort or weighted cohort could vary from the original 
sample, resulting in potential differences in statistical significance due to sample size alone.   
It may be more appropriate to assess the distance between the matched (or weighted) 
treatment and comparison samples across all measured variable simultaneously, instead of a 
single variable at a time.   A multivariate distance metric like the Mahalanobis distance,  
Y : ^?xb @ xcA\Sde?xb @ xcA 
based on the mean vectors x\ and x] for the treated and comparison groups, respectively, and 
the pooled covariance matrix S (Mahalanobis, 1936), would result in a scalar that could be 
used for this purpose.  Currently, however, there is no guidance on the use of such a measure 
within propensity score-based analyses.   
 
The Role of the Provider in Clinical Research 
Provider Effects on Treatment and Outcome 
In clinical practice, a provider is the individual or collection of individuals that 
provides healthcare to patients.  This could be an individual physician, a physician practice, a 
clinic, or even a hospital.  Practically, in research evaluating specific healthcare treatments, 
providers are often whatever identifiable unit available in the data is most proximate to the 
assignment of that treatment to the patient.  Substantial evidence exists to demonstrate that 
providers can have profound effects on both treatment assignment and outcomes. 
The Dartmouth Health Atlas is a primary source of information about how the 
likelihood of treatment varies by location, beyond that which would be expected by patient 
characteristics alone.  They note that some care is preference-sensitive—varying because of 
physician preferences for different alternative treatments—and some care is supply-
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sensitive—varying because of differences in physician availability or technological capacity 
(Wennberg, 2002).  Recent research based on Dartmouth Health Atlas data has demonstrated 
that there is, often substantial, regional variability in rates of joint replacement procedures 
(Fisher et al., 2010), interventional carotid procedures (Goodney et al., 2010), and even 
prescription drug utilization (Munson et al., 2013).  
Diffusion of technological and pharmaceutical innovations is another factor in the 
differences between treatment rates by provider.  Research has suggested that certain 
provider factors are associated with adoption of newer treatments.  For example, providers 
associated with an oncology research network were more likely to implement novel 
diagnostic procedures (Carpenter et al., 2011); larger hospitals and teaching hospitals were 
more likely than other hospitals to adopt robotic surgical technology (Barbash et al., 2014); 
and prescription of novel schizophrenia drugs varied by location in ways that correlated with 
the distribution of ethnic minorities (Horvitz-Lennon, Alegría, & Normand, 2012).  All of 
these mechanisms of diffusion affect the probability that a patient will receive the treatment 
and may also be relevant for patient outcomes.  
There is also abundant research demonstrating that providers have effects on 
outcomes.  Some of the earliest organized programs to publicly report provider quality was 
undertaken by cardiac surgeons.  Patients in New York (New York State Department of 
Health, 2012), Massachusetts (Massachusetts Department of Public Health, 2013), and 
Pennsylvania (Pennsylvania Health Care Cost Containment Council, 2013), among others, 
have access to reports detailing physician-specific risk-adjusted mortality rates associated 
with common cardiovascular surgical procedures.  Similarly, the Hospital Compare program 
was initiated by the Centers for Medicare and Medicaid Services (web) to report on and draw 
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attention to hospital-level differences in outcomes experienced by patients hospitalized for 
specific conditions.  Published reports based on these data demonstrate the hospital-level 
variability in short-term mortality and readmission outcomes, after controlling for patient 
factors, among patients admitted for pneumonia, heart failure and acute myocardial infarction 
(Bernheim et al., 2010; Krumholz et al., 2009; Lindenauer et al., 2009).  And the Dartmouth 
Health Atlas, in addition to documenting different in treatment rates, reports differences in 
outcomes by geography (Goodman, Fisher, & Chang, 2011). 
Health services researchers have delved into reasons why certain providers may have 
different outcome profiles.  They have found differences associated with whether or not the 
hospital was located in an urban or rural setting (Casey, Burlew, & Moscovice, 2010; 
Goldman & Dudley, 2008); whether or not the hospital was a teaching facility (Shahian et al., 
2012); whether or not the hospital was considered a safety net hospital treating primarily 
uninsured or underinsured patients (Ross et al., 2007); and to what extent the hospital 
invested in major medical equipment and information technology (Coye & Kell, 2006).  
Even within these broad categories of hospitals, however, there was still broad variation. 
 
Provider as a Confounding Factor 
Figure 1.1 shows the potential role of providers in an analysis of a treatment on an 
outcome.  If, controlling for measured patient factors, providers do not exert an effect on 
either treatment assignment or outcome (panel A), then provider is not a confounding factor.  
If, on the other hand, provider exerts either a direct or indirect effect on both treatment and 
outcome (panel B), provider is a confounding factor.  Direct effects on outcomes could be 
provider-specific factors such as the skill or experience of a surgeon or the care processes in 
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place at a hospital.  Indirect effects on outcomes could arise if providers don’t have a direct 
influence on the outcome, but the patient population they serve is distinct in ways that may 
advantage or disadvantage their outcomes.  Factors that may differentiate patient populations 
could include socioeconomic status, disease severity, or cultural attitudes toward healthcare, 
in general.  As examples, providers who serve distinct patient populations could include 
those at safety net hospitals that treat the uninsured and those at exemplary hospitals that 
attract the most difficult cases for a specific condition.  A key point is that whatever is 
generating the provider effect is otherwise unmeasured.  To account for provider is to 
control, implicitly, for all these other factors that are common to their patient population, but 
different from other providers’ patient populations.   
There are numerous examples within the epidemiology literature where the idea that 
providers have an effect on outcome is explicitly discounted.  Arguing that this provider-
outcome link is ignorable (Walker, 2013) allows them to leverage the variability in provider 
treatment rates as instrumental variables (Brookhart & Schneeweiss, 2007).  Such 
preference-based instruments have been used to estimate the safety and effectiveness of 
specific pharmaceutical therapies (Rassen et al., 2010; Schneeweiss et al., 2006), radiation 
therapy among prostate cancer patients (Sheets et al., 2012), and drug-eluting stents among 
patients undergoing coronary interventions (Venkitachalam et al., 2011). 
Of course, these epidemiologic studies may not be wrong to ignore the provider-
outcome link.  The specific treatments, outcomes, and healthcare settings involved may 
affect whether or not the analysis question suffers from confounding by provider.  For 
example, outcomes of surgical treatments are subject to direct physician effects in ways that 
outcomes of pharmaceutical treatments are not.  Similarly, brief office visits may not be 
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associated with the intensity of care that is associated with hospital stays.  And finally, 
provider effects may be of primary interest in the study of short-term outcomes, as compared 
to long-term outcomes.  Indirect provider effects—those associated with the patient 
population served—should be less differentiated by specific treatment or setting, however. 
As noted by Bhattacharya and Vogt (2007), because there is no test to determine if a 
variable is an instrument, researchers must use their own understanding of the problem to 
guide them.  And because providers have been documented as affecting both treatment and 
outcomes, it is reasonable to at least consider them as potential confounding factors in any 
analysis examining treatment effectiveness.  Clinical trials routinely stratify randomization 
by provider to account for potential confounding at the provider level (Friedman, Furberg, & 
DeMets, 2010); and the importance of accounting for clustering by provider within 
observational clinical studies is recognized (Localio, Berlin, Ten Have, & Kimmel, 2001).  
Specific to the propensity score methods of interest here, excluding provider when it is truly 
a confounding factor should result in biased estimates of treatment effect just as it would if 
we excluded any confounding factor (Brookhart et al., 2006; Austin et al., 2007).   
 
Accounting for Provider in Propensity Score Methods 
Assuming for a particular clinical question that provider acts as a confounding factor 
between an exposure and an outcome, then it needs to be accounted for in the methods.  As 
with any confounding factor in a propensity score analysis, the goal is to achieve balance in 
the distribution of that factor between treatment groups.  Currently, there is no consensus 
about how best to incorporate provider into an analysis that utilizes propensity score 
methods.  Note that because propensity score matching and inverse probability of treatment 
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weighting are the most theoretically sound and most commonly utilized propensity score-
based methods, these will be the only methods discussed in this section.   
For inverse probability of treatment weighting, the decision to incorporate provider 
effects into the treatment model should be all that is needed.  This will be typically be done 
using a set of provider-specific indicator variables as covariates, specified as either fixed 
effects or random effects in the logistic regression predicting treatment.  These covariates 
may allow for provider-specific intercepts and/or provider-specific covariate effects.  Typical 
model fit metrics can be used to guide the specification of the model.  A full review of the 
choice between using fixed or random effects will not be undertaken here, but factors such as 
the number of providers, the average number of records per provider, and the overall 
treatment prevalence should guide the decision.   Weights based on probability of treatment 
estimates from such a model should balance providers between study groups along with 
balancing all other covariates.  There should be no assumption that provider will balance 
between study groups if not included in the treatment model.   
For propensity score matching, there are two ways to incorporate provider into the 
analysis.  First, in the treatment model, as described above.  Second, as strata within which 
the matching takes place.  This leads to a few possible strategies: (1) Matching within 
provider based on a treatment model that ignores provider; (2) matching within provider 
based on a treatment model that incorporates provider; or possibly (3) matching across 
providers based on a treatment model that incorporates provider.  The first strategy could be 
problematic.  If provider is not included in the treatment model, the parameter estimates 
associated with the other covariates will be biased (Neuhaus, Hauck, & Kalbfleisch, 1992) 
and will not reflect the actual, within-site treatment assignment mechanism.  This may be a 
17 
problem for matching when there are substantial between-site differences in the distribution 
of covariates at the patient level.  The second strategy would account for this potential 
problem.  The third strategy does not guarantee balance on providers by study group.  Since 
matching necessarily only results in a fraction of the original study sample being utilized, it 
may be that treated patients at providers with high treatment rates may match to comparison 
patients at providers with low treatment rates. 
 
Prior Research on Clustering and Propensity Score Methods 
 Much of the previous research on incorporating clustering into propensity score 
analyses has taken place within the social science literature to evaluate educational 
interventions applied to students within schools.   Hong and Raudenbush (2006) were some 
of the first researchers to attempt to incorporate school membership into a propensity score-
based analysis.  Their question of interest was whether or not grade retention (i.e. holding a 
student back a grade), compared to social promotion, led to increased academic learning.  
Because some schools are more likely than others to retain students making slow progress, 
they incorporated school effects into the grade retention (treatment) model.  The resulting 
propensity scores were used to create strata of students within which outcomes were 
compared.  There were other aspects of their analysis—later formalized (Hong, 2010) and 
called marginal mean weighting through stratification—that went beyond the standard 
propensity score approach.  
Similar to Hong and Raudenbush, Thoemmes & West (2011) studied the effect of 
early grade retention on future test scores using propensity score stratification.  They 
performed substantial simulation work that examined stratifying within schools and across 
schools using treatment probabilities from both pooled models and hierarchical models.  
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When the intraclass correlation of the covariates was low, there were very few differences in 
the results by stratification method or treatment model.  When intraclass correlation was 
high, the within-school stratification methods outperformed the across-school methods, as 
long as a treatment model that allowed for school-specific effects was used. 
Arpino and Mealli (2008) and Kelcey (2011) approach the problem of cluster-level 
confounding as a missing variable problem.  Although this may implicitly be the scenario 
described earlier, both of these researchers explicitly generated data for their simulation work 
using contextual, or cluster-level, factors that were then treated as unmeasured.  Using 
propensity score matching, their results were similar to those from Thoemmes and West, 
above, in that methods were least biased if the treatment model incorporated cluster in some 
way.  Additionally, they found that within-cluster matching based on a pooled treatment 
model did not perform well. 
Kim and Seltzer (2007) was interested in evaluating a program that provided 
enrichment during high school to certain students, with the goal of promoting enrollment in 
post-secondary education.  As with many researchers in the education literature, one of their 
primary focuses was estimating school-specific treatment effects.  [The only example found 
in the clinical literature that used propensity score methods and considered estimating 
provider-specific treatment effects was Griswold, Localio, and Mulrow (2010), summarized 
below.]  While they do not present any simulation results, they discuss and demonstrate 
matching on propensity scores within site; noting that treatment models which allow for 
random slopes and intercepts will balance student-level factors within schools better than 
treatment models that do not.   
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 There has been some work on or discussion about incorporating clustering into 
propensity score analyses within the clinical literature as well.   One of the earliest articles 
that discussed the role of provider as a potential confounding factor within clinical research 
was Joffe, et al. (2004).  From their perspective, there was widespread understanding that 
provider may affect outcome, but there was less understanding that they may also affect 
treatment assignment.  They propose that marginal structural models or inverse probability of 
treatment weighting could be done using weights based on provider-specific probabilities of 
treatment and demonstrate this within an analysis of the complication rates associated with 
different type of coronary percutaneous interventions.  They found substantial differences in 
results when provider-specific weights were used compared to weights from a pooled 
treatment model was used.  
In a short editorial, Griswold, et al. (2010) noted that a safety study regarding proton 
pump inhibitors (Ray et al., 2010) used propensity score methods without accounting for 
provider.  They reanalyzed the data incorporating provider in the treatment model in multiple 
ways—as fully stratified models and as hierarchical models with provider-specific random 
effects.  They used propensity score covariate adjustment and found no differences in the 
overall conclusions.  They concluded by suggesting that researchers using propensity score 
methods run sensitivity analyses that incorporate provider, to see if the results are robust.   
 A working group report from the Mini-Sentinel program (Cook, et al. 2012) 
examined whether or not effect estimates from analyses that used inverse probability of 
treatment weighting where the treatment model was estimated correctly (i.e. incorporating 
provider) using all data were comparable to an IPTW analysis where the treatment model 
was fully stratified by provider.  This work answers a slightly different question than other 
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research that compared methods that did or did not ignore provider.  Their research question 
was less about whether or not providers (or data partners, in their project) were sources of 
confounding, and more about whether or not combining treatment estimates generated by 
each provider using IPTW would result in similar estimates from a pooled approach.  This 
question is important for their program since patient-level data cannot leave the data partner, 
requiring all analyses to be stratified.  They found that results between methods were similar 
when estimating the risk difference.   
Li, Zaslavsky, and Landrum (2013) examined, in more theoretical detail, methods to 
incorporate clustering into analyses that use inverse probability of treatment weighting.  In 
simulation studies, they found that modeling the propensity score correctly, by including 
cluster-specific parameters, resulted in less bias than methods that ignore cluster.  They also 
showed, as may be expected, that estimates were more efficient when there were large 
clusters, as opposed to small clusters.  Their data generation process was complicated in 
many ways.  Similar to work described above, they generated data including a cluster-level 
covariate that was then ignored in the estimation of the treatment model.  In the outcome 
model, they also specified cluster-specific treatment effect heterogeneity in addition to 
cluster-specific intercepts.  Finally, the clinical example presented was unusual.  They 
estimated the “average controlled difference” in receipt of breast cancer screening between 
black patients and white patients.  Race is the type of non-manipulable exposure that fails to 
satisfy the requirements of the potential outcomes framework (Hernán, 2005). 
 Drawing conclusions from this prior work is challenging.  Results from simulations 
seem to indicate that incorporating cluster into the treatment model is important for achieving 
balancing and minimizing bias in the treatment effect estimate when there is strong cluster-
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level confounding and/or large differences in covariate distributions between clusters.   
Results from actual clinical questions analyzed with and without provider-specific propensity 
score methods sometimes demonstrated a difference in the results and sometimes did not.  It 
is likely that the characteristics of the data used for these questions were responsible for these 
findings, but relatively little is known about the data conditions that should lead researchers 
to anticipate problems. 
 
Objectives of the Current Research 
 There are a number of unanswered questions regarding the use of propensity score 
methods in situations where confounding by provider exists.  The chapters that follow will 
address a few key, practical issues that should guide researchers.  Chapter 2 will examine the 
impact that different data scenarios have on the results of propensity score analyses when 
confounding by provider exists.  Specifically, it is assumed providers exhibit a distribution 
on treatment rate, outcome rate, population size, and distribution of patient characteristics.  
When using propensity score matching or inverse probability of treatment weighting 
methods, it is not known whether the mere existence of these differences leads to bias or if 
these factors need to be correlated for there to be an important effect on the results.   
Chapter 3 will address the question of whether or not there are risks to incorporating 
provider into propensity score methods when the provider effects on treatment and outcomes 
are not correlated.  In addition, we will explore whether or not the standard errors associated 
with estimates based on different propensity score methods properly account for the 
clustering of patients within providers.  Most researchers, when using multivariable 
regression models, will incorporate provider in some manner if clustering by provider exists 
in the data, so perhaps that should be a default for propensity score analyses as well.    
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Chapter 4 will present a SAS macro for performing optimal matching and full 
matching on the propensity score, as alternatives to less optimal greedy matching methods.  
Full matching, in particular, does not result in reduced sample size and should lead to more 
efficient treatment estimates compared to greedy matching.  The macro includes a provision 
to match within strata, like providers.  While full matching was proposed as a propensity 
score matching method decades ago, its use is limited due to the complexity of 
implementation.  This goal of the SAS macro and of this paper is to make full matching 
methods available to researchers. 
Each of these chapters will provide an applied clinical research example.  In addition, 
Chapters 2 and 3 will include results from Monte Carlo simulations.   

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Figure 1.1. Potential relationships between treatment (A), outcome (Y), measured patient factors (X), unmeasured patient factors (U), 
and healthcare provider (P) 
A
Provider is not a confounding factor 
B
Provider is a confounding factor 
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CHAPTER 2 
DATA CHARACTERISTICS AND THE PERFORMANCE OF PROPENSITY  
SCORE METHODS IN THE PRESENCE OF CONFOUNDING BY PROVIDER 
Introduction 
In comparative effectiveness research, confounding may arise at the level of the 
healthcare provider because both treatment assignment and outcome can vary by provider.  
Numerous studies have documented the variability of treatment rates by geography (e.g. 
Wennberg, 2002; Fisher et al., 2010; Munson et al., 2013) or provider (e.g. Carpenter et al., 
2011; Barbash et al., 2014).  Treatment rates may differ for a variety of reasons, including 
differential rates of adoption for new therapies or simple provider preferences for a specific 
therapy.  In addition, there is evidence that outcomes differ by provider.  Provider profiling 
reports produced by Hospital Compare (Centers for Medicare and Medicaid Services, web) 
and regional programs (e.g. New York State Department of Health, 2012; Massachusetts 
Department of Public Health, 2013; Pennsylvania Health Care Cost Containment Council, 
2013) among others, demonstrate that substantial provider-level variation exists in different 
patient populations after controlling for patient risk.  These differential outcomes may result 
from provider differences in the quality of patient care or from unmeasured differences in 
provider case-mix.  
Previous research on the use of propensity score methods in the presence of 
confounding by some clustering level, such as provider, has demonstrated the risks of 
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ignoring cluster in the analysis (Thoemmes & West, 2011; Arpino & Mealli, 2008; Kelcey, 
2011; Li, Zaslavsky, & Landrum, 2013).  These risks include inefficient or biased treatment 
effect estimates.  Previous applications of propensity score methods, however, have been less 
conclusive about the benefit of conditioning on provider (Joffe, 2004; Griswold, Localio, & 
Mulrow, 2010).  Compared to results from pooled analyses that ignore provider, sometimes 
the results have differed and sometimes they have been similar.  It is very likely that the 
characteristics of the data, for both simulation work and real-world clinical examples, dictate 
when incorporating provider into propensity score methods is most essential. 
Relevant provider-level data characteristics include treatment rate, outcome rate, 
patient population size, and average patient characteristics.  For there to be confounding by 
provider, it is necessary that providers exhibit a distribution on treatment rate and outcome 
rate beyond that expected by the characteristics of the patients they care for.  Additionally, it 
is reasonable to expect that providers differ by the size of their patient population and by the 
distribution of patient characteristics.  I conducted a simulation study to explore whether or 
not the mere existence of these differences leads to bias and inefficiency in the treatment 
effect estimate or if these factors need to be correlated for there to be important effects on the 
results.  We then explored the characteristics of provider data in a clinical example.  
 
Simulation Study 
We used Monte Carlo methods to simulate situations where patients were clustered 
within healthcare providers, and where those providers exhibited effects on both the 
treatment assignment and the resulting outcome of patients, independent of the observed 
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patient-level covariates.  We were specifically interested in examining different cluster-level 
specifications within the data generation process.  
 
Data Generation Process 
For each provider j in the simulated data, we first generated provider-level 
information that was subsequently used to generate patient-level data.  Specifically, we 
generated five random variables—fgF O<gF higF jgF kg—distributed as: 
NfgPlm?nF -+/A 
O<glm?@.F -+/A 
higlm?-F .A 
jglm?-F .A 
kglm?-F .A 
These variables were generated with the following correlations: 
o
pq
. rst rsu rsv rswrst . rtu rtv rtwrsu rtu . ruv ruwrsv rtv ruv . rvwrsw rtw ruw rvw . x
yz :
o
pq
. - {su {sv {sw- . - - -{su - . - -{sv - - . {vw{sw - - {vw . x
yz 
The correlations that remain unspecified are noted below in the specific data scenarios.   
Each of these provider-level variables has a specific purpose.  The number of patients 
per provider was set by fg, which was rounded to the nearest integer.  The distribution of 
provider sizes is log-normally distributed and the mean of the log-distribution ?nA was set to 
either 5.0 to generate “large” providers or 3.5 to generate “small” providers.  The large 
providers range in size (based on ±2 standard deviations) from about 55 to 400 patients.  The 
small providers range in size from about 12 to 90 patients.  The proportion of patients within 
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each provider having characteristic |<Fdescribed below, is determined by O<g. Provider-level 
proportions for this variable ranged from about 12% to 50%.  The provider-level mean value 
of |iFdescribed below, is determined by hig. And the values of jg and  kg are deviations 
about the overall intercept in the treatment and outcome models, respectively.  The terms 
O<gF higF jgFandkg all induce intraclass correlation for the associated covariates, for the 
treatment, or for the outcome.   
Next, for each patient } within provider ~, we generated four random variables—
|<TgF |`TgF |TgF |iTg—distributed as: 
|<TglKf logitd<NO<gP 
|`Tglm?h`F .A 
|Tglm?hF .A 
|iTglmNhigF .P 
The terms O<gandhigare provider-specific terms described above and resulted in intraclass 
correlations of about 0.10 and 0.50 for |< and |i respectively. The terms h`andhare set 
based on the value of |<Tg+  When |<Tg : .Fthen h` : -+/andh : @-+/.  When |<Tg :
-Fthen h` : @-+/andh : -+/.  The three normal random variables were generated with the 
following correlations: 
 . rF rFrF . rFrF rF .  : 
. @+ @+.@+ . + .@+. + . .  
The idea was to generate a set of covariates for each patient that exhibited interesting 
correlation and were not all independent of each other.  
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We then randomly assigned each patient a treatment, Aij, as a Bernoulli random 
variable having a mean parameter equal to probability pij,A, which was determined by the 
following function: 
logitNaTgFP : = X jg X <|<Tg X `|`Tg X |Tg X i|iTg 
The parameters =F <F `F F i were fixed within all simulations to the values [–1.5, 
ln(1.5), ln(1.5), ln(0.8), ln(0.67)].  This yielded a treatment rate of just over 20%. We also 
randomly generated an outcome, Yij, for each patient as a normal random variable having a 
standard deviation equal to 1 and a mean parameter equal to ij,Y, which was determined by 
the following function: 
BTgF : = X kg X <|<Tg X `|`Tg X |Tg X i|iTg X \\9Tg 
The terms jgandkgare provider-specific terms described above, leading to intraclass 
correlations of about 0.25 and 0.50 for the treatment and outcome, respectively.  While some 
of the intraclass correlations indicated may be higher than typically seen in actual data, they 
serve to make patterns in the results more recognizable.  The parameters 
=F <F `F F iF \\ were fixed within all simulations to the values [0, –1, –1, 1, 1, 2].  
This resulted in an observed outcome equal to about 0.8 in the unexposed group. Note that 
covariates associated with higher probability of treatment were associated with lower 
outcomes values, and vice versa.  If we assume that a higher outcome value is optimal, then 
the treatment is working to improve outcomes and is assigned most frequently to the patients 
that would otherwise have poor outcomes. 
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Simulation Scenarios 
We generated 1000 data sets with “large” providers and 1000 data sets with “small” 
providers for six different scenarios involving correlations between the provider-level 
quantities generated—provider size, mean of |i, deviation from average treatment rate, and 
deviation from average outcome.  Scenario #1 specified zero correlation between each of 
these quantities.  Scenario #2 specified a positive correlation between provider size and 
deviation from average treatment rate ?{sv : -+/A; meaning large providers were more 
likely than average to assign treatment.  Scenario #3 specified a positive correlation between 
provider size and deviation from average outcome ?{sw : -+/A; meaning large providers 
were more likely than average to be associated with better outcomes.  Scenario #4 specified a 
positive correlation between provider size and mean of |i?{su : -+/A; meaning larger 
providers were more likely to have higher averages for that covariate.  Scenario #5 specified 
a positive correlation between a provider’s deviation from average treatment rate and it’s 
deviation from average outcomes ?{vw : -+/A; meaning providers that were more likely to 
assign treatment were also more likely to have better outcomes.  And scenario #6 specified 
each of these correlations simultaneously.   
Within each generated data set, we applied different of propensity score matching and 
inverse probability of treatment weighting methods.  After matching or weighting, we 
estimated the balance between treatment and comparison groups with respect to both 
covariates and providers and we estimated the treatment difference. 
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Propensity Score Methods 
We first estimated three different treatment regression models.  All models were 
specified as generalized linear models with logit links and binary error distributions having 
treatment A as the dependent variable and patient-level covariates X1 to X4 as predictors.  
They differed in how provider was incorporated.  The first, or pooled, model ignored 
provider.  The second model incorporated provider through the specification of provider-
specific fixed effects.  The third model incorporated provider through the specification of 
random effects as provider-specific deviations around the intercept.  These random effects 
were assumed to be normal with mean 0 and this third model was estimated using 
generalized linear mixed model methods. 
Using the predicted probabilities of treatment from each of the models described 
above, we applied two general propensity score-based methods—propensity score matching 
(Rosenbaum & Rubin, 1985) and inverse probability of treatment weighting (Robins, 
Hernán, & Brumback (2000); Hirano & Imbens, 2001).  Inverse probability of treatment 
weighting (IPTW) creates pseudo-populations in which the other measured covariates are not 
associated with treatment, allowing outcomes between the weighted study groups to be 
compared directly.  Patient-level weights were calculated as the inverse of the estimated 
probability of receiving the treatment that the patient actually received.  For a patient that 
received treatment, this weight was the inverse of the predicted probability generated from 
the treatment models.  For a patient in the comparison group, this weight was the inverse of 1 
minus the model-based predicted probability.  Propensity score matching creates sets of 
treated and comparison patients on the basis of their estimated propensity scores.  Outcomes 
can be compared between the matched sets.  We made 1:1 matches between treated and 
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comparison patients both within provider and ignoring provider.  Matches were made on the 
linear predictor from each treatment model using a greedy matching algorithm within 
calipers having a width of 0.2 SD of the linear predictor (Austin, 2011).   
To estimate the adjusted effect of treatment on outcome when using IPTW methods, 
we calculated the difference between the weighted mean outcomes for each study group.  To 
estimate the adjusted effect of treatment on outcome when using propensity score matching, 
we calculated the difference between the mean outcomes for each study group among the 
matched patients.  For comparison to the treatment effect estimated by these propensity score 
methods, we estimated the observed treatment effect by taking the difference between the 
mean outcomes for each study group in the full data set prior to weighting or matching.   
 
Metrics 
Within each simulation scenario and for each combination of propensity score 
method and treatment model, we describe the validity and efficiency of the treatment effect 
estimates.  Metrics to assess the treatment effect estimates include the mean, bias, variance, 
and mean squared error of each estimator, defined as: 
Mean : d<  C< : C 
Bias : C @ C\\ 
Variance : ? @ .Ad<  C @ C`<  
Mean squared error : d<  C @ C\\`<  
where S is the number of simulated data sets; C\\ is the true treatment effect; and C is the 
estimated treatment effect for data set s.   
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All simulations were conducted in SAS version 9.3 (SAS Institute Inc, Cary, North 
Carolina).  Sample SAS code for estimating propensity scores, calculating weights, 
performing matching, and estimating treatment effects and standard errors is shown in 
Appendix 1. 
 
Simulation Study Results 
Table 2.1 reports the simulation results for inverse probability of treatment 
weighting.  The most striking result occurred for the scenarios where the provider-level 
average treatment rate was correlated with the outcome rate, even after controlling for patient 
characteristics (#5 and #6).  In these situations, using weights based on a treatment model 
that does not incorporate provider effects yielded substantially biased estimates of treatment 
effect.  Including provider-specific effects into the treatment model, as either fixed or random 
effects, largely ameliorated this problem.  These findings were true for both small providers 
and large providers.   
 For the other simulation scenarios (#1 through #4), when the provider sizes were 
small, the results were less clear.  In each of these four scenarios, weights based on the 
pooled treatment model led to treatment effect estimates with the lowest mean squared error.  
Use of weights based on a treatment model that included provider-specific random effects 
tended to produce estimates that were less biased than those based on other weights.  But 
these estimates also tended to have higher variance, resulting in little, if any, reduction in 
mean squared error compared to estimates based on other weights.  Weights based on a 
treatment model with fixed provider-specific effects were consistently biased.   
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When provider sizes were large, some of these inconsistencies disappeared.  Weights 
based on a treatment model that included provider-specific random effects were least biased, 
and these estimates exhibited similar mean squared error to those from weights based on a 
treatment model with fixed provider effects.  Results from using a pooled treatment model 
always had highest mean squared error.   
Table 2.2 reports the simulation results for propensity score matching that was not 
conditional on provider.  Similar to results based on weighting, results from unconditional 
matches based on estimates from the pooled treatment model were severely biased when the 
provider-level outcome rate was correlated with the provider-level treatment rate.  Unlike 
above, this problem did not always disappear when matching was done based on estimates 
from provider-specific treatment models.   
For small providers, unconditional matches made based on results from treatment 
models that incorporated providers as fixed effects resulted in treatment effect estimates that 
exhibited substantial bias across all scenarios.  Using random effects instead did not 
completely solve the problem for small providers either.  In fact, within small providers, the 
least biased estimates for Scenarios #1 through #4 were those from matching based on 
estimates from the pooled treatment model.  The variability of these estimates, however, was 
always higher.  
Matching without regard to provider, when provider sizes were large, exhibited more 
predictable behavior.  Estimates from matching based on treatment models with provider-
specific random effects had the lowest mean squared error.  And estimates from matching 
based on pooled treatment models had the highest mean squared error—sometimes five or 
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times as high as others within the same simulation scenario.  This inflated MSE was not due 
to higher bias, but rather to substantially more variable estimates. 
Table 2.3 reports the results for propensity score matching performed within 
provider.  Across all of the simulation scenarios and all of the treatment model specifications, 
results were remarkably similar.  In general, both bias and variance of the treatment estimates 
were minimal—especially when compared to results obtained from unconditional matching 
(Table 2.2).  While the mean squared error for estimates from matching within provider 
based on results from the pooled treatment model was always higher than those from 
matching based on results from either provider-specific treatment model, the differences 
were not substantial.  The problem noted above for the other two methods—when provider-
level treatment and outcome rates were correlated and a pooled treatment model was used—
was not found here.   
 
Clinical Example
 To demonstrate the potential impact of these different statistical methods, we present 
an analysis of the association between receipt of high-dose intravenous loop diuretics and in-
hospital mortality among a population of patients admitted to the hospital for acute 
decompensated heart failure.  Intravenous diuretics are a recommended therapy to address 
volume overload in patients with decompensated heart failure.  Loop diuretics act in the 
kidney to block sodium and water reabsorption, which leads to effective symptomatic relief 
and decreased blood pressure.  The benefits associated with diuretic use need to be balanced 
against the potential harms.  It is suggested that diuretics, potentially because of the drop in 
blood pressure they induce, may lead to increased risk of renal dysfunction, which can lead 
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to increased morbidity or mortality.  For this reason, dosing of diuretics is important and 
should be limited to the lowest effective dose.  Receipt of high doses of diuretics are often 
observed in a hospitalized heart failure population because response to diuretics decreases as 
heart failure severity progresses.   
Higher mortality associated with high-dose diuretics has previously been reported by 
Peacock, et al. but that analysis did not consider the role of provider (Peacock, 2009).  For 
this study, providers were hospitals.  It is of interest to see if the strength or direction of the 
association changes when provider is taken into account.    Many aspects of this research 
question make it plausible that provider is a confounding factor.  Across different hospitals, it 
is likely that case-mix differs in systematic ways, leading patients who are more like each 
other to be clustered.  The exposure is directly under the control of the hospital and, at the 
time of patient enrollment, there were no guidelines regarding the ideal dosing of diuretics in 
decompensated heart failure patients.  Finally, it is possible that hospitals differ in the care 
they provide to heart failure patients, which may result in differences in outcomes by 
hospital.  
 For this analysis, we used data from heart failure hospitalizations that occurred 
between January 2001 and December 2003 and were entered into the Acute Decompensated 
Heart Failure National Registry (ADHERE) (Adams, et al., 2005).  Similar to the previous 
study, we identified patients aged 65+ years old, not on vasoactive therapy, who received 
diuretics within one day of presenting to the hospital.   The treatment of interest was receipt 
of high-dose diuretics.  The dosing window of interest was the 24 hours following initiation 
of intravenous diuretics.  A high dose was defined as 160 mg.  The comparison group 
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comprised those who received <160 mg of diuretic during that 24 hour dosing period.  The 
outcome of interest was in-hospital mortality.   
All of the propensity score-based methods and treatment model specifications used in 
the simulation study were used for this study as well.  The estimation of treatment effect 
from these data differed from the simulation study since the outcome here was binary and the 
treatment effect of interest was the relative risk.  To estimate the relative risk directly, we 
used a generalized linear mixed model with a log link and the binary error distribution.  
When applying IPTW methods, we estimated this model on the weighted patient data and 
requested robust standard errors with clusters defined by patient.  When applying propensity 
score matching, we estimated this model using only patients in the resulting matched sets.  
Generalized estimating equation methods with an exchangeable working correlation matrix 
were used to account for the potential correlation of patients outcomes within the matched 
sets.  We present the relative risk estimates and 95% confidence intervals from each method.  
All analyses were conducted in SAS v9.3. 
 
Clinical Example Results 
There were 43,434 patients within 236 providers in the study population.  The 
number of patients per provider ranged from 9 to over 1,000, with the median (Q1, Q3) equal 
to 144 (63, 259).  Among study patients, 9,469 (21.8%) were treated with a high dose of 
diuretics.  High-dose diuretic treatment rates across providers ranged from 1.6% to 55.6% 
with median (Q1, Q3) rates equal to 19.7% (12.3%, 29.8%).  Controlling for patient 
demographics, the intraclass correlation of treatment was 0.14.  This intraclass correlation 
coefficient was estimated as r :   , where  v`  was the estimated variance of the 
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provider random effects about the overall intercept in a hierarchical logistic model 
(Rodrguez & Elo, 2003). 
 The observed in-hospital mortality rate in the high-dose group was 3.3%, about 30% 
higher than the rate among the low-dose group.  Outcome rates for comparison patients 
across providers ranged from 0% to over 10%. The estimated intraclass correlation of the 
outcome, estimated among the comparison patients, was 0.03.  The correlation between the 
estimated provider effects on treatment and outcomes was about –0.10. 
Table  2.4 describes the sample characteristics and outcome rates for the two study 
groups.  There were some differences between the groups with respect to age and gender.  
The high-dose group was, on average, two years younger than the low-dose group and had a 
higher proportion of males.  Many of the medical history variables were similar between the 
groups.  The largest differences were seen for chronic renal insufficiency and diabetes 
mellitus, both of which were more prevalent in the high-dose group.  The high-dose group 
also had substantially higher rates of edema at initial evaluation and higher average blood 
urea nitrogen (BUN) values than the low-dose group.   
Table 2.4 also shows the intracluster correlation of the patient characteristics.  For the 
medical history and laboratory variables, these correlations ranged from near 0 to just over 
0.06, except for hemoglobin, which had an intraclass correlation equal to 0.155.  And while 
age and gender had low intraclass correlations, those associated with race were quite high, 
around 0.40 for each category shown.  Clustering by provider was more pronounced for the 
initial evaluation characteristics.  Indications of rales and congestion had intraclass 
correlations over 0.10 and the value associated with fatigue was 0.20.   
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The relative risks estimated by each different propensity score method and treatment 
model specification are shown in Table 2.5.  Estimates from application of inverse 
probability of treatment weighting methods differed by treatment model used.  Estimates of 
the risk associated with treatment were higher when weights were based on results from 
models that incorporated provider.  The results from both matching methods did not show 
this same pattern.  However, relative risk estimates from matches made without regard to 
provider were substantially lower than estimates from matches made within provider.  The 
variability of these estimates did not appear to differ by propensity score method or treatment 
model specification. 
 
Discussion
 When a healthcare provider has measurable impacts on both a patient’s treatment 
assignment and their downstream outcomes, we found that not accounting for these provider 
effects could lead to biased estimates of relative risk when using propensity score methods.  
This was true for our simulation study specifically when a provider’s direct effect on 
treatment was correlated with their effect on outcome; a situation that occurs when providers 
with better patient outcomes use therapies at higher (or lower) rates than other providers.  
Propensity score methods that incorporated provider in some manner were able to control 
this error. 
 We examined the performance of propensity score matching and inverse probability 
of treatment weighting for estimating treatment effects across a number of data scenarios.  
For both large and small provider sizes, we examined the impact that correlation had on 
different combinations of provider-level characteristics.  We were specifically interested in 
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provider treatment rate, outcome rate, patient population size, and average patient 
characteristics.  Only scenarios that included a correlation between provider treatment rate 
and outcome rate led to bias in the resulting effect estimates when provider was not 
incorporated into the propensity score analysis.  When provider was ignored in other 
scenarios, variance of the effect estimates tended to be inflated when compared to effect 
estimates from analyses that incorporated provider.  
 These findings are consistent with prior research that found that ignoring provider, or 
some other sort of clustering, in propensity score methods led to biased estimates of 
treatment effect (Arpino & Mealli, 2008; Kelcey, 2011; Li, Zaslavsky, & Landrum, 2013).  
In the simulation work reported by these authors, the problem of cluster-level confounding 
was approached as a missing variable problem.  Data was generated that included contextual, 
or cluster-level, factors which had consistent effects on both treatment and outcome.  In the 
propensity score methods applied to these data, these cluster-level factors were treated as 
unmeasured, but cluster-level indicators were used instead.  Naturally, the effect of these 
cluster-level indicators on treatment and their effect on outcomes were correlated as a result 
of the data generation process.  That is the situation we found that led to the most bias if not 
properly handled. 
Our findings are also consistent with results from Griswold, Localio, & Mulrow 
(2010).  In a re-analysis of data from a safety study of proton pump inhibitors, they found 
that including provider effects into the propensity score treatment model did not lead to a 
different estimate of effects compared to results based on a treatment model without provider 
effects.  This result may be expected, as we have demonstrated, when the provider effects on 
treatment are not correlated with provider effect on outcome.   
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 Clusters, generally, can be incorporated into propensity score analyses in different 
ways.  First, in the treatment model, through the inclusion of either fixed or random cluster-
specific effects.  If using inverse probability of treatment weighting, creating weights from 
the results of these conditional treatment models suffices.  In our simulations, estimates 
based on these weights performed well when clusters were large, even when cluster effects 
on treatment and outcome were correlated.  For smaller clusters, IPTW may not always be 
the best choice.   
Second, cluster can be controlled directly through the use of conditional matching.  In 
our simulations, estimates based on matching within cluster performed well regardless of the 
treatment model specification and regardless of the cluster size.  The estimates having the 
least error, in general, were those from matching within cluster based on treatment models 
that incorporated cluster effects.  When the treatment rate is low and there are sufficient 
number of comparison patients available for matching within cluster, it may make sense to 
use this method as a primary strategy.   
There are times when within-cluster matching may not be the best strategy though.  
First, if there are many providers with high treatment rates, it may be impossible to match all 
treated patients with comparison patients, even using 1:1 matching.  More flexible matching, 
where the number of treatment and comparison patients within each matched set is not 
rigidly fixed, should be explored in these situations.  Second, within-provider matching 
requires that each provider, or at least the substantial majority of providers, contribute a 
relatively large number of patients to the data.  A study having a large number of providers, 
each with a small number of patients, is not well-suited to this this approach since many 
providers may not be represented at all in the final sample.  Third, exclusive providers, those 
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with 0% or 100% treatment rates, will fall out of the analysis.  Theoretically, the loss of these 
providers is sound, because their patients will have a true probability of treatment equal to 0 
or 1, which violates a basic assumption underlying propensity score analysis. 
It is difficult to recommend the use of a pooled treatment model when strong cluster 
effects on both treatment and outcome are found to exist, even though propensity score 
methods that used treatment probabilities from these models did not always fare poorly.  Our 
simulations were primarily designed to identify problems due to correlations among specific 
cluster-level quantities, and thus we did not vary the strength of the associations between 
covariates and treatment by cluster.  It is possible that substantial differences in the treatment 
mechanism across clusters would lead to problems when using a pooled treatment model, 
since it may not lead to the balance expected when propensity score methods conditional on 
cluster are used.  
In a clinical example examining diuretic dosing and in-hospital mortality among 
hospitalized heart failure patients, these different propensity score methods and treatment 
model specifications yielded quite different estimates of risk.  While we did not have a gold 
standard against which to compare, it should be noted that the results from IPTW methods 
indicated higher risk when cluster was included in the treatment model.  Similarly, all 
estimates associated with within-provider matching were higher than estimates that matched 
across providers.   
The presumption that providers can act as a confounding factor has intuitive appeal.  
They certainly act to affect the treatment rates of patients and can, through different direct or 
indirect pathways, be associated with differential outcome rates for their patients.  A 
provider’s effect on patient-level treatment assignment, as modeled in this study, can be 
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thought of as a simple preference for one treatment over another.  More complicated provider 
effects could result if different providers weighed certain patient characteristics differentially 
when determining a treatment strategy.  Provider effects on outcomes could be direct or 
indirect.  Indirect effects would include unmeasured factors associated with the provider’s 
patient case-mix.  Urban safety net hospitals, for example, serve a very different patient 
population than other hospitals, and it’s possible that those patients would have had less 
favorable outcomes regardless of the provider they saw.  Direct provider effects would 
include factors that are, in some way, under the control of the provider.  This could be the 
provision of high-quality care by a hospital.   
Indirect provider effects on outcomes, due to systematic differences in case-mix, are 
possible in all analyses.  These effects may be relatively weak, but may be expected to persist 
regardless of the length of follow-up in the study.  Direct provider effects on outcome, on the 
other hand, may only arise in specific settings or for specific treatments and may have a time-
limited effect.  For example, there may be no plausible direct provider effect associated with 
outcomes of a medication that was prescribed in an office setting.  This differs from the 
likely provider effect associated with outcomes of a complex surgical procedure or medical 
device implant that requires hospitalization; and it is likely that these effects are most 
pronounced during the hospitalization and during the period immediately following 
discharge.   
Ignoring the role of providers in the face of this confounding can therefore lead to 
effect estimates for a treatment that are contaminated with provider effects.  When we 
account for provider properly, we estimate a treatment effect that controls for any otherwise 
unmeasured provider-level factors common to both the treated and comparison groups. The 
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use of these methods does not, however, relieve us of the assumption that there is no 
unmeasured confounding.  If providers assign treatment according to criteria that are related 
to outcome and not fully measured, resulting estimates of treatment effects can be biased. 
One argument against conditioning analyses on provider is that treatment decisions 
are highly protocol-driven and consistently made by applying the same criteria to all patients.  
If this happens, assuming all confounders are measured, then the treated and comparison 
groups within a provider should be clinically distinct groups and have propensity score 
distributions that do not overlap, rendering within-provider propensity score methods 
unusable.  Ignoring provider in this scenario is not the solution, since any systematic 
differences in outcomes by provider would remain unaccounted for.  In some way, this 
suggests that we rely on inconsistency within provider regarding treatment assignment in 
order to properly estimate that treatment’s effect on outcome.  A provider’s consistency in 
treatment assignment may differ by type of therapies, whether due to supply of the therapy—
which is relatively unlimited for pharmaceuticals and can be limited for major devices or 
surgical procedures—due to the level of patient involvement in the treatment decision, or due 
to a provider’s equipoise regarding treatment options.  Inconsistency may also arise when the 
provider in an analysis is actually a practice group, hospital, or other conglomeration of 
physicians, since physicians within such groups may not always act in concert.   
Related to the above scenario, consider a situation where providers are consistently 
making treatment decisions based on information that is not measured and that may also 
affect outcomes.  As an example, analyses that use administrative health data (e.g. Medicare 
claims) often do not have information about patient frailty or disease severity.  Even though 
some providers may decide to treat sicker patients more frequently than other providers 
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would, there is no way around the fact that this variation is not benign, but systematic.  
Whether or not provider is taken into account during the analysis, this is a basic example of 
unmeasured confounding, which violates a fundamental assumption of propensity score 
analyses (Rosenbaum & Rubin, 1983) and will almost certainly yield incorrect treatment 
effect estimates. 
There are a number of issues that a researcher will want to consider before using 
conditional propensity score methods.  The most important of which is the plausibility of 
confounding by provider for the research question being asked.  Certain treatments, 
outcomes, and healthcare settings are more likely than others to require attention.  For 
example, outcomes of surgical treatments are patient to direct physician effects in ways that 
outcomes of pharmaceutical treatments are not.  Similarly, brief office visits may not be 
associated with the intensity of care and effect on outcomes that are more likely to be 
associated with hospital stays.  And provider effects may be a more important and relevant 
factor in the study of short-term outcomes, as compared to long-term outcomes.  Indirect 
provider effects on outcomes—those associated with the patient population served by the 
provider—should be less differentiated by specific treatment or setting, however.  It is 
possible to estimate the observed provider effects, as simple intraclass correlation 
coefficients, on treatment and outcomes using hierarchical regression models.  Non-zero 
intraclass correlation coefficients for both treatment and outcome may suggest confounding 
and favor the use cluster-specific methods for propensity score analyses.  Our clinical 
example, for example, had non-zero intraclass correlation coefficients for both treatment and 
outcome, controlling for other patient covariates.  The hospital setting and short-term nature 
of the outcome made the possibility of confounding by provider plausible.  The success of 
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cluster-specific propensity score methods may also depend on cluster sizes.  Study data that 
has information from a very large number of very small clusters may be inappropriate for 
these methods.  In the simulation work, our “small clusters” still included over 25 patients, 
on average, which was sufficient to give consistent estimates of treatment effects when 
propensity score matching within clusters was used.  With larger clusters, both conditional 
matching and inverse probability of treatment weighting methods performed very well. 
In conclusion, when the possibility of confounding by provider exists, we recommend 
estimating propensity scores using a provider-specific treatment model.  Appropriate 
estimates of treatment effect can then be found using either within-provider matching or 
inverse probability of treatment weighting. 
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Table 2.1 - Simulation results for inverse probability of treatment weighting methods.  Mean estimated treatment difference, relative 
bias, variance, and mean squared error of treatment effect estimators for each scenario by provider size distribution.  True treatment 
difference = 2.0. 
Simulation Scenario /  
Treatment Model Specification 
Treatment Different Estimates 
for Small Providers 
 Treatment Different Estimates 
for Large Providers 
Mean  Relative 
Bias
Variance 
(x1000) 
MSE
(x1000) 
 Mean  Relative 
Bias
Variance 
(x1000) 
MSE
(x1000) 
Scenario #1: No correlation between provider-level quantities
Pooled  1.988 –0.60% 9.68 9.83  1.975 –1.25% 6.55 7.17 
Provider fixed effects  1.888 –5.62% 6.78 19.42  1.959 –2.03% 2.44 4.09 
Provider random effects  1.987 –0.63% 14.05 14.21  1.992 –0.41% 3.27 3.34 
Scenario #2: Correlation between provider size and deviation from average treatment rate
Pooled  1.972 –1.40% 7.59 8.37  1.975 –1.23% 5.64 6.24 
Provider fixed effects  1.880 –6.01% 5.65 20.12  1.965 –1.73% 2.10 3.30 
Provider random effects  1.977 –1.13% 9.87 10.38  2.001 0.05% 3.03 3.03 
Scenario #3: Correlation between provider size and deviation from average outcome
Pooled  1.973 –1.37% 10.15 10.90  1.973 –1.34% 6.80 7.52 
Provider fixed effects  1.893 –5.36% 8.35 19.85  1.973 –1.33% 2.03 2.73 
Provider random effects  2.007 0.36% 16.67 16.72  2.006 0.32% 3.08 3.12 
Scenario #4: Correlation between provider size and mean of X4
Pooled  1.972 –1.41% 11.28 12.08  1.970 –1.49% 6.61 7.50 
Provider fixed effects  1.894 –5.32% 12.11 23.45  1.970 –1.49% 3.98 4.86 
Provider random effects  2.009 0.45% 18.84 18.92  2.005 0.24% 5.39 5.41 
Scenario #5: Correlation between a deviation from average treatment rate and deviation from average outcomes
Pooled  2.385 19.26% 9.89 158.28  2.387 19.36% 7.95 157.93 
Provider fixed effects  1.998 –0.10% 6.86 6.86  1.998 –0.09% 2.19 2.20 
Provider random effects  2.011 0.55% 10.78 10.90  1.999 –0.06% 3.13 3.13 
Scenario #6: All mentioned correlations simultaneously
Pooled  2.403 20.15% 14.12 176.50  2.404 20.20% 11.81 175.09 
Provider fixed effects  2.011 0.53% 6.57 6.68  2.008 0.38% 1.92 1.98 
Provider random effects  2.036 1.78% 11.17 12.44  2.002 0.10% 2.69 2.69 
Abbreviation: MSE = Mean squared error 
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Table 2.2 - Simulation results for propensity score matching methods (not conditional on provider).  Mean estimated treatment 
difference, relative bias, variance, and mean squared error of treatment effect estimators for each scenario by provider size 
distribution.  True treatment difference = 2.0. 
Simulation Scenario /  
Treatment Model Specification 
Treatment Different Estimates 
for Small Providers 
 Treatment Different Estimates 
for Large Providers 
Mean  Relative 
Bias
Variance 
(x1000) 
MSE
(x1000) 
 Mean  Relative 
Bias
Variance 
(x1000) 
MSE
(x1000) 
Scenario #1: No correlation between provider-level quantities
Pooled  2.002 0.09% 5.62 5.62  1.992 –0.40% 5.64 5.70 
Provider fixed effects  2.206 10.29% 3.19 45.53  2.039 1.95% 0.63 2.15 
Provider random effects  1.944 –2.82% 4.01 7.20  1.988 –0.61% 0.67 0.82 
Scenario #2: Correlation between provider size and deviation from average treatment rate
Pooled  1.990 –0.52% 6.33 6.44  1.990 –0.52% 5.14 5.25 
Provider fixed effects  2.169 8.45% 2.84 31.41  2.032 1.61% 0.61 1.65 
Provider random effects  1.933 –3.33% 3.44 7.89  1.983 –0.85% 0.48 0.77 
Scenario #3: Correlation between provider size and deviation from average outcome
Pooled  1.992 –0.42% 6.76 6.83  1.991 –0.45% 6.03 6.11 
Provider fixed effects  2.193 9.66% 3.99 41.30  2.033 1.63% 0.71 1.78 
Provider random effects  1.936 –3.22% 2.26 6.40  1.989 –0.54% 0.67 0.79 
Scenario #4: Correlation between provider size and mean of X4
Pooled  1.994 –0.31% 7.64 7.68  1.991 –0.45% 5.75 5.83 
Provider fixed effects  2.200 10.00% 2.68 42.67  2.043 2.17% 0.70 2.59 
Provider random effects  1.939 –3.07% 3.49 7.25  1.983 –0.83% 0.84 1.11 
Scenario #5: Correlation between a deviation from average treatment rate and deviation from average outcomes
Pooled  2.394 19.70% 6.57 161.84  2.398 19.92% 5.92 164.61 
Provider fixed effects  2.237 11.86% 3.56 59.79  2.052 2.61% 0.74 3.47 
Provider random effects  1.948 –2.60% 2.70 5.40  1.992 –0.41% 0.77 0.84 
Scenario #6: All mentioned correlations simultaneously
Pooled  2.421 21.05% 12.34 189.53  2.421 21.03% 9.72 186.63 
Provider fixed effects  2.208 10.42% 3.28 46.74  2.047 2.33% 0.62 2.79 
Provider random effects  1.929 –3.56% 3.06 8.14  1.985 –0.74% 0.67 0.88 
Abbreviation: MSE = Mean squared error 
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Table 2.3 - Simulation results for propensity score matching methods (within provider).  Mean estimated treatment difference, relative 
bias, variance, and mean squared error of treatment effect estimators for each scenario by provider size distribution.  True treatment 
difference = 2.0. 
Simulation Scenario /  
Treatment Model Specification 
Treatment Different Estimates 
for Small Providers 
 Treatment Different Estimates 
for Large Providers 
Mean  Relative 
Bias
Variance 
(x1000) 
MSE
(x1000) 
 Mean  Relative 
Bias
Variance 
(x1000) 
MSE
(x1000) 
Scenario #1: No correlation between provider-level quantities
Pooled  1.985 –0.76% 2.10 2.33  1.987 –0.65% 0.44 0.61 
Provider fixed effects  1.992 –0.39% 1.99 2.05  1.990 –0.48% 0.33 0.42 
Provider random effects  1.990 –0.50% 1.94 2.04  1.991 –0.47% 0.37 0.46 
Scenario #2: Correlation between provider size and deviation from average treatment rate
Pooled  1.975 –1.23% 2.28 2.88  1.979 –1.04% 0.37 0.80 
Provider fixed effects  1.985 –0.73% 1.98 2.20  1.986 –0.70% 0.26 0.46 
Provider random effects  1.985 –0.76% 1.86 2.10  1.985 –0.74% 0.23 0.45 
Scenario #3: Correlation between provider size and deviation from average outcome
Pooled  1.976 –1.19% 1.18 1.75  1.982 –0.92% 0.36 0.70 
Provider fixed effects  1.985 –0.75% 1.46 1.69  1.987 –0.65% 0.37 0.53 
Provider random effects  1.986 –0.71% 1.29 1.49  1.987 –0.67% 0.33 0.51 
Scenario #4: Correlation between provider size and mean of X4
Pooled  1.975 –1.27% 1.34 1.99  1.982 –0.92% 0.45 0.79 
Provider fixed effects  1.980 –1.01% 1.32 1.73  1.990 –0.49% 0.37 0.47 
Provider random effects  1.983 –0.87% 1.39 1.70  1.991 –0.47% 0.38 0.47 
Scenario #5: Correlation between a deviation from average treatment rate and deviation from average outcomes
Pooled  1.977 –1.13% 1.91 2.43  1.983 –0.86% 0.40 0.70 
Provider fixed effects  1.986 –0.70% 1.52 1.72  1.989 –0.53% 0.28 0.39 
Provider random effects  1.981 –0.93% 1.56 1.90  1.989 –0.55% 0.27 0.39 
Scenario #6: All mentioned correlations simultaneously
Pooled  1.981 –0.94% 1.55 1.90  1.981 –0.94% 0.35 0.71 
Provider fixed effects  1.985 –0.73% 1.49 1.71  1.987 –0.67% 0.38 0.56 
Provider random effects  1.984 –0.79% 1.36 1.61  1.986 –0.68% 0.34 0.53 
Abbreviation: MSE = Mean squared error   
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Table 2.4 - Characteristics of ADHERE-HF patients receiving low-dose and high-dose intravenous diuretics
 Variable Low-Dose 
(N = 33,965) 
High-Dose 
(N = 9,469) 
Standardized 
Difference, % 
Intracluster 
Correlation
Demographics Age (years), Mean (SD) 80.0 (7.9) 78.0 (7.6) 25.3 0.036 
 Gender, Male 13,782 (40.6%) 4,432 (46.8%) 12.6 0.051 
 Race   11.9  
 White 26,889 (79.2%) 7,190 (75.9%)  0.398 
 Black 4,396 (12.9%) 1,621 (17.1%)  0.460 
 Other/unknown 2,680 (7.9%) 658 (6.9%)  0.409 
Medical History Anemia 17,763 (52.3%) 5,639 (59.6%) 14.7 0.054 
 Atrial fibrillation 12,157 (35.8%) 3,692 (39.0%) 6.6 0.025 
 Coronary artery disease 19,172 (56.4%) 5,887 (62.2%) 11.7 0.029 
 Chronic renal insufficiency 7,952 (23.4%) 3,366 (35.5%) 26.9 0.041 
 Chronic obstructive pulmonary disease/Asthma 10,296 (30.3%) 3,290 (34.7%) 9.5 0.026 
 Diabetes mellitus 12,912 (38.0%) 4,677 (49.4%) 23.1 0.011 
 Hyperlipidemia 11,009 (32.4%) 3,408 (36.0%) 7.5 0.058 
 Hypertension 24,749 (72.9%) 7,058 (74.5%) 3.8 0.041 
 Prior myocardial infarction 9,861 (29.0%) 3,015 (31.8%) 6.1 0.034 
 Peripheral vascular disease 5,897 (17.4%) 1,994 (21.1%) 9.4 0.063 
 Prior stroke/Transient ischemic attack 6,297 (18.5%) 1,859 (19.6%) 2.8 0.030 
 Current smoker 2,502 (7.4%) 740 (7.8%) 1.7 0.046 
Initial Evaluation Fatigue 10,559 (31.1%) 2,790 (29.5%) 3.5 0.204 
 Rales 24,281 (71.5%) 7,037 (74.3%) 6.4 0.127 
 Edema 22,311 (65.7%) 7,277 (76.9%) 24.9 0.041 
 Congestion 24,131 (71.0%) 6,870 (72.6%) 3.3 0.103 
 Ejection fraction, <40% 11,036 (32.5%) 3,427 (36.2%) 8.5 0.044 
Laboratory results Systolic blood pressure (mmHg), Mean (SD) 146.4 (29.9) 144.8 (30.3) 5.3 0.019 
 BUN (mg/dL), Mean (SD) 28.8 (16.8) 34.3 (20.6) 29.6 0.013 
 Serum sodium (mmol/L), Mean (SD) 138.3 (4.7) 138.4 (4.6) 1.9 0.054 
 Hemoglobin (g/dL), Mean (SD) 12.4 (2.5) 12.0 (2.3) 15.9 0.155 
Values for Low-Dose and High-Dose groups presented as N (%) unless otherwise specified 
Abbreviation: SD = Standard deviation 
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Table 2.5 - Estimated relative risk and 95% confidence interval for association between 
receipt of high-dose diuretic and in-hospital mortality by propensity score method and 
treatment model specification  
Propensity Score Method /  
Treatment Model Specification 
Relative Risk (95% CI) 
Inverse probability of treatment weighting  
Pooled  1.32 (1.22, 1.43) 
Provider fixed effects  1.53 (1.42, 1.66) 
Provider random effects  1.56 (1.45, 1.69) 
Propensity score matching (unconditional)  
Pooled  1.15 (0.98, 1.36) 
Provider fixed effects  1.12 (0.94, 1.32) 
Provider random effects  1.19 (1.00, 1.41) 
Propensity score matching within provider  
Pooled  1.30 (1.08, 1.55) 
Provider fixed effects  1.26 (1.06, 1.52) 
Provider random effects  1.33 (1.11, 1.60) 
Abbreviation: CI = Confidence interval 
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CHAPTER 3 
STANDARD ERROR OF TREATMENT EFFECT ESTIMATES FROM 
PROPENSITY SCORE METHODS IN THE PRESENCE OF  
CONFOUNDING BY PROVIDER 
Introduction 
Data used for clinical research are often collected among patients clustered within 
providers.  These providers may affect the assignment of the treatment and may be associated 
with differential outcomes, above and beyond those expected by patient characteristics.  We 
demonstrated that propensity score methods that do not account for provider resulted in 
biased treatment effect estimates when provider effects on treatment are correlated with 
provider effects on outcome.  This could happen, for example, if certain hospitals that are 
more likely to offer certain treatments also tend to have lower adverse events rates than other 
hospitals.
Such correlation may not be the most common scenario encountered in practice, 
however.  It may be more likely that these provider effects are present, but uncorrelated.  In 
these scenarios, we showed that treatment effect estimates resulting from either propensity 
score matching or inverse probability of treatment weighting are generally unbiased.  We did 
not check to see how appropriate the related standard error estimates were for these treatment 
effects, though.  Typically, when clustered data are utilized for analysis, statistical methods 
must account for the correlation of subjects within the cluster (Gelman & Hill, 2006).  It is 
not clear when using propensity score methods (Rosenbaum & Rubin, 1983) if matching 
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within provider or including provider-specific effects in the estimation of the treatment 
model is adequate to yield standard error estimates that have the proper coverage of nominal 
95% confidence intervals.
We sought to understand how well various propensity score methods estimated the 
standard error of treatment effects in the presence of confounding by provider.  Using 
simulation studies and a clinical example, we aim to identify the analysis strategies that yield 
both unbiased estimation of the treatment effect and appropriate inference.   
Simulation Study 
We used Monte Carlo methods to simulate situations where patients were clustered 
within healthcare providers, and where those providers exhibited effects independent of the 
observed patient-level covariates on both patient-level treatment assignment and outcomes.  
We were specifically interested in examining different estimators based on data from 
situations where the provider effects on treatment and outcome were uncorrelated.  The only 
data generation parameter we varied between scenarios was the strength of the intraclass 
correlation (ICC) of the outcome. 
Data Generation Process 
For each provider j in the simulated data, we first generated provider-level
information that was subsequently used to generate patient-level data.  Specifically, we 
generated five independent random variables—fgF O<gF higF jgF kg—distributed as: 
NfgPlm?/F -+/A
O<glm?@.F -+/A
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higlm?-F .A
jglm?-F .A
kglm?-F  w` A
The number of patients per provider is set by fg, which was rounded to the nearest integer. 
The distribution of provider sizes is log-normally distributed and the mean of the log-
distribution was set to 5.0 to generate providers that ranged in size from about 55 to 400 
patients.  The proportion of patients within each provider having characteristic |<Fdescribed
below, is determined by O<g. Provider-level proportions for this variable averaged about 35% 
and ranged from about 12% to 50%.  The provider-level mean value of |iFdescribed below, 
is determined by hig. And the values of jg and kg are deviations around the overall intercept 
in the treatment and outcome models, respectively.  The terms jgandkg induce intraclass 
correlation. The value of  w`  was allowed to vary. 
For each patient } within provider ~, we generated four random variables—
|<TgF |`TgF |TgF |iTg—distributed as: 
|<TglKf logitd<NO<gP
|`Tglm?h`F .A
|Tglm?hF .A
|iTglmNhigF .P
The provider-specific quantities O<gandhigresulted in intraclass correlations of about 0.10 
for |< and 0.50 for |i respectively. The terms h`andhare set for each patient based on that 
patient’s value for |<Tg.
h` : ¡ -+/F |<Tg : .@-+/F |<Tg : -
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h : ¡@-+/F |<Tg : .-+/F |<Tg : -
The three patient-level normal random variables, |`F |, and |i were generated with the 
following correlations: 
 . rF rFrF . rFrF rF .  : 
. @+ @+.@+ . + .@+. + . . 
  We then randomly assigned each patient to a treatment, Aij, as a Bernoulli random 
variable having a mean parameter equal to probability pij,A, determined by the following 
function:
logitNaTgFP : = X jg X <|<Tg X `|`Tg X |Tg X i|iTg
The parameters =F <F `F F i were fixed within all simulations to the values [–1.0, 
ln(1.5), ln(1.5), ln(0.8), ln(0.67)].  This yielded a treatment rate of just over 30%. Due to the 
provider-specific term, jg, the intraclass correlation of the treatment was about 0.25. 
Finally, we randomly generated an outcome, Yij, for each patient as a normal random 
variable having a standard deviation equal to 1 and a mean parameter equal to ij,Y, which 
was determined by the following function: 
BTgF : = X kg X <|<Tg X `|`Tg X |Tg X i|iTg X \\9Tg
The provider-specific term, kg, also resulted in intraclass correlation for the outcome.  The 
magnitude of this correlation was allowed to vary by scenarios described below. 
The parameters =F <F `F F iF \\ were fixed within all simulations to the 
values [0, –1, –1, 1, 1, 2].  This resulted in an observed outcome equal to about 0.8 in the 
unexposed group. These parameters were set such that covariates associated with a higher 
probability of treatment were associated with a lower outcomes value, and vice versa.  By 
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defining higher outcome values as optimal, the treatment is seen to improve the outcome and 
is assigned more frequently to patients, based on their covariate values, that would otherwise 
had poor outcomes. 
Simulation Scenarios 
We generated 1000 data sets with 50 providers for three different values of  w` , the 
parameter that controls the provider-level intraclass correlation of the outcome.  At  w` :
-+--, there was no intraclass correlation for the outcome ( : -+-).  At  w` : -+-/, the 
intraclass correlation for the outcome was weak ( ¢ -+-/).  And at  w` : -+££, the intraclass 
correlation for the outcome was relatively strong ( ¢ -+,/).  In clinical research, it would 
likely be unusual to observe an intraclass correlation stronger than this for most outcomes.  
We applied multiple propensity score methods to each data set and calculated both the 
treatment effect point estimate and its standard error. 
The data generation specifications described above include many parameters that are 
provider-specific.  As a comparison to these data, we thought it would be helpful to 
additionally generate 1000 data sets that did not rely on any provider-specific quantities.  To 
do this, we generated data sets with 4000 records where |<F |`F |F |iF 9Fand; were created 
as described above, but with the quantities O<gF higF jgFandkgall equal to zero.  We applied 
the same pooled propensity score and estimation methods described below to these data sets. 
Propensity Score Methods 
We first estimated two treatment regression models that differed in how provider was 
incorporated.  Both models were specified as generalized linear models with logit links and 
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binary error distributions having treatment A as the dependent variable and patient-level 
covariates X1–X4 as predictors.  The first model ignored provider.  This is referred to as the 
pooled model.  The second model was fit using generalized linear mixed model methods and 
incorporated provider through the specification of provider-specific intercepts, estimated 
using random effects.  These effects were assumed to be normal with mean 0.  This model is 
referred to as the provider-specific model. 
We applied multiple propensity score-based methods to the predicted probabilities 
from each of these models.  First, we used inverse probability of treatment weighting (Hirano 
& Imbens, 2001; Robins, Hernán, & Brumback, 2000).  This method utilizes patient-specific 
weights defined as the inverse of the estimated probability of treatment for the treatment that 
patient received.  For a patient who received treatment, this weight is the inverse of the 
predicted probability generated from the treatment models.  For a patient in the comparison 
group, this weight is the inverse of one minus the model-based predicted probability.
Second, we used 1:1 greedy matching (Rosenbaum & Rubin, 1985a), where treated patients 
(randomly ordered) were matched one at a time to comparison patients.  Third, we used full 
matching (Rosenbaum, 1991), where treated patients were matched to comparison patients in 
sets where the number of treated and comparison patients could vary and the overall distance 
between matched sets was minimized.  Both of these matches were made using the linear 
predictor from the treatment models with calipers equal to 0.2 SD of that quantity (Austin, 
2011), based on the values of the linear predictor within the entire sample.   
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Estimation Methods 
 Methods that are appropriate to estimate the treatment effect and its standard error 
differ by propensity score method used.  The list of different methods we use is shown in 
Table 3.1. For 1:1 matching, the treatment effect can be estimated by taking the difference 
between the averages of the matched patients from each set, as: 
C<0< : .m< ¤9T;T
¥
T< @
.m= ¤?. @ 9TA;T
¥
T< :
.m< ¤E9T;T @ ?. @ 9TA;TH
¥
T<
where m< is the number of treated patients who were matched and m= is the number of 
comparison patients who were matched.  For any 1:1 matching, of course, m< : m=.  The 
standard error of this estimate can be estimated in two ways, treating the observations as 
pooled and treating the observations as paired.  For continuous outcomes, this is the 
difference between the standard error estimated when using a pooled t-test or a paired t-test.
The group differences will be identical, but the standard error estimates will differ.  Instead 
of using t-tests in this study, however, we will use two general linear regression models for 
the outcome, which will give the same results.  Using regression models allows for flexibility 
in estimation by letting us include other factors in addition to treatment as independent 
variables.  These other factors may be used to correct residual imbalance between groups or 
may account for factors that were not present at the treatment decision.  For this study, both 
models will include the treatment indicator as the only independent variable. The first 
outcome model will ignore the matched sets [labeled in the results tables as “GLM”] and will 
report the usual regression standard errors.  The second model will account for matched sets 
by using generalized estimating equation (GEE) methods (Liang & Zeger, 1986) where the 
clusters are matched sets and an exchangeable working correlation matrix is specified 
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[labeled “GEE”].  For 1:1 matching, the specification of the working correlation is not 
critical, since all structures are equivalent. 
 Adjustments in estimation are necessary when full matching is used, since full 
matching results in matched sets that can have differing numbers of treated and comparison 
patients.  Unweighted estimates from a t-test or basic linear model will be incorrect. Abadie 
& Imbens (2012) defines the treatment effect estimate from full matching results as 
C¦§ : .m< ¤9T ;T @ .¨T ¤ ;gg©ª?TA 
¥
T<
with its variance as 
 «¦§` : .m< @ .¤9T ;T @ .¨T ¤ ;gg©ª?TA @ C¦§
`¥
T<
where m< is the number of treated patients who were matched; T¨ is the number of patients 
matched to patient }; and ª?}A contains the indices of the T¨ patients matched to patient }.
For matched sets that contain one treated patient and multiple comparison patients, the right-
hand term in C¦§ is the difference between the outcome of the treated patient and the 
average of the outcomes of the matched comparison patients.  For matched sets that contain 
multiple treated patients and one comparison patient, the right-hand term in C¦§ is just the 
difference between one of those matched treated patients and the comparison patient, 
meaning the comparison patient will be represented in the overall average multiple times.  
We present these results labeled as “Abadie”.
Similar to the Abadie estimator, Hansen (2004) proposes weighting entire matched 
sets by the number of treated patients in the set.  This is referred to as ETT (effect of 
treatment on the treated) weighting.  Although not explicitly defined, the idea behind ETT 
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weighting is to first calculate the within-matched-set differences in the outcome by study 
group, and then calculating the weighted average of those differences across all sets.  It is 
easier to make this calculation by assigning patient-level weights to each matched record.  
Having weights is also useful when using methods that require patient-level data, such as 
regression models. For matched set ¬ with ¬ : .F­ F¨Flet ª® contain the indices for the 
m<F® treated patients and the m=F® comparison patients in the set. Consider a two-stage 
weight.  The first stage weight is a patient-level weight.  Within each set, equally weight each 
of the patients in each study group, as: 
S<T : ¯m=F®d<F 9T : -F } © ª®m<F®d<F 9T : .F } © ª®
The second stage weight is a set-level weight reflecting the number of treated patients in the 
set:
S`T : m<F®for } © ª®
The combined weight is therefore: 
ST : S<T ° S`T : ±m<F®m=F® F 9T : -F } © ª®.F 9T : .
The treatment effect estimate based on these weights is given by: 
C²\\ : .m< ¤E9TST;T @ ?. @ 9TAST;TH
¥
T<
We used three different regression models to estimate the treatment effect and its 
standard error for the results of full matching.  The first two models used ETT-weighted data 
and included a general linear model without any variance correction [labeled “GLM (ETT)”] 
and a general linear model with variance correction through the estimation of robust standard 
errors [labeled “GLM (ETT, robust)”].  These robust standard errors were estimated using 
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GEE methods with the matched set as the cluster and an independence working correlation 
structure.  The third model we used also utilized GEE methods, but was run on unweighted 
data, included matched set as the cluster, and specified an exchangeable working correlation 
structure [labeled “GEE”]. 
For inverse probability of treatment weighting methods, the basic definition of the 
treatment effect is given by 
C³´\µ : B¶<F³´\µ @ B¶=F³´\µ
where
B¶<F³´\µ : ¤9TK¶T
¥
T< 
d< ¤9T;TK¶T
¥
T<
and
B¶=F³´\µ : ¤. @ 9T. @ K¶T
¥
T< 
d< ¤?. @ 9TA;T. @ K¶T
¥
T<
Its standard error can be estimated as the square root of large-sample variance, given by 
 «³´\µ` : fd` ¤ U·³´\µFT`¥s<
where
U·³´\µFT : 9TN;T @ B¶<F³´\µPK¶T @ ?. @ 9TAN;T @ B¶=F³´\µP. @ K¶T @ ?¸T @ K¶TA¹º» ¼ººd<GT
¹º : fd< ¤¯9TN;T @ B¶<F³´\µP?. @ K¶TAK¶T @ ?. @ 9TAN;T @ B¶=F³´\µPK¶T. @ K¶T ½
¥
T< GT
and
¼ººd< : fd< ¤K¶T?. @ K¶TAGTG¾»¥T<
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We refer to this as the Lunceford method [labeled as such in the results], because their 
manuscript (Lunceford & Davidian, 2004) was one of the first to present a formula for the 
large-sample variance of the estimate. 
The regression-based method typically used to estimate C³´\µ and approximate 
 «³´\µ`  is a generalized linear model on the weighted data with robust standard errors.  For our 
study, we estimated these robust standard errors in two ways.  The first estimated standard 
errors using GEE methods with the patient as the (single-member) grouping variable and an 
independence working correlation structure [labeled “GLM (robust, patient)”].  The second 
estimated standard errors using GEE methods with provider as the grouping variable and an 
independence working correlation structure [labeled “GLM (robust, provider)”].  It may 
seem appropriate to researchers to incorporate provider-level correlations at this stage to 
correct the standard errors for the grouping of patients within providers.  We include this 
specification to see how it affects results.  For comparison, we also present results from a 
general linear model without any post-hoc correction of the standard errors [labeled “GLM”].
We do not present results from regression models estimated using GEE methods with 
provider as the grouping variable and an exchangeable working correlation structure because 
the results would be incorrect.  IPTW creates appropriately weighted pseudo-populations in 
which the patient characteristics are balanced between study groups, and GEE methods with 
non-diagonal working correlation structures would disrupt this weighting. 
Finally, we used doubly robust (DR) estimation (Robins, Rotnitzky & Zhao, 1994), 
which is an extension of IPTW methods that augment the IPTW estimates with predicted 
values from outcomes models.  As long as either the treatment model or the outcome model 
is correctly specified, doubly robust methods give consistent results.  These methods may be 
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appropriate for situations like ours where providers have effects on both treatment 
assignment and outcomes.  For example, if we used a provider-specific treatment model 
along with a pooled outcome model, results should be correct.  Because we used both pooled 
and provider-specific treatment models, we also estimate DR results using pooled and 
provider-specific outcome models [labeled “Doubly robust (pooled)” and “Doubly robust 
(provider-specific)”].  In the formulas below, ¿W< is the vector of parameter estimates 
associated with patient characteristics, GT, from an outcome regression model based solely on 
data from treated patients.  These parameter estimates can be applied to each patient to 
estimate their predicted response, ¬<?GTF ¿W<A, had they received treatment.  Similarly, ¿W= is 
the vector of parameter estimates associated with patient characteristics from an outcome 
regression model based solely on data from the comparison patients.  Applying these 
parameter estimates to each patient’s covariate vector yields their predicted response, 
¬=?GTF ¿W=A, had they not received treatment.  The DR estimate of treatment effect is 
C§ : B¶<F§ @ B¶=F§
where
B¶<F§ : fd< ¤9T;T @ ?9T @ K¶TA¬<?GTF ¿W<AK¶T
¥
T<
and
B¶=F§ : fd< ¤?. @ 9TA;T X ?9T @ K¶TA¬=?GTF ¿W=A. @ K¶T
¥
T<
The standard error is the square root of the large-sample variance, given by 
 «§` : fd` ¤ U·§FT`¥s<
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where
U·§FT : 9T;T @ ?9T @ K¶TA¬<?GTF ¿W<AK¶T @ ?. @ 9TA;T X ?9T @ K¶TA¬=?GTF ¿W=A. @ K¶T @ C§
Metrics 
For each simulation scenario (including the comparison data) and for each 
combination of propensity score method, treatment model and estimation method, we 
calculated the following metrics: Mean treatment estimate, bias, mean squared error, mean 
width of the 95% confidence interval based on the standard error of the estimate, and 
coverage probability.  These were defined as: 
Mean : d<  C< : C
Bias : C @ C\\
Variance : ? @ .Ad<  C @ C`<
Mean squared error : d<  C @ C\\`<
Mean width of estimated 95% CI = d<  , À .+ÁÂÃW<
where S is the number of simulated data sets, C\\ is the true treatment effect, C is the 
estimated treatment effect for data set s and  « is the estimated standard error of the treatment 
effect for data set s.  The coverage probability is the proportion of the S simulated data sets 
for which C\\ falls within the estimated 95% confidence interval.   
All simulations were conducted in SAS version 9.3 (SAS Institute Inc., Cary, North 
Carolina).  Sample SAS code for estimating propensity scores, calculating weights, 
performing matching, and estimating treatment effects and standard errors is shown in 
Appendix 1. 
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Simulation Study Results 
 Results from propensity score matching applied to the data generated without 
provider effects are shown in Table 3.2.  These results demonstrate how well different 
methods perform before introducing provider effects into both the treatment assignment and 
outcome processes.  All combinations of matching methods and estimation methods shown 
resulted in unbiased estimates of treatment effect, but only three had coverage probabilities 
close to the nominal value: (1) Full matching + GEE methods, (2) full matching + ETT-
weighted GLM with robust standard errors, and (3) greedy matching + GEE methods.  The 
use of methods without any variance adjustment—weighted GLM applied to full matching 
results or unweighted GLM applied to greedy matching results—resulted in confidence 
intervals that were too wide.  We also found that confidence intervals based on the Abadie 
estimators were too narrow. 
 Results from inverse probability of treatment weighting methods applied to the data 
generated without provider effect are shown in Table 3.3.  Again, all treatment effect 
estimates were unbiased.  The confidence intervals for the doubly robust estimator and 
Lunceford estimator had appropriate coverage.  The GLM without variance adjustment 
resulted in confidence intervals that were too wide, while the use of robust standard errors 
overcompensated and resulted in confidence intervals that were too narrow. 
 In all the results that follow, the data used were generated with provider effects on 
treatment assignment.  The mean treatment effect estimates and mean squared errors from 
estimation methods applied to propensity score matching results are shown in Table 3.4.
None of the methods used exhibited substantial bias, with the average estimates all within 
3% of the true value.  For unstratified matches made using the linear predictor from the 
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pooled treatment model, mean squared error increased as the outcome ICC increased.  This 
was not observed when stratified matching was used or when a provider-specific treatment 
model was used.
 The mean width of nominal 95% confidence intervals and the Monte Carlo coverage 
probabilities for estimation methods applied to propensity score matching results are shown 
in Table 3.5.  When the outcome ICC was 0, the coverage probabilities associated with 
unstratified matches based on the pooled treatment model were similar to those found for 
data without any provider effects, where the use of GEE methods or robust standard errors 
performed best.  Coverage probabilities declined noticeably when the outcome ICC was non-
zero.  Even a weak outcome ICC (0.05) dropped coverage probabilities with these methods to 
about 85%. Coverage probabilities associated with stratified matching and a pooled treatment 
model were highly variable.  Stratified full matching and GEE methods resulted in especially 
poor coverage, although this may have been due somewhat to the bias of the actual effect 
estimate. 
 When a provider-specific treatment model was used along with propensity score 
matching methods, the coverage probabilities were closer to nominal for all estimation 
methods.  Full matching and ETT-weighted GLMs with robust standard errors performed 
very well whether the matching was stratified or unstratified.  Full matching and GEE 
methods performed best for unstratified matches, however, while greedy matching and GEE 
methods performed best for stratified matches.   
To summarize, when propensity score matching was used in data situations where 
patients were clustered within providers and there were independent provider-level effects on 
both treatment and outcome, the following combinations of methods performed best: (1) 
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Unstratified full matching and ETT-weighted GLM with robust standard errors, (2) 
unstratified full matching and GEE methods, (3) stratified full matching and ETT-weighted 
GLM with robust standard errors, and (4) stratified greedy matching and GEE methods.  All 
of these matches were made on the linear predictor from a provider-specific treatment model.  
Use of a pooled treatment model did not lead to estimators which had appropriate coverage 
when the outcome ICC was greater than zero. 
 The mean treatment effect estimates and mean squared errors from estimation 
methods applied to inverse probability of treatment weighted data are shown in Table 3.6.
As with matching, none of these estimators exhibit substantial bias, with all mean treatment 
estimates within 2% of the true value; and higher outcome ICC values led to higher MSE for 
most estimation methods when a pooled treatment model was used.  The exception here was 
the doubly robust estimator that used a provider-specific outcome model.  The doubly robust 
estimators consistently had the lowest mean squared errors among all methods, controlling 
for outcome ICC.  And, in general, there was more error associated with methods based on 
the provider-specific treatment model and the pooled treatment model.   
 The mean width of nominal 95% confidence intervals and the Monte Carlo coverage 
probabilities for estimation methods applied to inverse probability of treatment weighted data 
are shown in Table 3.7.  When a pooled treatment model was used, there were no methods 
that consistently achieved nominal coverage.  When the outcome ICC was 0, all methods 
except the doubly robust methods had confidence intervals that were too wide.  But when the 
outcome ICC was high (0.25) all estimation methods except the GLM with provider-level 
robust standard errors led to confidence intervals that were too narrow.  In fact, the use of 
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provider-level robust errors substantially overcorrected the standard errors, leading to 
confidence intervals that were twice, or more, as wide as those from other methods.   
 For IPTW methods using weights based on a provider-specific treatment model, 
coverage probabilities were much closer to nominal across all values of the outcome ICC.  
The exception was when a GLM was used without any variance correction.  As above, the 
doubly robust estimators had the smallest confidence interval width coupled with, perhaps, 
the most appropriate coverage probabilities. 
 To summarize, when inverse probability of treatment weighting methods were used in 
situations where patients were clustered within providers and there were independent 
provider-level effects on both treatment and outcome, the following estimation methods 
performed best: (1) GLM with patient-level robust standard errors, (2) GLM with provider-
level robust standard errors, (3) the Lunceford estimator, and (4) either doubly robust 
method.  All methods that made use of weights based on treatment probabilities from a 
pooled model led to estimators with undercoverage at high ICC values for the outcome.  
Clinical example 
 To demonstrate how different estimation methods associated with propensity score 
matching and inverse probability of treatment weighting may lead to difference variance 
estimates in practice, we revisit an analysis of the effect of different inotropes on short-term 
mortality.  Milrinone and dobutamine are both inotropic agents that are used to increase the 
cardiac output of patients with decompensated heart failure (Coons, McGraw, & Murali, 
2011), but the mechanism of action for each differs.  (Dopamine is also in this class of 
medications, but its use in the population we studied, described below, was negligible.)  Very 
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few studies have compared milrinone and dobutamine directly.  A few small studies found no 
difference in the effect of each medication on improvement of clinical symptoms (Karlsberg 
et al., 1996; Aranda et al., 2003; Yamani et al., 2001), but these studies were too small to 
evaluate clinical endpoints like short-term or long-term mortality.  Abraham, et al. (2005) 
used data from the Acute Decompensated Heart Failure Registry (ADHERE) to examine 
over 5000 patients who received inotropes.  After adjustment, they found significantly lower 
in-hospital mortality associated with milrinone compared to dobutamine [odds ratio (95% 
confidence interval) = 0.81 (0.65, 0.97)].  Their statistical methods differ from ours in that 
they did not account for clustering of patients within hospitals and they included the 
estimated propensity score as a covariate in a regression analysis, instead of using propensity 
score matching or inverse probability of treatment weighting. 
 For this analysis, we also used data from ADHERE registry (Adams, et al., 2005).  
This registry included heart failure hospitalizations from over 300 hospitals, so in this 
analysis providers are hospitals.  Between 2001 and 2004, the registry collected information 
about the timing of specific medications received.  We included only patients who received 
either milrinone or dobutamine within the first 48 hours of admission.  This differs from the 
population used by Abraham, et al. (2005), which included inotrope receipt at any point in 
the hospitalization.  We used this definition of exposure to identify patients receiving 
inotropes as an initial therapy, excluding those patients who may have received inotropes as a 
response to worsening heart failure later in a hospital stay.  For the purposes of this analysis, 
we considered patients receiving milrinone as the treatment group and patients receiving 
dobutamine as the comparison group.  The outcome of interest was in-hospital mortality, as 
recorded in the registry. 
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 As above, we estimated each patient’s probability of treatment (milrinone) using two 
different regression models.  The first treatment model was a pooled model, ignoring 
potential hospital effects.  The second treatment model was hospital-specific, estimated using 
a hierarchical logistic regression with hospital-specific random effects around the mean 
intercept.  Predictors included in the treatment model were those that were believed to impact 
both medication selection and in-hospital mortality.  These are shown in Table 3.8.
After estimating these models, we used the methods similar to those described above 
to estimate the treatment effect and associated confidence interval of milrinone, compared to 
dobutamine, on in-hospital mortality.  The methods for this example differed from those used 
in the simulation since the research question required methods appropriate for dichotomous 
outcomes.  Any regression models utilized—those with and without robust standard errors, 
including those that used GEE methods—were specified as generalized linear models with a 
log link and a binary error distribution.  This specification leads to the direct estimation of 
relative risk, which is important for any models that utilize weighting, as relative risks are 
collapsible, unlike odds ratios.  The IPTW and doubly robust relative risk estimators are  
ÄÄÅ³´\µ : B¶<F³´\µB¶=F³´\µ
and
ÄÄÅ§ : B¶<F§B¶=F§
respectively, given same B¶<F³´\µ, B¶=F³´\µ, B¶<F§, and B¶=F§ calculated above.  The Lunceford 
large-sample variance estimator for the IPTW treatment effect is specific to linear outcomes 
(and risk differences), but we used a similar estimator from Williamson, Forbes & White 
(2014) for the variance of the log-relative risk, given as 
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 «F³´\µ` : fd<ÆÇÈvs @ É«ÊN,Ë< @ Ë`PÉ«Ì
where
ÇÈvs : .fSW<` B¶<F³´\µ` ¤9TN;T @ B¶<F³´\µP
`
K¶T`
s
T< X
.fSW=` B¶=F³´\µ` ¤?. @ 9TAN;T @ B¶=F³´\µP
`
?. @ K¶TA`
s
T<
É« : .fSW<B¶<F³´\µ ¤ÍT9TN;T @ B¶<F³´\µP?. @ K¶TAK¶T
s
T<
X .fSW=B¶=F³´\µ ¤ÍT?. @ 9TAN;T @ B¶=F³´\µPK¶T. @ K¶T
s
T<
Ë< : fd< ¤ÍTÍTÊsT< K¶T?. @ K¶TA
d<
Ë` : Ë< fd< ¤ÍTÍTÊsT< ?9T @ K¶TA`Ë<
SW< : fd< ¤9TK¶T
s
T<
and
SW= : fd< ¤. @ 9T. @ K¶T
s
T<
The large-sample variance of the log of the doubly robust relative risk estimator was taken 
from a SAS macro by Funk, Westreich, Weisen, & Davidian (2010), as: 
 «F§` : fd< Î_<F§`B¶<F§` X _=F§
`B¶=F§` @ ,_<=F§B¶<F§B¶=F§Ï
where _<F§`  and _=F§`  are the estimated variances of the patient-level components of B¶<F§`
and B¶=F§` , say Y<T and Y=T, respectively, given by 
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Y<T : 9T;T @ ?9T @ K¶TA¬<?GTF ¿W<AK¶T
and
Y=T : ?. @ 9TA;T X ?9T @ K¶TA¬=?GTF ¿W=A. @ K¶T
and _<=F§ is the estimated covariance of these values.  The only method from the simulation 
study without an analogue for dichotomous data was the Abadie estimator. 
Clinical Example Results 
 In the ADHERE-HF data, 6112 patients with heart failure from 81 hospitals received 
either milrinone or dobutamine within 48 hours of hospital admission.  The milrinone 
treatment rate was 38%, but ranged from 5% to 85% at different hospitals.  The intraclass 
correlation for this treatment was 0.33.  The in-hospital mortality outcome rate was just under 
10%.  This ranged from 0% to 32% across hospitals and had an associated intraclass 
correlation of 0.05.  The correlation between the hospital effects on treatment and outcome 
was neglible (<0.02).  These intraclass correlation coefficients were estimated as r :
  , where  v`  was the estimated variance of the hospital random effects about the overall 
intercept in a hierarchical logistic model (Rodrıguez & Elo, 2003).  Characteristics of each 
study group are shown in Table 3.8.  While there were some statistically significant 
differences between the groups with respect to demographics and initial symptoms (e.g. 
rales, edema, and congestion), there were many similarities in medical history and initial lab 
results. The observed relative risk of the effect of milrinone vs. dobutamine on mortality was 
0.76.
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The relative risks and confidence intervals estimated by inverse probability of 
treatment weighting methods are shown in Table 3.9.  All estimates of relative risk are near 
0.92 and none were found to be significantly different from null (1.0).  These estimates did 
not vary by the specification of the treatment model, although we did see slightly wider 
confidence intervals for most estimation methods that used weights based on the hospital-
specific treatment model compared to weights based on the pooled treatment model.  The 
relative risk of 0.94 estimated by doubly robust methods was the result most unlike the 
others.  Given that this estimate was based on a pooled treatment model and a pooled 
outcome model, both of which ignore hospital effects that are known to exist, it is probably 
safe to assume this result is incorrect.   
As expected based on the simulation results, the confidence intervals from the 
weighted model without any variance correction [labeled GLM] were the narrowest among 
all the IPTW methods.  Also as expected, the widest confidence intervals were those 
associated with hospital-level robust standard errors [GLM (robust, provider)].  Among the 
other methods with more appropriate standard error estimates, the Williamson estimator had 
the smallest confidence interval.  Theoretically, the doubly robust methods should have the 
smallest confidence intervals (Lunceford & Davidian, 2004), but these were based on 
approximations and not more precise large-sample formulas. 
The relative risks and confidence intervals estimated by propensity score matching 
methods are shown in Table 3.10.  There is more variability in the treatment effect estimates 
among these methods than there was among the IPTW methods, although almost all 
estimates are still not significantly different from 1.0.  This variability may be related to the 
proportion of records that were able to be matched by each method.  Only the unstratified full 
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matches were able to assign all patients to matched sets.  Because of the calipers employed in 
the matching, about 70% of the dobutamine patients and about 90% of the milrinone patients 
were able to be matched when full matching was performed within hospitals.  Unstratified 
greedy matching based on the pooled treatment model was able to match 96% of milrinone 
patients to 59% of dobutamine patients.  When a hospital-specific treatment model was used, 
these dropped to 67% and 41%, respectively.  For greedy matches performed within 
hospitals, fewer than 60% of milrinone patients were matched and only 35% of dobutamine 
patients were matched.  Incomplete matching can result in biased treatment effect estimates 
(Rosenbaum & Rubin, 1985), especially if the true effect differs by estimated propensity 
score, which may be happening here. 
The proportion of patients matched does not explain why the estimates from GEE 
methods applied to unstratified full matching results were consistently stronger in favor of 
milrinone than estimates from the other estimation methods based on the same matches.  
Differences were less noticeable between results from GEE methods and other methods 
applied to stratified full matching results.  More exploration is needed to explain these 
results.
For the two methods that seemed to result in estimators with the appropriate coverage 
based on the simulation work—ETT-weighted regressions with robust standard errors based 
from full matching results and GEE methods applied to greedy matching results, where both 
matches were based on hospital-specific treatment model results—the width of the estimated 
confidence intervals were similar. 
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Discussion
 We sought to understand how well different propensity score methods performed 
when patients were clustered, as by provider, and there were cluster-level effects on both 
treatment and outcomes.  Unlike previous work, we only examined situations where the 
cluster effects on treatment and outcome were uncorrelated, since this is a scenario that is 
more likely to be encountered in clinical research than a scenario in which these effects are 
correlated.  Also, because we knew, from prior work, that treatment effect estimates from 
most propensity score methods would be unbiased, we were keen to investigate the quality of 
inference for these methods.  To do so, we applied multiple treatment effect estimation 
methods that calculated standard errors of the estimate in different ways.   
 The estimation methods that consistently led to appropriate standard errors for and 
confidence intervals about the treatment effect estimate were those that started by estimating 
a provider-specific propensity score treatment model.  Inverse probability of treatment 
weighting methods apply weights to each patient based on the patient-specific probabilities 
estimated by this model.  The following IPTW estimation methods led to confidence 
intervals having the proper coverage: A GLM with patient-level or provider-level robust 
standard errors; the Lunceford estimator; and doubly robust methods.   
The only IPTW-based method that did not lead to accurate confidence intervals was 
the GLM without any sort of variance correction.  It is worth noting that because of how the 
weights are created, the sum of the weights within each study group is roughly the total 
number of patients in the entire sample.  This means the total effectively sample size for the 
weighted data is twice the original sample size.  This extra sample size is irrelevant for the 
Lunceford estimator or for the doubly robust estimators.  Even the use of GEE methods to 
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calculate robust standard errors handles these weights correctly.  But maybe this extra sample 
size is what led to artificially small standard errors from the basic GLM.  To test this, we 
performed post-hoc simulations based on standardized weights (Robins, Hernán, & 
Brumback, 2000).  Standardized weights are created by scaling the weights for patients in 
each study group by the observed proportion of patients in that study group, yielding a new 
set of weights that sum to the original sample size.  We found that the use of standardized 
weights was not enough to inflate the standard errors up to where they should have been 
when using a basic GLM.  Confidence intervals were still too narrow. 
 The use of doubly robust estimators in this situation should be appealing.  They are 
relatively easy to calculate and resulted in the narrowest confidence intervals of all methods 
that achieved nominal coverage of the estimated 95% confidence intervals.  These estimators 
may appeal to researchers who do not want to estimate a provider-specific treatment effect, 
since it is possible to model the treatment process as a provider-specific process while 
modeling the outcome process as a pooled process. 
Propensity score matching methods that performed best were those that used the 
linear predictors from a provider-specific treatment model to match treated patients to 
comparison patients for analysis.  The combinations of matching and estimation methods that 
were most effective were: Unstratified full matching and either GEE methods or ETT-
weighted GLM with robust standard errors; stratified full matching and ETT-weighted GLM 
with robust standard errors; and stratified greedy matching and GEE methods. 
 We found that estimation methods that were conditional on the matched sets 
outperformed those that ignored the matched sets.  In this way, our results agree with Austin 
(2008) and others that argue for the use of conditional methods.  While Shafer and Kang 
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(2008) are correct that there is no overt dependence between matched treated and comparison 
patients, the idea that their outcomes may be correlated is not so far-fetched.  In our 
simulation, patients who were more likely to receive the treatment were also more likely to 
have poor outcomes. 
 It was reassuring to see that full matching performed well in our simulations.  Full 
matching addresses a major drawback associated with 1:1 matching methods—the problem 
of discarded data.  Full matching methods utilize all records in a sample, whereas the 
maximum possible proportion of records matched with 1:1 greedy (or optimal) matching is 
twice the rate of the smaller study group.  In a sample with a 20% treatment rate, this leaves 
over half of the sample unused when estimating the treatment effect.  Trying to match more 
comparison records to treated records through the use of m:1 fixed ratio matching is often 
ineffective.  It has been shown that as m increases, substantial imbalance between study 
groups can be introduced (Hansen, 2004).  The issue of discarded data may not be of utmost 
importance when comparing a treatment group to an untreated comparison group, but it is 
potentially very important for comparative effectiveness research when both study groups 
include actively treated patients.  Head-to-head comparisons of medication, of dosage, or of 
different treatment modalities are examples where this occurs.  Full matching may be the 
most appropriate matching method for these questions, since it is the only way to ensure 
complete matching of patients in both study groups. 
It is worth mentioning that we did briefly explore optimal matching methods in our 
simulation study, but found an unusual situation.  While optimal matching was able to match 
more treated patients to comparison patients than greedy matching, these extra matches were 
made at the far end of the allowable matching range (i.e. near the size of the calipers used).
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And because of the data generation process used, small changes in the linear predictor were 
so highly associated with changes in outcome that there was bias in the effect estimates due 
to these additional matched sets.  In practice we would not expect this.  Rather, we would 
expect results from optimal matching that are quite close to those from greedy matching. 
 One set of methods available for non-parametric estimation of confidence intervals 
around an estimated treatment effect that we did not explore is bootstrap methods (Efron & 
Tibshirani, 1994).  This has been advocated for use with inverse probability of treatment 
weighting methods (Curtis, Hammill, Eisenstein, Kramer & Anstrom, 2007) although it is 
time consuming and can be resource intensive.  For propensity score matching, the proper 
use of bootstrap methods is less clear.  Austin and Small (2014) presented a bootstrap method 
for matching that he found to generate appropriate confidence intervals.  But Abadie and 
Imbens (2008) have argued strongly that bootstrap estimates, in general, are inappropriate 
when applied to matching methods.   
In general, there are a few ways to consider addressing clustering of patients within 
provider in an analysis that uses propensity score methods.  First, clustering can be addressed 
by including provider-specific factors in the treatment model.  This, as noted above, most 
consistently led to accurate confidence intervals and the correct inference.  Both doubly 
robust estimators worked well, for example, because for our simulated data a provider-
specific treatment model was the correct specification of that model.  Second, clustering can 
be addressed in the application of the propensity score methods.  This is a method specific to 
matching.  We found that if provider was ignored in the treatment model, but used for 
stratified matching, the confidence intervals were often too narrow, sometimes considerably 
so.  However, if provider was incorporated into the treatment model, it turns out that 
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matching within provider was not absolutely necessary for the calculation of appropriate 
standard errors.  Third, clustering can be addressed during the estimation of the treatment 
effect.  This is a method specific to inverse probability of treatment weighting methods, since 
there is no practical way to include provider in regression models when propensity score 
matching is used and the matched sets themselves need to be accounted for.  Unfortunately, 
regression methods using inverse probability of treatment weighted data based on a pooled 
treatment model did not yield accurate confidence intervals by simply requesting provider-
level robust standard errors. It’s likely, by the way, that the provider-level robust standard 
errors performed as well as the patient-level robust standard errors when a provider-specific 
treatment model was used because weights based on that treatment model minimized or 
eliminated the correlation between provider and treatment.  In short, as found in prior 
research (Austin, Grootendorst, & Anderson, 2007; Brookhart et al., 2006) when cluster is a 
confounding factor between treatment and outcome, even if it does not have the kind of 
correlated effect that would yield bias of the treatment estimate, it seems that it should be 
included in the treatment model like any other confounder.

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Table 3.1 - List of Estimation Methods Utilized 
 
Label Weight Estimation Method 
Associated with propensity score matching 
GLM None General linear model 
GLM (ETT) ETT General linear model 
GLM (ETT, robust) ETT General linear model with robust standard errors via GEE methods with matched set-level independence working correlation structure 
GEE None GEE methods with matched set-level exchangeable working correlation structure  
Abadie -- Abadie method: C¦§,  «¦§`  
   
Associated with inverse probability of treatment weighting 
GLM  General linear model 
GLM (robust, patient)   
General linear model with robust standard errors via GEE methods with patient-level 
independence working correlation structure 
GLM (robust, provider) 
IPTW 
	 
General linear model with robust standard errors via GEE methods with provider-level 
independence working correlation structure 
Lunceford   Lunceford method: C³´\µ,  «³´\µ`  
Doubly robust (pooled)  
Doubly robust method: C§ ,  «§` Ð  Pooled outcome model Doubly robust (provider-specific)   Provider-specific outcome model 
   
Abbreviations: GLM = Generalized linear model; ETT = Effect of treatment on the treated; GEE = Generalized estimating equations
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Table 3.2 - Simulation results for propensity score matching methods on data generated 
without provider effects, by match type and estimation method.  True treatment difference = 
2.0. 
 
Match type Estimation method 
Mean Treatment 
Estimate 
Mean Squared 
Error (x1000) 
Mean Width 
of 95% CI 
Coverage 
Probability 
Full  GLM (ETT) 1.998 2.37 0.315 99.9 
 GLM (ETT, robust) 1.998 2.37 0.194 95.1 
 GEE 1.997 1.66 0.169 95.8 
 Abadie 1.998 2.37 0.164 90.4 
Greedy GLM 1.991 2.09 0.406 100.0 
 GEE 1.991 2.09 0.185 95.3 
 
Abbreviations: CI = Confidence interval; GLM = Generalized linear model; ETT = Effect of treatment on the 
treated; GEE = Generalized estimating equations 
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Table 3.3 - Simulation results for inverse probability of treatment weighting methods on data 
generated without provider effects, by match type and estimation method.  True treatment 
difference = 2.0. 
 
Estimation method 
Mean treatment 
estimate 
Mean Squared 
Error (x1000) 
Mean width of 
95% CI 
Coverage 
probability 
GLM 1.998 2.37 0.315 99.9 
GLM (robust, patient) 1.998 2.37 0.164 90.4 
Lunceford  1.998 2.37 0.194 95.1 
Doubly robust (pooled) 1.991 2.09 0.185 95.3 
 
Abbreviations: CI = Confidence interval; GLM = Generalized linear model 
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Table 3.4 - Simulation results for propensity score matching methods.  Mean estimated 
treatment difference and mean squared error, by match type and estimation method.  True 
treatment difference = 2.0. 
 
Match type Estimation method 
Mean Treatment Estimate 
Mean Squared Error 
(x1000) 
ICC 
0.00 
ICC 
0.05 
ICC 
0.25 
ICC 
0.00 
ICC 
0.05 
ICC 
0.25 
Pooled treatment model 
Unstratified        
 Full GLM (ETT) 1.999 2.000 2.001 1.03 2.14 7.15 
 GLM (ETT, robust) 1.999 2.000 2.001 1.03 2.14 7.15 
 GEE 1.999 2.001 2.001 0.71 1.73 6.86 
 Abadie 1.999 2.000 2.001 1.03 2.14 7.15 
 Greedy GLM 1.992 1.992 1.991 1.00 2.10 7.56 
 GEE 1.992 1.992 1.991 1.00 2.10 7.56 
Stratified        
 Full GLM (ETT) 1.973 1.971 1.971 2.78 2.99 2.95 
 GLM (ETT, robust) 1.973 1.971 1.971 2.78 2.99 2.95 
 GEE 1.943 1.941 1.942 5.15 5.64 5.57 
 Abadie 1.973 1.971 1.971 2.78 2.99 2.95 
 Greedy GLM 1.968 1.969 1.966 2.64 2.75 2.88 
 GEE 1.968 1.969 1.966 2.64 2.75 2.88 
        
Provider-specific treatment model 
Unstratified        
 Full GLM (ETT) 2.041 2.042 2.045 5.99 5.92 6.54 
 GLM (ETT, robust) 2.041 2.042 2.045 5.99 5.92 6.54 
 GEE 2.028 2.024 2.017 3.26 3.49 3.96 
 Abadie 2.041 2.042 2.045 5.99 5.92 6.54 
 Greedy GLM 2.024 2.023 2.019 9.36 9.63 10.76 
 GEE 2.024 2.023 2.019 9.36 9.63 10.76 
Stratified        
 Full GLM (ETT) 1.983 1.983 1.983 1.77 1.69 1.88 
 GLM (ETT, robust) 1.983 1.983 1.983 1.77 1.69 1.88 
 GEE 1.966 1.966 1.965 2.33 2.47 2.64 
 Abadie 1.983 1.983 1.983 1.77 1.69 1.88 
 Greedy GLM 1.985 1.986 1.985 1.33 1.32 1.40 
 GEE 1.985 1.986 1.985 1.33 1.32 1.40 
 
Abbreviations: ICC = Intraclass correlation coefficient; GLM = Generalized linear model; ETT = Effect of 
treatment on the treated; GEE = Generalized estimating equations 
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Table 3.5 - Simulation results for propensity score matching methods.  Mean width of 95% 
confidence interval and coverage probability, by match type and estimation method.   
 
Match type Estimation method 
Mean width of 95% CI Coverage probability 
ICC 
0.00 
ICC 
0.05 
ICC 
0.25 
ICC 
0.00 
ICC 
0.05 
ICC 
0.25 
Pooled treatment model 
Unstratified        
 Full GLM (ETT) 0.232 0.233 0.237 100.0 98.4 84.2 
 GLM (ETT, robust) 0.135 0.138 0.151 96.8 85.8 63.3 
 GEE 0.117 0.119 0.131 97.2 83.9 57.2 
 Abadie 0.111 0.114 0.125 92.2 78.3 53.0 
 Greedy GLM 0.283 0.284 0.290 100.0 99.6 90.4 
 GEE 0.125 0.128 0.140 95.5 83.8 58.0 
Stratified        
 Full GLM (ETT) 0.232 0.233 0.238 97.0 95.9 97.1 
 GLM (ETT, robust) 0.156 0.156 0.156 87.4 86.1 87.1 
 GEE 0.125 0.125 0.125 56.8 56.6 55.0 
 Abadie 0.114 0.115 0.114 75.1 73.0 73.1 
 Greedy GLM 0.316 0.318 0.325 99.5 99.3 99.3 
 GEE 0.139 0.139 0.139 84.0 84.5 81.9 
        
Provider-specific treatment model 
Unstratified        
 Full GLM (ETT) 0.232 0.233 0.238 86.7 87.1 85.5 
 GLM (ETT, robust) 0.321 0.323 0.333 97.2 97.2 95.8 
 GEE 0.244 0.246 0.252 97.9 97.5 96.4 
 Abadie 0.220 0.221 0.227 84.6 85.4 83.6 
 Greedy GLM 0.315 0.316 0.323 89.3 89.0 88.5 
 GEE 0.268 0.270 0.276 84.1 83.0 82.2 
Stratified        
 Full GLM (ETT) 0.230 0.231 0.236 99.4 99.8 99.1 
 GLM (ETT, robust) 0.156 0.156 0.156 93.8 94.3 93.1 
 GEE 0.122 0.122 0.122 79.1 77.9 75.7 
 Abadie 0.112 0.112 0.112 82.4 81.5 79.7 
 Greedy GLM 0.316 0.318 0.324 100.0 100.0 100.0 
 GEE 0.136 0.136 0.136 94.5 93.9 92.4 
 
Abbreviations: CI = Confidence interval; ICC = Intraclass correlation coefficient; GLM = Generalized linear 
model; ETT = Effect of treatment on the treated; GEE = Generalized estimating equations 
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Table 3.6 - Simulation results for inverse probability of treatment weighting methods.  Mean 
estimated treatment difference and mean squared error, by estimation method.  True 
treatment difference = 2.0. 
 
Estimation method 
Mean Treatment Estimate 
Mean Squared Error 
(x1000) 
ICC 
0.00 
ICC 
0.05 
ICC 
0.25 
ICC 
0.00 
ICC 
0.05 
ICC 
0.25 
Pooled treatment model 
GLM 1.983 1.986 1.983 2.37 3.58 8.84 
GLM (robust, patient) 1.983 1.986 1.983 2.37 3.58 8.84 
GLM (robust, provider) 1.983 1.986 1.983 2.37 3.58 8.84 
Lunceford  1.983 1.986 1.983 2.37 3.58 8.84 
Doubly robust (pooled) 2.000 1.999 2.000 0.68 1.77 7.02 
Doubly robust (provider-specific)  2.000 2.000 2.000 0.68 0.90 1.00 
       
Provider-specific treatment model 
GLM 1.964 1.970 1.962 7.23 6.78 7.26 
GLM (robust, patient) 1.964 1.970 1.962 7.23 6.78 7.26 
GLM (robust, provider) 1.964 1.970 1.962 7.23 6.78 7.26 
Lunceford  1.964 1.970 1.962 7.23 6.78 7.26 
Doubly robust (pooled) 2.001 2.001 2.000 1.05 1.12 1.27 
Doubly robust (provider-specific)  2.001 2.001 2.000 1.05 1.12 1.20 
 
Abbreviations: ICC = Intraclass correlation coefficient; GLM = Generalized linear model 
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Table 3.7 - Simulation results for inverse probability of treatment weighting methods.  Mean 
width of 95% confidence interval and coverage probability, by estimation method.   
 
Estimation method 
Mean width of 95% CI Coverage probability 
ICC 
0.00 
ICC 
0.05 
ICC 
0.25 
ICC 
0.00 
ICC 
0.05 
ICC 
0.25 
Pooled treatment model 
GLM 0.241 0.242 0.246 98.5 95.8 80.9 
GLM (robust, patient) 0.328 0.330 0.333 99.9 99.2 91.9 
GLM (robust, provider) 0.637 0.650 0.696 100.0 100.0 99.9 
Lunceford  0.303 0.306 0.308 99.8 98.8 88.6 
Doubly robust (pooled) 0.103 0.106 0.118 95.8 79.3 52.1 
Doubly robust (provider-specific)  0.103 0.103 0.103 95.6 91.7 89.7 
       
Provider-specific treatment model 
GLM 0.241 0.242 0.246 84.0 85.7 85.4 
GLM (robust, patient) 0.426 0.431 0.428 97.9 98.7 98.3 
GLM (robust, provider) 0.403 0.410 0.405 97.5 98.5 97.8 
Lunceford  0.402 0.408 0.404 96.9 98.0 97.3 
Doubly robust (pooled) 0.126 0.130 0.145 94.3 95.0 96.3 
Doubly robust (provider-specific)  0.126 0.125 0.123 94.3 93.9 93.0 
 
Abbreviations: CI = Confidence interval; ICC = Intraclass correlation coefficient; GLM = Generalized linear 
model 
  
86 
Table 3.8 - Characteristics of ADHERE-HF patients receiving milrinone and dobutamine  
 
Variable 
Dobutamine 
(N = 3794) 
Milrinone 
(N = 2318) 
Standardized 
Difference, % 
Demographics    
Age (years), Mean (SD) 69.4 (13.8) 65.7 (14.3) 26.3 
Gender, Male 2,445 (64.4%) 1,595 (68.8%) 9.3 
Race   8.7 
White 2,788 (73.5%) 1,612 (69.5%)  
Black 683 (18.0%) 478 (20.6%)  
Other/unknown 323 (8.5%) 228 (9.8%)  
    
Medical History    
Anemia 1,970 (51.9%) 1,207 (52.1%) 0.3 
Atrial fibrillation 1,358 (35.8%) 822 (35.5%) 0.7 
Coronary artery disease 2,555 (67.3%) 1,496 (64.5%) 5.9 
Chronic renal insufficiency 1,559 (41.1%) 912 (39.3%) 3.6 
Chronic obstructive pulmonary disease/Asthma 1,178 (31.0%) 645 (27.8%) 7.1 
Diabetes mellitus 1,617 (42.6%) 979 (42.2%) 0.8 
Hyperlipidemia 1,481 (39.0%) 874 (37.7%) 2.7 
Hypertension 2,317 (61.1%) 1,377 (59.4%) 3.4 
Prior myocardial infarction 1,514 (39.9%) 812 (35.0%) 10.1 
Peripheral vascular disease 759 (20.0%) 427 (18.4%) 4.0 
Prior stroke/Transient ischemic attack 564 (14.9%) 373 (16.1%) 3.4 
Current smoker 460 (12.1%) 278 (12.0%) 0.4 
    
Pacemaker, any 1,256 (33.1%) 821 (35.4%) 4.9 
Implantable cardioverter defibrillator 790 (20.8%) 616 (26.6%) 13.6 
    
Initial evaluation    
Fatigue 1,580 (41.6%) 1,020 (44.0%) 4.8 
Rales 2,439 (64.3%) 1,336 (57.6%) 13.7 
Edema 2,571 (67.8%) 1,409 (60.8%) 14.6 
Congestion 2,294 (60.5%) 1,266 (54.6%) 11.9 
Ejection fraction   15.7 
< 40 2,797 (73.7%) 1,859 (80.2%)  
 40 589 (15.5%) 257 (11.1%)  
Unknown 408 (10.8%) 202 (8.7%)  
    
Initial vital signs and laboratory results    
Systolic blood pressure (mmHg), Mean (SD) 120.1 (28.5) 119.5 (26.3) 2.1 
BUN (mg/dL), Mean (SD) 43.3 (27.1) 40.5 (25.8) 10.6 
Serum sodium (mmol/L), Mean (SD) 136.4 (5.3) 136.6 (5.0) 4.4 
Hemoglobin (g/dL), Mean (SD) 12.6 (2.5) 12.5 (2.4) 2.2 
   
Values for Dobutamine and Milrinone groups presented as N (%) unless otherwise specified 
Abbreviation: SD = Standard deviation 
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Table 3.9 - Estimated relative risk and 95% confidence interval from inverse probability of 
treatment weighting methods for association between milrinone (vs. dobutamine) and in-
hospital mortality.  
 
Estimation method Relative Risk (95% CI) 
Pooled treatment model 
GLM 0.92 (0.83, 1.03) 
GLM (robust, patient) 0.92 (0.78, 1.09) 
GLM (robust, provider) 0.92 (0.73, 1.17) 
Williamson 0.92 (0.79, 1.08) 
Doubly robust (pooled) 0.94 (0.79, 1.12) 
Doubly robust (provider-specific)  0.91 (0.77, 1.08) 
  
Provider-specific treatment model 
GLM 0.92 (0.83, 1.03) 
GLM (robust, patient) 0.92 (0.74, 1.15) 
GLM (robust, provider) 0.92 (0.71, 1.19) 
Williamson  0.92 (0.79, 1.07) 
Doubly robust (pooled) 0.93 (0.76, 1.14) 
Doubly robust (provider-specific)  0.92 (0.75, 1.12) 
 
Abbreviations: CI = Confidence interval; GLM = Generalized linear model   
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Table 3.10 - Estimated relative risk and 95% confidence interval from propensity score 
matching methods for association between milrinone (vs. dobutamine) and in-hospital 
mortality. 
 
Match type Estimation method Relative Risk (95% CI) 
Pooled treatment model 
Unstratified   
 Full GLM (ETT) 0.90 (0.75, 1.09) 
 GLM (ETT, robust) 0.90 (0.75, 1.10) 
 GEE 0.81 (0.69, 0.95) 
 Greedy GLM 0.94 (0.78, 1.14) 
 GEE 0.94 (0.78, 1.13) 
Stratified   
 Full GLM (ETT) 0.86 (0.71, 1.04) 
 GLM (ETT, robust) 0.86 (0.66, 1.11) 
 GEE 0.82 (0.69, 0.97) 
 Greedy GLM 0.85 (0.67, 1.07) 
 GEE 0.85 (0.67, 1.07) 
   
Provider-specific treatment model 
Unstratified   
 Full GLM (ETT) 0.86 (0.72, 1.04) 
 GLM (ETT, robust) 0.86 (0.65, 1.14) 
 GEE 0.77 (0.66, 0.91) 
 Greedy GLM 0.90 (0.73, 1.11) 
 GEE 0.90 (0.73, 1.11) 
Stratified   
 Full GLM (ETT) 0.89 (0.74, 1.09) 
 GLM (ETT, robust) 0.89 (0.66, 1.21) 
 GEE 0.91 (0.75, 1.09) 
 Greedy GLM 0.89 (0.69, 1.13) 
 GEE 0.89 (0.70, 1.13) 
 
Abbreviations: CI = Confidence interval; GLM = Generalized linear model; ETT = Effect of treatment on the 
treated; GEE  = Generalized estimating equations 
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CHAPTER 4 
A SAS MACRO FOR OPTIMAL MATCHING AND FULL MATCHING ON  
PROPENSITY SCORES 
Introduction 
 The use of propensity score matching methods to balance covariates between a 
treated group of patients and a comparison group of patients in clinical and epidemiological 
research is widespread (Stürmer et al., 2006).  Greedy matching (Rosenbaum & Rubin, 
1985a), a method in which patients from each study group are matched one at a time and 
without reconsideration, is the most frequently used matching method in these studies 
(Austin, 2008).  This preponderance of greedy matching is potentially unwarranted, given 
that other, often superior, matching methods have been described.  
Optimal matching (Rosenbaum, 1989) and full matching (Rosenbaum, 1991) are two 
such methods proposed as alternatives to greedy matching.  Unlike greedy matching, which 
seeks closely matched pairs without regard to the overall distance between matched sets, both 
optimal matching and full matching allow matches to be reconsidered in order to minimize 
the total distance between matched sets of treated and comparison patients.  The difference 
between optimal matching and full matching is in the make-up of the matched sets.  Optimal 
matching, like greedy matching, is a type of fixed ratio matching, where all resulting 
matched sets contain the same number of patients from each study group, with 1:1 matches 
most common.  With fixed ratio matching, many records remain unmatched.  Full matching 
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addresses this limitation by allowing flexibility in the make-up of the matched sets—multiple 
treatment records can be matched to a single comparison record and vice versa—which 
results in the utilization of all records in both study groups. 
When these matching methods have been compared, full matching has been shown to 
produce closer matched sets and better covariate balance between study groups than either 
optimal or greedy 1:1 matching (Ming & Rosenbaum, 2000; Gu & Rosenbaum, 1993).   
Others have demonstrated that trying to utilize more control patient data by performing m:1 
matches introduces greater imbalances in the matched sets (Hansen, 2004) compared to 1:1 
matching.  When matching on a single variable, greedy matching and optimal matching often 
produce similar results, especially if there are a substantial number of control patients 
available for matching to each treated patient.  When the number of controls per treated 
patient is low, optimal matching produces better matches (Gu & Rosenbaum, 1993). 
 The scarcity of optimal matching and full matching applications in the literature is 
likely due to fact that, as optimization problems, they are difficult to implement. Rosenbaum 
(1989 & 1991) demonstrated that one way to approach both optimal matching and full 
matching is by leveraging the theory and mechanics of network flow problems.  By casting 
these matching problems as network flow problems, linear programming solvers can be 
employed to find the minimum distance between the two sets of records (Tardos & 
Kleinberg, 2006).  Submitting data to these solvers requires understanding how to 
appropriately specify and program the nodes and arcs of a network problem.  And recovering 
the matched sets from the solution require understanding how to identify connected records 
in the resulting network (Tardos & Kleinberg, 2006).  Neither are trivial.  And while SAS 
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macros exist for greedy matching, full-featured macros for optimal matching and full 
matching do not exist (Bergstralh & Kosanke, 2003). 
 In this paper, we present a SAS macro for implementing both optimal matching and 
full matching on a scalar variable, such as the propensity score, using optimization tools 
found within SAS/OR, SAS’s operations research software.  We also review the methods and 
mechanics of matching and we will demonstrate the use of the macro with data from a 
clinical application. 
 
Matching Methods
 The propensity score was introduced by Rubin and Rosenbaum in the mid-1980s as a 
balancing score to be used for balancing measured characteristics between two study groups 
(Rosenbaum & Rubin, 1983).  [Note that in comparative effectiveness research, these two 
study groups may both be treatment groups, treated with different modalities or strengths of 
the same therapy.  For the purposes of this manuscript and for simplicity, we will refer to the 
two study groups as the treatment group and the comparison group; and we will refer to the 
members of these groups as patients.]  The propensity score is the probability of treatment 
associated with each study patient.  Propensity scores are usually estimated with a logistic 
regression having the treatment indicator as the dependent variable and factors that may 
confound the relationship between treatment and outcome as the predictors.   
 Different propensity score-based methods utilize these estimated probabilities in 
different ways to achieve balance, but a very common method is simply matching each 
patient in the treatment group to one or more patients in the comparison group having similar 
values on the propensity score or some function of the propensity score (e.g. linear 
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predictor).  Matching on the propensity score is a way to perform a multivariate match using 
a single variable, and Rubin and Rosenbaum (1985a) showed that such matching results in 
sets of patients from each study group that had similar distributions on measured 
confounders.  This, in turn, allows for a direct assessment of the outcomes in each group 
without further adjustment for confounders.  The resulting treatment effect estimate was 
shown to be a consistent estimator of the population-level treatment effect (Rosenbaum & 
Rubin, 1983). 
 There are many different ways to match records between two groups on a single 
variable like the propensity score.  The simplest way to do this is to perform greedy 
matching, which is also sometimes referred to as nearest neighbor matching (Rosenbaum & 
Rubin, 1985).  Implementation of greedy matching is easily programmable as a series of 
steps.  The general algorithm can be described as follows.  First, randomly order patients in 
the treatment group and work through them one-by-one.  For each treated patient, find the 
comparison patient with the closest match on the matching variable and output both records 
as a matched set.  Continue until all treated patients have been matched.  This match is 
“greedy” in that once a patient from the comparison group is assigned, that assignment is not 
revisited.  Most greedy matches are specified as 1:1 matches, resulting in two patients per 
matched set.  Alternatively, researchers may specify m:1 fixed ratio matches.  In this case, 
the above procedure is repeated for all patients in the treatment group and all remaining 
unmatched patients in the comparison group.  This continues until m matches have been 
made for each treated patient.   
One drawback with greedy matching is that it does not consider the total distance on 
the matching variables across all matched sets of treated and comparison patients.  Optimal 
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matching addresses this drawback.  Optimal matching methods, in general, assign every 
patient in the treated group to a different patient in the comparison group simultaneously.  It 
uses the total distance on the matching variable across all matched sets as the minimization 
criteria.  Matching assignments are reconsidered until it is believed that the optimal solution, 
with the lowest possible total distance, has been found.  As with greedy matching, most 
optimal matches are 1:1 matches, although it is possible to create m:1 matches in a manner 
similar to what is described above.  After 1:1 matches are match, another m-1 optimal 
matches would be performed using all the treated patients and the unmatched comparison 
patients. 
An obvious limitation with both greedy matching and optimal matching is that fact 
that there are, by definition, many records left unmatched at the end of the process that will 
not contribute to the outcomes analysis.  While m:1 matching attempts to utilize more of 
these unmatched records than 1:1 matching, it has been shown that requiring a fixed ratio of 
treated to comparison patients can result in very poor matches (Hansen, 2004) which in turn 
can lead to bias in the treatment effect estimate.  Full matching addresses these issues.  The 
core principle of full matching is to match all records in the treatment group to all records in 
the comparison without requiring a fixed ratio of treated to comparison patients in the 
matched sets.  In other words, matched set treated-to-comparison ratios are flexible and can 
be m:1 or 1:m, with almost no limit on the size of m in either direction.  As with optimal 
matching, full matching uses the total distance on the matching variable across all matched 
sets as the minimization criteria and reconsiders assignments until an optimal solution has 
been found. 
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The complexity of simultaneous assignment and optimization in both optimal 
matching and full matching make them less amenable to programming as a series of discrete 
steps.  Rosenbaum (1989 & 1991) recognized that each could be thought of as a minimum-
cost network flow problem, a standard optimization problem (Tardos & Kleinberg, 2006).  
Once recast as an optimization problem, it is possible to use existing linear programming 
solvers to perform optimal matching and full matching.  Setting up the necessary data 
structures and constraints for these solvers, however, can be a challenge.   
Network flow problems are described using nodes and links.  Links are also often 
referred to as arcs or edges.  Figure 4.1, Panel A shows the general set-up for a matching 
problem as a network flow problem.  Consider all the treated patients (1–5) in the center left-
hand column, T, and all the comparison patients (a–e) in the center right-hand column, C.  
Each patient is a node in the network.  All nodes in the treated column have directed links 
into all nodes in the comparison column.  By adding a source node, , to the left of the 
treated patients, a sink node, , to the right of the comparisons patients and all appropriately 
directed links, we can imagine “flow” moving from left to right across the network.  Using 
costs assigned to the links between patients in the treatment group and patients in the 
comparison group, it is possible to find the lowest cost way to move a specified amount of 
flow (in units) from the source node through each study group to the sink node.  The 
resulting paths represent the final links in the matching.  Figure 4.1 shows example paths for 
solved 1:1 optimal matching (Panel B) and solved full matching (Panel C).  Note in Panel C 
that the full matching here has resulted in two 1:1 matches, a single 1:2 match, and a single 
2:1 match.  This imbalance is handled in the eventual statistical analysis.  
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Before the network flow problem can be solved, constraints need to be specified, 
including the supply of flow to put through the network, the flow costs of the links to and 
from the source and sink nodes, and flow capacities for all links.  The first panel of Table 4.1 
lists these constraints for both optimal matching and full matching performed without 
stratification.  The total network flow is determined by the input quantity of supply node.  
The sink node balances this quantity to ensure that the entire flow moves across the network.  
No other nodes (i.e. none of the patient nodes) initiate or terminate flow.  The total units of 
network flow for optimal matching is the size of the smaller of the treated or comparison 
groups.  This will result in all the patients of the smaller group being matched, but, as 
expected, only some patients within the larger group being matched.  Total flow for full 
matching is, at a minimum, the size of the larger study group, which ensures all patients in 
both study groups get matched.  For full matching, the total flow will equal the size of the 
larger study group only if all matched sets include only one member of the smaller study 
group and one or more members of the larger study group.  Additional flow will be required 
if any of the matched sets include one member of the larger study group matched to multiple 
members of the smaller study group.  For both unstratified optimal and full matching, the 
cost of a single unit of flow associated with each link from a treated patient to a comparison 
patient is the difference in the matching variable between those patients.  In propensity score 
matching, this might be the difference in the linear predictors from the treatment model for 
each pair of patients. The capacity limits on these links are always [0, 1], with the minimum 
flow through the link as 0 units, or no flow, and the maximum flow as 1 unit.  In other words, 
each link between patients can be used either once or not at all.  For full matching, the link 
capacities out of the source node and into the sink node are all [1, 
], meaning each of those 
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links must be used once, but can be used multiple times.  This enables both 1:m and m:1 
matching.  For optimal matching, the link capacities from the source node and to the sink 
nodes differ.  For the smaller study group, the appropriate links will require 1 unit of flow 
across them, resulting in every patient being used.  For the larger study group, the appropriate 
links have capacity [0, 1].  Only the patients associated with the lowest costs will be used 
from this group. 
For stratified matches, some of these quantities change and some do not.  See Figure
4.2, Panel A for the network set-up of a stratified matching problem.  The difference from an 
unstratified match is that there are no links available from treated patients in one stratum to 
comparison patients in another.  This has effects on the constraints of the problem, shown in 
the second panel of Table 4.1.  The total flow through the network is now determined by the 
sum of the sizes of the smaller study group, for optimal matching, or larger study group, for 
full matching, within each stratum.  This will only lead to a different amount of flow 
compared to the unstratified match of the same type if some strata have a treatment 
proportion under 0.5, while others have a treatment proportion greater than 0.5.  Link 
capacities between treated and comparison patients are again based on the difference in the 
matching variable between pairs, with the additional note that this only applies to patients in 
the same stratum.  Patients from different strata are not linked.  One final difference has to do 
with the link capacities for links between the source node and the treated patients and 
between the comparison patients and the sink node.  These capacities are now based on the 
sizes of the study groups within each strata.  An example solution for a stratified optimal 
match is shown in Figure 4.2, Panel B.  Note that only 4 of the 5 patients in each group are 
able to be matched, due to the size of each study group within each strata. An example 
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solution for a stratified full match is shown in Figure 4.2, Panel C.  Here, all patients are still 
matched.  
There are a few common variations on the matches described above.  One important 
variation on all matching methods is the use of calipers.  In caliper matching, only records 
within a specified distance of each other are considered eligible to be matched.  Calipers are 
useful for preventing the matching of records deemed to be too far apart.  Unrestricted 
matches may result in too many disparate matches, which in turn can affect the balance on 
confounding factors between matched groups.  The width of calipers to be used can be set by 
the researcher, but at least one simulation study led to a recommendation of calipers equal to 
0.2 standard deviations of the matching variable (Austin, 2011).  While some researchers 
recommend trimming when the distribution of the matching variables do not entirely overlap 
(Stürmer, Rothman, Avorn & Glynn, 2010), the use of calipers may be an alternative, if the 
width of the caliper is set at the largest difference desired.  At one point, Rosenbaum (1989) 
actually called optimal matching within calipers his “method of choice”.  He also pointed out 
that greedy matching, compared to optimal matching, was less likely to result in a complete 
matching of treated patients when calipers were used.  As a network problem, implementing 
caliper matching is as simple as removing links between treated patients and comparison 
patients for whom the difference in the matching variable is too large (Figure 4.3, Panel A). 
Another variation on full matching, proposed by Hansen (2004), was to limit the 
maximum size of the matched sets through the use of ratio caps.  Typical full matches do not 
constrain the number of treated patients matched to a comparison patient, or vice versa.  It is 
possible to have matched sets from an unconstrained full match that contain an extreme 
number of treated or control patients—e.g. a set with a 100:1 treated to comparison ratio.  
98 
Hansen notes that constraining the ratios in the final matched set should have some 
advantages in the precision of estimates based on the matched data.  He introduced the idea 
of thinning and thickening ratio caps that, when applied to the observed treatment odds, 
define the minimum and maximum ratios allowable for matching.  He defined these as 
follows.  Given observed Group 1:Group 2 treatment odds, YOBS, a thickening cap of u (> 1) 
and a thinning cap of l (< 1), the maximum matching ratio, YMAX,  is given by: 
YMAX : ¡ ÑjYOBSÒ Ó .F jYOBS Ô .. Ó Õ?jYOBSAd<ÖF jYOBS × . 
And the minimum matching ratio, YMIN, is given by: 
YMIN : ¡ ÕØYOBSÖ Ó .F ØYOBS Ô .. Ó Ñ?ØjYOBSAd<ÒF ØYOBS × . 
These ratio limits can be implemented through manipulation of the minimum and maximum 
values for the link capacity associated with links out of the source node to the treated patients 
and associated with links from the comparison patients into the sink node.  This involves 
replacing the 
 found in the capacity limits shown in Table 4.1 with the finite number 
determined by the formulas above. 
Table 4.2 shows what different values of the minimum and maximum allowable 
matching ratios would be for a given treatment rate and for different combinations of 
thinning and thickening caps.  For example, assuming Group 1 is the treatment group, a 
treatment proportion of 25% is the same as an observed treated odds of 1:3.  A thinning cap 
of 0.2 yields a minimum matching ratio of 1:15 and a thickening cap of 5 yields a maximum 
matching ratio of 2:1.  While the sets of caps shown in this table are symmetric, they need 
not be in practice.  Hansen (2004) gives some guidance on how to choose these caps. 
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Once the problem is fully specified, with or without calipers and with or without ratio 
caps, it can be solved using optimization algorithms.  SAS solves general minimum cost 
network flow problems using the primary network simplex algorithm developed by Ahuja, 
Magnanti, and Orlin (1993).  Because optimal matching results in 1:1 matches, it is actually a 
special case of minimum cost network flow problem called a linear assignment problem.  
While linear assignment problems can be solved with the simplex algorithm, it may be more 
efficiently solved by algorithms developed especially for such problems.  SAS employs one 
developed by Jonker and Volgenant (1987). 
The solution to a minimum cost network flow problem is a list of all links utilized to 
move the specified flow across the network.  For matching, we are not interested in links 
from the source node to the treated patients or from the comparison patients to the sink node, 
and instead we need look only at the links from the treated patients to the comparison 
patients.  Given the list of links, the next requirement is to identify connected components, 
defined as the set of nodes that are reachable from one another through the determined links.  
Identifying matched sets allows us to take account for them in the outcomes analysis.  This is 
essential for full matching, since the size and composition of the matched sets can vary.  
Identifying connected components from optimal matches is simple.  The two patients 
associated with a link are a connected component.  It is not possible for other patients to be 
reachable by those patients because the matched sets only include one patient from each 
study group.  In full matching, on the other hand, multiple treated patients can be matched to 
a single comparison patient, and vice versa.  In this case, we need to use a depth-first search 
to traverse the network solution to identify all records in each matched set (Tardos & 
Kleinberg, 2006). 
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SAS Macro Details 
 The fmatch.sas macro presented here is available from 
http://people.duke.edu/~hammill/software.  The macro utilizes optimization procedures 
available in SAS/OR, the operations research software available from SAS Institute, to solve 
the network problems described above.  This macro transforms the input dataset into the 
format required by SAS/OR and appropriately specifies the constraints for the requested 
match type and match options.  The macro does not estimate a propensity score, but instead 
requires that it, or any other quantity to be used for matching, is pre-calculated and available 
on the data set.  There is some other, minor data preparation that must occur before calling 
the macro. 
The macro requires users to specify an input dataset, the matching variable, the study 
group variable, and the record-level identifier.  The matching variable must be numeric and is 
typically the estimated propensity score or the linear predictor from the treatment model.  
The study group variable typically reflects assigned treatment and must be a 2-level numeric 
variable.  The first level of this variable, sorted numerically, defines Group 1 and the other 
defines Group 2.  In this macro, the ordering of this variable is unimportant.  A reverse-coded 
group variable will yield identical results.  The record-level identifier can contain either 
numeric or character values, but must uniquely identify the records in the input dataset.   
 The default matching method used by the macro is full matching, but users may 
request an optimal match instead.  Additionally, users may specify a stratification variable in 
the macro call, to request that matching occur within strata.  For both unstratified and 
stratified full matching, the macro uses the network simplex algorithm described above.  For 
unstratified optimal matching without calipers (option described below), the macro uses the 
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linear assignment algorithm provided by SAS.  For unstratified optimal matching with 
calipers and for all stratified optimal matches, however, the macro uses the network simplex 
algorithm.  For stratified optimal matches, this is done because of the possibility that the 
number of matches to be made is less than the linear assignment algorithm expects (see Table 
4.1).  Regardless of the problem set-up, the linear assignment algorithm always expects 
?mÙF mÚA matches to be made.  For stratified matches where some strata have mÙFÛ Ô mÚFÛ 
while others have mÙFÛ M mÚFÛ, the actual number of matches to be made will be less than 
?mÙF mÚA and the linear assignment algorithm will report the solution to be, incorrectly, 
infeasible.  For unstratified optimal matching with calipers, it may not be possible to make 
?mÙF mÚA matches due to the caliper-limited number of potential links between patients in 
each study group.  Figure 4.3, Panel A shows how this might happen.  The algorithm would 
expect to make 5 matched sets where only 4 are possible.  In this case (Figure 4.3, Panel B), 
extra arcs are created by the macro from all treated patients to an “excess” node and from 
that “excess” node to all comparison patients.  The weight of these links are set high such 
that they are only used as a last resort to accommodate flow that would otherwise not be able 
to flow through the network.  While this leaves some patients unmatched who we would 
otherwise expect to be matched, it avoids the optimization algorithms from reporting the 
problem as infeasible. The links utilized to direct flow for the 4 resulting matched sets will 
still reflect minimum cost.  
 Other macro options that can be specified are calipers and ratio caps, neither of which 
are used by default.  To request calipers matching, users must specify the width of the 
calipers.  This width can either be given directly or given as a multiple of the standard 
deviation.  To constrain the size of the matched sets within full matching, users can specify 
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the thinning or thickening ratio caps, discussed above, to be used.  Thinning caps must be < 1 
and thickening caps must be > 1.  It should be noted that the thinning and thickening caps are 
applied to the observed Group 1:Group 2 odds.  For stratified matches, these odds and ratio 
limits are determined within each stratum. 
Two output datasets are created for the user.  The link-level output dataset includes 
one record for every pair of linked records and contains the distance on the matching 
variables between each pair.  The main, patient-level output dataset, includes one patient per 
record, along with a variable to identify the set number to which that patient belongs.  Each 
record also includes the number of treated patients in the set, the number of comparison 
patients in the set, and the total number of patients in the set, which allows for the creation of 
individual or set weights as desired.  The patient-level dataset is easily merged back to the 
source data.  Both of these datasets include the stratification variable, if one was used. 
A sample macro call is shown in Figure 4.5.  Samples of the two output datasets 
created are shown in Figure 4.6 and 4.7.  The full code for the macro is shown in Appendix 
2. 
 
Clinical Example 
To demonstrate this macro, we used data from the Acute Decompensated Heart 
Failure National Registry (ADHERE) Core 1 registry (Adams, et al., 2005), which included 
patients hospitalized with acute decompensated heart failure from 2001 to 2003.  The 
exposure of interest is receipt of high-dose intravenous loop diuretics.  As the original study 
(Peacock, et al., 2009) noted, the optimal dose of diuretics is uncertain and some safety 
concerns had been raised about high doses of diuretics.  For this analysis, a high dose of 
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intravenous loop diuretics was defined as 160 mg within the first 24 hours of medication 
initiation.  The comparison group comprised those who received <160 mg. There were 
43,434 patients within 236 hospitals in the study population.  Of these patients, 9,469 
(21.8%) were treated with a high dose of diuretics. The hospital-level proportion of patients 
received high-dose diuretics varied substantially, ranging from under 2% to almost 56%. 
We estimated a propensity score treatment model and used the linear predictor from 
this model to match patients in the high dose group with patients in the low dose group under 
multiple matching specifications.  The treatment model was specified as a hierarchical 
logistic regression model, allowing for hospital-level random intercepts.  Independent 
variables included in this model (shown in Table 4.3) were those deemed to be factors that 
could potentially confound the relationship between diuretic dose and in-hospital mortality, 
the outcome studied in the manuscript referenced above.   
We used the fmatch.sas macro to perform optimal matching and full matching.  For 
comparison, we also performed greedy matching.  For optimal matches, we performed both 
an unrestricted match and a match with calipers.  For full matching, we performed an 
unrestricted match as well as a match with thinning/thickening ratio caps and a match with 
calipers.  For greedy matching, we performed 1:1 and 2:1 (treatment:comparison) matches 
with and without calipers.  For all caliper matches, the width of the caliper was set to 0.2 
standard deviations (SD) of the linear predictor, as recommended by Austin (2011).  Of 
special interest was the impact of stratification on each of these matches.  Therefore, all 
matches were performed both unstratified and stratified by hospital.   
Several metrics were used to compare these different matches.  First, we calculated 
the total distance between all matched patients from the treatment and comparison groups on 
104 
the matching variable, the linear predictor from the treatment model.  We also summarized, 
for matches that did not use calipers, the proportion of matches for which this distance was 
over 0.2SD of the matching variable.  We calculated the percentage of patients in each of the 
treatment and comparison groups that were matched.  We report the amount of computing 
time each match took to complete.  And we calculated the standardized difference between 
the matched study groups for selected variables.   
 
Clinical Example Results 
As an objective measure of match quality, the total distance between all matched 
pairs of records is useful.  Among the unstratified, unrestricted matches, Table 4.4 shows 
how well full matching performs compared to all other types of matches.  Even though full 
matching utilizes all records in both the treatment and comparison groups, its total distance is 
substantially lower than similarly unrestricted optimal and greedy 1:1 matches, both of which 
leave over 70% of the comparison patients unmatched.  The proportion of matches after full 
matching with a distance over 0.2SD is also minimal, whereas both optimal and greedy 
matches result in about 5% of matches that exceed that distance.  While greedy matching was 
the quickest method to finalize the matches, as might be expected, full matching was about 8 
times quicker to finish than optimal matching.  [Actual computing times will vary by specific 
hardware available, but the trends we observe should hold.] 
Among stratified, unrestricted matches, full matching does not display quite the 
advantages reported above.  In this case, the cost of matching all comparison patients to 
treated patients within hospitals comes at a cost reflected in the total distance metric.  And all 
three matches—full, optimal, and greedy (1:1)—result in nearly 9% of matched pairs having 
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a distance greater than 0.2SD on the linear predictor.  There was no time advantage for any 
matching method when stratification was used.  The limited number of potential matches 
resulted in very quick processing times even for those that required the use of optimization 
algorithms. 
There are a few reasons for the differences in performance observed between 
unstratified and stratified full matching.  The first is the often limited number of treated 
patients within a given hospital, which is associated with the total number of patients at that 
hospital.  The second, which is related, is the lack of common support across the range of 
estimated propensity scores within each hospital.  Consider an extreme example.  When there 
is only 1 treated patient at a hospital, all comparison patients will be matched to that patient 
in 1 large matched set, by default.  It is nearly certain that some of those comparison patients 
will have a value of the linear predictor that is far from that of the treated patient.  When 
there are a large number of treated patients at a hospital (or when the match is unstratified) it 
is more likely that there will be patients from both study groups at all levels of the estimated 
propensity score.  Figure 4.4, Panel A confirms this notion.  When there are small numbers 
of treated patients at a hospital (i.e. <20), the proportion of matched sets created by 
unrestricted full matching that have a large difference on the matching variable is high.  As 
the number of treated patients increases, this proportion decreases.  For large hospitals with 
sufficient numbers of treated patients (Figure 4.4, Panel B) the proportion of matches having 
a large difference is low. 
It may be advisable, therefore, to either only pursue stratified full matching for large 
hospitals with sufficient numbers of treated patients or to perform stratified full matching 
after disallowing distant matches.  One way to do the latter is through trimming (Stürmer, 
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2010), which reduces the data in both study groups to the region of common support.  
Trimming is done by removing treated patients from the data who have values of the 
estimated propensity score outside the range found for the comparison patients, and vice 
versa.  We do not perform trimming here, but instead use calipers to restrict potential 
matches.  By defining calipers, the maximum distance acceptable for a match, one has still 
effectively trimmed the data.  Note that both trimming and calipers can be used for stratified 
and unstratified matches. 
Table 4.4 shows the effect of the use of calipers on the different types of matches.  
Because the unrestricted, unstratified full match did not result in many distant matches, the 
use of calipers did not generate much improvement in the total distance.  It did substantially 
speed up the computing, however.  The results were similar for unstratified optimal 
matching—a slight improvement in total distance with a noticeable speed improvement.  For 
both of these matches, only a handful of patients that were able to be matched without the 
caliper restrictions were not able to be matched with them—1 patient remained unmatched 
by full matching and 10 patients remained unmatched by optimal matching.  When calipers 
were used in conjunction with unstratified greedy matching, the total distance dropped 
substantially, but at the expense of the number of matched patients.  Over 300 treated 
patients that were matchable when using optimal matching were not able to be matched by 
greedy matching.  It is worrisome when this many patients in the treated group are not able to 
be matched to comparison patients, as incomplete matching of treated patients has been 
shown to be a source of bias when estimating the treatment effect (Rosenbaum & Rubin, 
1985).  This pattern was seen among stratified matches as well.  The use of calipers yielded 
107 
lower total distance and lower numbers of matched patients.  Again, the decline in number of 
matched patients was greatest for greedy matching.   
The application of ratio caps to full matching, to restrict the size of matched sets, did 
not result in close matches.  Intuitively, this makes sense.  When the matching ratios are 
limited, excess comparison patients that would have made close matches to a particular 
treated patient must be reassigned, at a higher cost, to another treated patient.  Whatever gain 
these ratio caps may offer for precision of estimates based on the matched sets may be offset 
by the imbalance they induce in the matched sets.  For unstratified full matching, 0.5x 
thinning and 2x thickening caps led to a total distance that was orders of magnitude greater 
than the unrestricted match. Additionally, nearly a quarter of all matches had a distance 
greater than 0.2SD.  Less restrictive 0.2x thinning and 5x thickening caps still resulted in 
noticeable gains in both total distance and proportion of distant matches, compared to the 
unrestricted match.  In addition, these restricted matches took 5 to 10 times longer to 
complete.  Some increase in total distance was seen for the stratified full matches, but the 
increase was not as large as for the unstratified full matches. 
The minimum and maximum study group ratios in the matched sets from full 
matching are shown in Table 4.5.  The effect of ratio caps is immediately noticeable.  The 
minimum and maximum treatment-to-comparison ratios without caps are 1:108 and 11:1.  
With 0.5/2 thinning/thickening caps, these fall to 1:8 and 1:1. With 0.2/5 caps, these fall to 
1:18 and 2:1.  Reductions in these extremes are not seen for the stratified matches, since 
these ratios were adjusted at the hospital level and there were hospitals with treatment rates 
less than 2%. 
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The use of 2:1 fixed ratio greedy matching in this dataset also resulted in poor 
matches.  Nearly half of the matches made without stratification and over 36% of matches 
made with stratification had a distance over 0.2SD of the matching variable.  Applying 
calipers reduced the total distance, but did not yield complete matches.  Neither of the 
stratified 2:1 greedy matches nor the unstratified 2:1 greedy match with calipers resulted in 2 
comparison patients for each treated patient.  For these matches, between 15% and 30% of 
the matched sets only had 1 comparison patient.  For matches performed within hospitals, 
this should have been expected, since many hospitals had treatment rates greater than 33%, 
the maximum that will support a 2:1 match.  When calipers were used, the pool of potential 
matches shrank further. 
To see the practical effects of each matching method on the distribution of potential 
confounders in the matched groups, Table 4.6 shows the standardized differences for 
selected covariates that were particularly unbalanced between study groups in the complete, 
unmatched data.  The rule of thumb typically used is that a difference of 10% or greater 
indicates substantial imbalance (Rosenbaum & Rubin, 1985a-match), although well-balanced 
study groups will typically exhibit much lower values.  Note for the unstratified, unrestricted 
full match that none of the standardized differences shown are greater than 1.4%, for 
example.  Even for the stratified, unrestricted full match, which led to a higher total distance 
between matched pairs, all standard differences are below 3.0%.  The use of calipers with full 
matching did little to change these values, but applying the very restrictive 0.5/2 ratio caps 
resulted in noticeable increases in the standardized differences for several variables.  The 
standardized difference for blood urea nitrogen (BUN) was 8.8% for the stratified full match 
with these caps applied. 
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The standardized differences associated with both unstratified optimal matches and 
both unstratified greedy 1:1 matches were very low.  The unstratified 2:1 greedy matches led 
to substantial imbalance, however.  Perhaps reflecting the relatively higher proportion of 
matched sets with differences on the matching variable over 0.2SD, the stratified, 
unrestricted optimal and greedy matches had a few variables with standardized differences 
between the study groups over 5%.  The use of calipers in these cases did work to reduce 
these differences.  As with the unstratified 2:1 greedy matches, the attempt to match multiple 
comparison patients to each treated patient within hospitals led to unacceptable imbalances. 
It is interesting to note that even though nearly 9% of the matched pairs within the 
stratified full match had a large (>0.2SD) difference on the matching variable, the 
standardized differences did not seem to reflect this in the same way the optimal and 
matches, with a similar proportion of distant matches, did.  The reason for this has to do with 
the full matching results themselves.  A comparison patient with a distant match to a treated 
patient within a matched set may be but one of 10 or 20 comparison patients matched to that 
same treated patient; and because the values for all of these comparison patients are 
averaged, the contribution of any single comparison patient to the standardized difference is 
only 5% to 10% what it would be if they were the only comparison patient matched to that 
treated patient.  In other words, there is greater tolerance of imperfect matches in full 
matching than there is in optimal or greedy matching. 
Discussion
 Full matching has been shown to have certain advantages over both greedy matching 
and optimal matching, not the least of which is the incorporation of all patients into the final 
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matched sets.  The macro presented here makes the implementation of full matching methods 
possible.  Using calipers to restrict the possible links full matching can make is also 
recommended.  In addition to reducing the computing time necessary to arrive at a solution, 
the use of calipers results in only minimal, if any, loss of patients in the final matched sets.  If 
there is a need to perform stratified matching, it is also recommended that researchers 
perform full matching with calipers.  The use of calipers in this situation is, perhaps, more 
essential, if the data contain small hospitals or hospitals with insufficient numbers of treated 
patients. 
 Data set size is likely to be the factor that most limits the usefulness of this macro.  
The clinical example above had a fairly substantial sample size of over 40,000 patients and 
ran without problems.  Of course, the maximum size of the data set size that can be processed 
by the macro is determined more directly by the computing environment in which it is run.  
Specifically, the available memory is critical.  SAS/OR optimization procedures perform 
tasks in memory, and the memory workpace needs of these procedures expand at non-linear 
rate with respect to the sample size. 
 The variable size of the matched sets from full matching requires attention during 
analysis, through either the use of appropriate cluster-level weights or cluster-level 
conditional statistical methods.  Analyses that completely ignore the clustering by matched 
sets will not yield correct results.  It has been recommended that the matched sets be 
weighted by the number of treated patients in the set.  As for most other matches, an 
outcomes analysis with this weighting will yield the average treatment effect among the 
treated.   
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 The use of greedy matching within analyses that use propensity scores has been 
prevalent primarily because it is an easy matching method to implement.  With a macro, like 
the one we present here, available to perform optimal and full matching, maybe this trend can 
change.  If researchers would like to perform propensity score matching, the use of full 
matching methods should be encouraged.   
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Figure 4.1 - Network representation of unstratified matching. Panel A shows the nodes and 
available links. Nodes include a flow source (), a flow sink (), treated patients (1–5) and 
comparison patients (a–e). Gray lines indicate potential links between nodes. Panel B shows 
an example solution for optimal matching. Panel C shows an example solution for full 
matching.
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Figure 4.2 - Network representation of stratified matching.  Panel A shows the nodes and 
available links. Nodes include a flow source (), a flow sink (), treated patients (1–5) and 
comparison patients (a–e). Gray lines indicate potential links between nodes. Panel B shows 
an example solution for optimal matching. Panel C shows an example solution for full 
matching. 
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Figure 4.3 - Network representation of matching with calipers. Panel A shows the nodes and 
available links. Nodes include a flow source (), a flow sink (), treated patients (1–5) and 
comparison patients (a–e). Gray lines indicate potential links between nodes. All potential 
links shown between patients in the treatment (T) and comparison (C) groups are those with 
distance less than the given caliper width. Panel B shows an example solution for optimal 
matching with calipers, which required the use of an excess node (). 
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Figure 4.4 - Proportion of differences on the matching variable greater than 0.2SD within 
matched sets at each site.  Panel A shows these proportions by number of treated patients at 
the site.  Panel B shows these proportions by number of total patients at the site, with sites 
additionally categorized by number of treated patients. 
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Figure 4.5 - Sample macro call for the full matching macro, FMATCH.SAS 
 
 
* Macro available at: 
* http://www.duke.edu/~hammill/software.html 
;
%include “fmatch.sas”; 
%macro fmatch( 
    INDS          = mydata, 
    MATCHVAR      = ps, 
    GROUPVAR      = trt,
    IDVAR         = ptid,
    STRATVAR      = site, 
    CALIPER       = 0.5, 
    CALIPER_TYPE  = sd, 
    RATIO_MAX     = 10, 
    RATIO_MIN     = 0.1, 
    MATCHTYPE     = full, 
    OUTLINKS      = matchlinks, 
    OUTDS         = matchrecs 
);
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Figure 4.6 - Sample records from the link-level output dataset generated by the full matching 
macro, FMATCH.SAS 
 
 
 GRP1    GRP2   STRATA      DIST 
 A153    Q224      1      0.05424 
 K197    Q224      1      0.49399 
 B171    Q224      1      0.06481 
 G136    M268      1      0.44148 
 L146    M268      1      0.42249 
 Q249    M268      1      1.17942 
 K193    M268      1      0.80213 
 H126    M268      1      0.38412 
 W139    E137      2      0.15742 
 W139    R016      2      0.00820 
               ... 
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Figure 4.7 - Sample records from the record-level output dataset generated by the full 
matching macro, FMATCH.SAS 
 
 
STUDY_ID    TRT   STRATA    SETNUM    SET_N1    SET_N2    SET_N 
  A153       0       1         1         3         1        4
  B171       0       1         1         3         1        4
  K197       0       1         1         3         1        4
  Q224       1       1         1         3         1        4
  G136       0       1         2         5         1        6
  H126       0       1         2         5         1        6
  K193       0       1         2         5         1        6
  L146       0       1         2         5         1        6
  M268       1       1         2         5         1        6
  Q249       0       1         2         5         1        6
  E137       1       2         4         1         2        3
  R016       1       2         4         1         2        3
  W139       0       2         4         1         2        3
                                    ...  
 
  
 
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Table 4.1. - Network characteristics associated with optimal matching and full matching, performed with and without stratification 
Network Characteristic 
Unstratified Stratified 
Optimal Matching Full Matching Optimal Matching Full Matching 
Total Network Flow (in units) ?mÙF mÚA Ü Ý?mÙF mÚA ¤ min¥ÞÛ< NmÙFÛF mÚFÛP Ü ¤ max¥ÞÛ< NmÙFÛF mÚFÛP 
Link Costs    
 ßT à ág â T¨ @ g¨â ¯â T¨ @ g¨âF ßTF ág same stratum     no linkF ßTF ág different stratum 
  à ßT 0 0 
 ág à  0 0 
Link Capacity [Min, Max]     
 ßT à ág -F . -F . 
  à ßT ¡.F .F mÙ × mÚ-F .F mÙ Ô mÚ .Fã ¯.F .F mÙFÛ × mÚFÛ-F .F mÙFÛ Ô mÚFÛ .Fã 
 ág à  ¡-F .F mÙ × mÚ.F .F mÙ Ô mÚ .Fã ¯-F .F mÙFÛ × mÚFÛ.F .F mÙFÛ Ô mÚFÛ .Fã 
WheremÙ = # of treated patients mÙFÛ = # of treated patients in strata h mÚ = # of comparison patients  mÚFÛ = # of comparison patients in strata h mÛ = # of strata ßT = Treated patient iT¨  = Value of the matching variable for treated patient i  ág = Comparison patient jg¨  = Value of the matching variable for comparison patient j = source node = Sink node 
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Table 4.2 - Ratio bounds for full matching associated with different combinations of thinning 
caps, thickening caps and treatment group proportions 
Group 1 
Proportion 
Observed 
Group 1:Group 2 
Thinning  
Cap 
Thickening 
Cap 
Group 1:Group 2  
Bounds for Matching 
Minimum Maximum 
0.05 1:19 0.8 1.25 1:24 1:15 
  0.5 2 1:38 1:9 
  0.2 5 1:95 1:3 
  0.1 10 1:190 1:1 
      
0.25 1:3 0.8 1.25 1:4 1:2 
  0.5 2 1:6 1:1 
  0.2 5 1:15 2:1 
  0.1 10 1:30 4:1 
      
0.40 1:1.5 0.8 1.25 1:2 1:1 
  0.5 2 1:3 2:1 
  0.2 5 1:8 4:1 
  0.1 10 1:15 7:1 
      
0.50 1:1 0.8 1.25 1:2 2:1 
  0.5 2 1:2 2:1 
  0.2 5 1:5 5:1 
  0.1 10 1:10 10:1 
      
0.60 1.5:1 0.8 1.25 1:1 2:1 
  0.5 2 1:2 3:1 
  0.2 5 1:4 8:1 
  0.1 10 1:7 15:1 
      
0.75 3:1 0.8 1.25 2:1 4:1 
  0.5 2 1:1 6:1 
  0.2 5 1:2 15:1 
  0.1 10 1:4 30:1 
      
0.95 19:1 0.8 1.25 15:1 24:1 
  0.5 2 9:1 38:1 
  0.2 5 3:1 95:1 
  0.1 10 1:1 190:1 
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Table 4.3 - Patient characteristics included as independent variables in the treatment model  
 
Category Characteristic 
Demographics Age (years) 
 Gender (Male, Female) 
 Race (White, Black, Other/unknown) 
  
Medical History Anemia 
 Atrial fibrillation 
 Chronic renal insufficiency 
 Chronic obstructive pulmonary disorder 
 Coronary artery disease 
 Diabetes mellitus 
 Hypercholesterolemia 
 Hypertension 
 Peripheral vascular disease 
 Prior myocardial infarction 
 Smoker (current) 
  
Medical devices in place Pacemaker 
 Implantable cardioverter defibrillator 
  
Initial examination Fatigue 
 Rales 
 Edema 
 Congestion 
 Ejection fraction 
 Systolic blood pressure 
 Blood urea nitrogen (mg/dL)  
 Serum sodium (mEq/L) 
 Hemoglobin (g/dL) 
 
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Table 4.4 - Metrics describing match results, by matching method  
 
Matching Method 
Total 
Distance 
% Matches with 
Distance > 0.2 SD 
% Treated 
Patients Matched 
% Comparison 
Patients Matched 
Computing Time 
Used (minutes) 
Unstratified matches 
Full matching      
 Unrestricted* 47.0 0.1 100 100 29 
 0.2SD calipers 40.0 -- 100 99.9 2 
 0.5 / 2 ratio caps** 7278.2 24.6 100 100 336 
 0.2 / 5 ratio caps 1487.2 6.8 100 100 155 
Optimal matching      
 Unrestricted 293.5 4.9 100 27.9 232 
 0.2SD calipers 273.6 -- 99.9 27.8 9 
Greedy matching      
 1:1 match, unrestricted 297.9 5.0 100 27.9 < 1 
 1:1 match, 0.2SD calipers 20.5 -- 96.7 27.0 < 1 
 2:1 match, unrestricted 3994.5 49.3 100 55.8 < 1 
 2:1 match, 0.2SD calipers 106.9 -- 96.8 46.3 < 1 
Matches stratified by clinical site 
Full matching      
 Unrestricted 2258.4 8.9 100 100 < 1 
 0.2SD calipers 945.6 -- 98.4 91.2 < 1 
 0.5 / 2 ratio caps 3413.0 15.0 100 100 < 1 
 0.2 / 5 ratio caps 2334.4 9.2 100 100 < 1 
Optimal matching      
 Unrestricted 554.3 8.8 99.8 27.8 < 1 
 0.2SD calipers 257.0 -- 96.4 26.9 < 1 
Greedy matching      
 1:1 match, unrestricted 616.4 8.9 99.8 27.8 < 1 
 1:1 match, 0.2SD calipers 158.2 -- 93.7 26.1 < 1 
 2:1 match, unrestricted 2807.3 36.5 99.8 51.3 < 1 
 2:1 match, 0.2SD calipers 328.9 -- 93.7 44.7 < 1 
* Unrestricted matches are those without calipers or (for full matching) thinning and thickening ratio caps 
** Thinning, thickening ratio caps applied to observed treated:comparison ratio 
Abbreviation: SD = Standard deviation 
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Table 4.5 - Minimum and maximum treated-to-comparison ratios in matched sets resulting 
from full matching  
 
Full Matching Specification 
Minimum 
Treated:Comparison 
Maximum 
Treated:Comparison 
Unstratified   
 Unrestricted* 1:108 11:1 
 0.2SD calipers 1:108 11:1 
 0.5 / 2 ratio caps** 1:8 1:1 
 0.2 / 5 ratio caps 1:18 2:1 
Stratified   
 Unrestricted 1:142 10:1 
 0.2SD calipers 1:100 10:1 
 0.5 / 2 ratio caps 1:127 3:1 
 0.2 / 5 ratio caps 1:142 5:1 
* Unrestricted matches are those without calipers or thinning / thickening ratio caps 
** Thinning, thickening ratio caps applied to observed treated:comparison ratio 
Abbreviation: SD = Standard deviation
 
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Table 4.6 - Standardized differences for selected covariates between matched treatment and control groups, by matching method used  
 
Matching Method Anemia 
Coronary 
Artery Disease 
Chronic Renal 
Insufficiency 
Diabetes 
Mellitus Edema Age 
Blood Urea 
Nitrogen Hemoglobin 
Observed 14.0 8.4 25.5 24.3 25.9 21.8 27.4 14.8 
Unstratified matches 
Full matching         
 Unrestricted* 0.9 1.4 1.2 0.9 1.1 0.3 1.3 0.4 
 0.2SD calipers 1.0 1.3 1.3 0.7 1.1 0.4 1.3 0.2 
 0.5 / 2 ratio caps** 1.6 0.4 3.2 2.9 2.3 2.8 5.5 3.4 
 0.2 / 5 ratio caps 0.1 1.7 0.6 0.2 0.4 0.8 0.3 0.8 
Optimal matching         
 Unrestricted 0.7 1.3 2.4 0.7 1.4 0.1 4.0 1.8 
 0.2SD calipers 0.6 1.4 2.2 0.8 1.5 0.2 3.7 1.6 
Greedy matching         
 1:1 match, unrestricted 0.5 1.2 2.2 0.5 1.5 0.1 3.7 1.4 
 1:1 match, 0.2SD calipers 0.4 1.5 0.1 0.3 1.9 0.6 0.1 0.8 
 2:1 match, unrestricted 5.4 3.6 11.1 7.6 6.4 8.0 14.6 5.1 
 2:1 match, 0.2SD calipers 3.2 1.6 6.5 4.6 3.6 4.5 8.2 2.9 
Matches stratified by clinical site 
Full matching         
 Unrestricted 2.2 0.9 1.1 0.8 0.6 0.5 2.9 0.9 
 0.2SD calipers 2.8 1.2 0.9 0.7 0.2 0.6 3.3 1.2 
 0.5 / 2 ratio caps 0.7 0.8 3.8 2.8 3.7 3.4 8.8 1.8 
 0.2 / 5 ratio caps 2.1 0.8 1.2 0.7 0.7 0.8 3.2 1.2 
Optimal matching         
 Unrestricted 1.5 1.1 6.3 3.6 1.6 1.5 8.9 1.9 
 0.2SD calipers 0.1 0.1 3.6 1.7 0.1 0.7 4.6 0.7 
Greedy matching         
 1:1 match, unrestricted 1.5 1.2 6.2 4.3 1.5 1.5 9.1 2.0 
 1:1 match, 0.2SD calipers 0.5 0.3 2.0 0.9 0.9 1.3 2.6 0.2 
 2:1 match, unrestricted 6.7 6.1 14.7 11.7 11.4 10.8 18.5 6.3 
 2:1 match, 0.2SD calipers 2.0 2.3 6.8 4.7 3.7 3.4 9.5 2.5 
* Unrestricted matches are those without calipers or (for full matching) thinning and thickening ratio caps 
** Thinning, thickening ratio caps applied to observed treated:comparison ratio 
Standardized differences presented as % of SD  
Abbreviation: SD = Standard deviation 
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CHAPTER 5 
CONCLUSION 
For research questions regarding the real-world effectiveness and safety of medical 
therapies and devices, researchers must often rely on observational data.  Unlike controlled 
clinical trials, the assignment of treatment to patients in routine medical practice is not 
randomized.  One class of methods used extensively by researchers to address this selection 
problem is propensity score methods.  The role of the healthcare provider has not typically 
been accounted for when propensity score methods are employed, despite the fact that 
provider, by imparting an effect on both patient-level treatment assignment and patient-level 
outcomes, is a potential confounding factor.
When a healthcare provider has measurable impacts on both a patient’s treatment 
assignment and their downstream outcomes, simulation results demonstrated that not 
accounting for these provider effects could lead to biased estimates of treatment effect when 
using propensity score methods. This was true specifically when a provider’s direct effect on 
treatment was correlated with their effect on outcome; a situation that occurs when providers 
having better patient outcomes use therapies at higher (or lower) rates than other providers.  
Propensity score methods that incorporated provider were able to control this error.  Even 
when provider effects on treatment and outcome were uncorrelated, it was still important to 
account for provider in the propensity score treatment model.  Failure to do so resulted in 
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confidence intervals around the estimated treatment effect that were either substantially too 
wide or too narrow, depending on the estimation methods used. 
It may be that these methods are applicable only to a specific subset of clinical 
research questions.  Researchers should take the time to understand if the question at hand 
could involve confounding by provider.  One question to ask is whether or not there is a 
reasonable expectation that provider has an effect on treatment and outcome.  It is often 
easier to expect that providers exhibit differential treatment propensities.  Some providers 
may have a preference for certain therapies as first-line therapies and others as second-line, 
while other providers prefer the opposite.  Some providers are more likely to incorporate new 
therapies or techniques more quickly than others.   As a result, there is often a noticeable 
distribution of treatment rates among providers.  Considering whether or not providers have 
an effect on outcome can be more difficult, as this can vary by the outcome, the time horizon, 
the treatment setting, etc.  In general, short-term outcomes associated with direct treatment 
(e.g. surgical procedure) or prolonged care (e.g. hospital-based care) are more likely to result 
in stronger provider effects on outcomes.  As a preliminary step in data analysis, the presence 
of provider effects on treatment and outcome can be checked using hierarchical models and 
provider-specific random intercept terms.  The extent of variability of the random intercepts 
for both treatment and outcome is a guide to the strength of these effects.  To prevent 
estimating the treatment effect prematurely, we recommend modeling the outcome, at this 
stage, using just the comparison group (or just a single study group, if both include treated 
patients).
Researchers should also check to see that the distribution of provider treatment rates 
is not extremely bimodal.  If one group of providers has a very high treatment rate and 
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another group has a very low treatment rate, there may not be enough within-provider 
variation to allow for appropriate comparisons when adjusting for provider in the analysis.
In fact, if there are too many providers who exclusively treat or exclusively don’t treat 
patients with the treatment of interest, methods that control for provider are not even 
possible.  Ideally, the distribution of provider treatment rates should be somewhat normally 
distributed.  Data may include too many providers who exclusively (or nearly exclusively) 
treat or don’t treat patients for a few reasons.  First, it may be that provider, in the data, 
reflects the practice of a single physician.  Any single physician is more likely than a group 
of physicians to have strong preferences for a particular therapy or course of treatment.  
When provider reflects a group of physicians in a practice or in a hospital, there is usually 
variability in the preferences across those physicians.  Second, it may be there are many 
providers who seem to exclusively treat (or don’t treat) because the number of patients per 
physician in the data is very small.  If there is interest in incorporating provider into 
propensity score methods, a relatively large number of patients per provider is desirable. 
Finally, as with any propensity score analysis, researchers need to ensure that they 
have the data necessary to fully characterize the treatment assignment.  A critical assumption 
of all these methods is that there is no unmeasured confounding.  Whether or not provider is 
included as a factor in the propensity score treatment model or not, data that lacks important 
confounders will lead to biased treatment estimates.  
 Once a researcher is comfortable with the idea that their clinical question may involve 
confounding by provider, estimation of the treatment effect still needs to be done properly.
After including provider in the treatment model, there are a few directions the analysis can 
go.  If there is interest in using inverse probability of treatment weighting methods, strong 
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consideration should be given to the Lunceford estimator and to doubly robust methods.  If 
there is interest in using propensity score matching, consideration should be given to full 
matching.  Patients within the resulting matched sets either need to be appropriately weighted 
for analysis or the use of GEE methods is required. 
Full matching may not be familiar to most analysts.  A criticism of typical 1:1 
propensity score matching, whether stratified by provider or not, is that the data from many 
patients are not utilized in the outcomes analysis.  Full matching addresses this issue by 
optimally assigning all treated patients and all comparison patients into variably-sized 
matched sets.  The result is closer matches between study groups than those obtained by 
other matching methods.  For comparative effectiveness research, where head-to-head 
comparisons of therapies involve two study groups that both include treated patients, full 
matching should be considered as a primary matching method.  Full matching is not currently 
utilized frequently because it is difficult to implement.  A macro to perform full matching by 
leveraging SAS optimization procedures was presented.   
There are a few obvious extensions of this work that need to be explored.  The first is 
how well propensity score methods that incorporate provider perform when the outcome of 
interest in dichotomous.  We showed that these methods are appropriate when the outcome is 
continuous and the treatment effect reflects a simple difference between mean group 
outcomes.  Quantities of interest for binary data include risk differences, risk ratios, and odds 
ratio.  It may also be important to examine the situation where treatment models are entirely 
provider-specific. We simulated data scenarios where providers had baseline levels of 
treatment that were higher or lower than average, but we did not otherwise alter the treatment 
assignment mechanism by provider.  This may not reflect reality, but it’s not clear if provider 
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-specific intercepts in a treatment model are sufficient to produce correct treatment effect 
estimates or if the treatment model would need to more closely reflect the each provider’s 
treatment process.  
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APPENDIX 1 
MISCELLANEOUS SAS CODE FOR ESTIMATING PROPENSITY SCORES, 
CALCULATING WEIGHTS, PERFORMING MATCHING, AND ESTIMATING 
APPROPRIATE TREATMENT EFFECT ESTIMATES 
/****************************************************************
* Generated data set information                                 * 
*   Data set name = DS                                           * 
*   Variables:                                                   * 
*     A = Treatment (0/1)                                        * 
*     Y = Outcome (continuous)                                   * 
*     X1 = Covariate (0/1)                                       * 
*     X2 = Covariate (continuous)                                * 
*     X3 = Covariate (continuous)                                * 
*     X4 = Covariate (continuous)                                * 
*     IDX = Patient ID variable                                  * 
*     SITE = Cluster ID variable                                 * 
*                                                                * 
* For greedy matching, there is a macro (gmatch.sas) at          * 
*    http://people.duke.edu/~hammill/software                    * 
* that can be used for matching on a single variable like PS.    * 
 ****************************************************************/ 
/****************************************************************
* Pooled propensity score treatment model 
*  - Propensity score (PS1) and linear predictor (XB1) saved back 
*    onto input dataset DS 
 ****************************************************************/ 
proc logistic descending data=ds; 
    model a = x1 x2 x3 x4; 
    output out=ds pred=ps1 xbeta=xb1; 
run;
/****************************************************************
* Cluster-specific propensity score treatment model #1 
*  - Random effects (intercept only) for cluster
*    [random slopes can be added, if desired] 
*  - Propensity score (PS2) and linear predictor (XB2) saved back 
*    onto input dataset A 
*  - Sometimes you need to specify a less stringent ABSPCONV value 
*    (PROC GLIMMIX statement option) than the default of 1E-8 for 
*    this model to converge 
 ****************************************************************/ 
proc glimmix data=ds abspconv=1e-4; 
    class site; 
    model a = x1 x2 x3 x4 / link=logit dist=bin s; 
    nloptions maxiter = 50; 
    random intercept / subject=site; 
    output out=ds pred(ilink)=ps2 pred=xb2; 
run;
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/****************************************************************
* Cluster-specific propensity score treatment model #2 
*  - Fixed effects (intercept only) for cluster
*    [cluster-specific slopes can be created by adding
*     interactions with the cluster variable, if desired] 
*  - Propensity score (PS3) and linear predictor (XB3) saved back 
*    onto input dataset A 
 ****************************************************************/ 
proc logistic descending data=ds; 
    class site; 
    model a = site x1 x2 x3 x4; 
    output out=ds pred=ps3 xbeta=xb3; 
run;
/****************************************************************
* Create inverse probability of treatment weights (W1, W2, W3)
* based on estimated propensity scores (PS1, PS2, PS3).
 ****************************************************************/ 
data ds; 
    set ds; 
    * Keep estimated probabilities of treatment (A = 1) for Lunceford
    * estimator, doubly robust estimators, etc. 
    ; 
    e1 = ps1; 
    e2 = ps2; 
    e3 = ps3; 
    * When A = 0, need to flip b/c we need the probability of receiving
    * the treatment actually received 
    ; 
    if a = 0 then do; 
        ps1 = 1 - ps1; 
        ps2 = 1 - ps2; 
        ps3 = 1 - ps3; 
    end; 
    w1 = 1 / ps1; 
    w2 = 1 / ps2; 
    w3 = 1 / ps3; 
run;
/****************************************************************
* Create matched study groups using 1:1 unstratified greedy
* matching with calipers = 0.2SD 
 ****************************************************************/ 
%gmatch(
    inds = ds, 
    matchvar = xb1, 
    groupvar = a, 
    idvar = idx, 
    caliper = 0.2, 
    caliper_type = SD, 
    randseed = 20150603, 
    outds = matched1 
)
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/****************************************************************
* Create matched study groups using 1:1 cluster-stratified greedy
* matching with calipers = 0.2SD 
 ****************************************************************/ 
%gmatch(
    inds = ds, 
    matchvar = xb1, 
    groupvar = a, 
    idvar = idx, 
    stratvar = site, 
    caliper = 0.2, 
    caliper_type = SD, 
    randseed = 20150603, 
    outds = matched2 
)
/****************************************************************
* Create matched study groups using variable ratio unstratified
* full matching with calipers = 0.2SD 
 ****************************************************************/ 
%fmatch(
    inds = ds, 
    matchvar = xb1, 
    groupvar = a, 
    idvar = idx, 
    caliper = 0.2, 
    caliper_type = SD, 
    matchtype = FULL, 
    outds = matched3 
)
/****************************************************************
* Create matched study groups using variable ratio cluster- 
* stratified full matching with calipers = 0.2SD 
 ****************************************************************/ 
%fmatch(
    inds = ds, 
    matchvar = xb1, 
    groupvar = a, 
    idvar = idx, 
    stratvar = site, 
    caliper = 0.2, 
    caliper_type = SD, 
    matchtype = FULL, 
    outds = matched4 
)
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/****************************************************************
* Create ETT weights assuming A is coded 0/1 and "treatment" is 
* when A = 1.  The FMATCH.SAS macro outputs set counts based on 
* the sorted value of A, so it is essential to understand your 
* data.  For full matching results based on these data, SET_N1 
* (produced by the macro on the output dataset) is the count of 
* comparison patients in the matched set while SET_N2 is the
* count of treated patients in the matched set. 
 ****************************************************************/ 
data matched3; 
    set matched3; 
    select (a); 
        when (0) SETWT = set_n2 / set_n1; 
        when (1) SETWT = 1; 
        * no otherwise; 
    end; 
run;
/****************************************************************
* For analysis code below: 
*   - Be sure to use appropriate dataset (DS, MATCHED1, etc.) 
*   - Use desired weight (W1, W2, etc.) -- Note that you can
*     create a null weight (e.g. W0 = 1) for use with matched 
*     data that is otherwise unweighted 
*   - Some of this code may need to be put within a macro wrapper 
*     b/c of %do loops, etc. 
 ****************************************************************/ 
/****************************************************************
* Pooled t-test 
 ****************************************************************/ 
proc ttest data=ds; 
    var y; 
    class a; 
    weight w1; 
run;
/****************************************************************
* Matched t-test (for 1:1 matched results) 
*   - Requires transpose to flatten data within matched pairs 
 ****************************************************************/ 
proc transpose data=ds out=dst prefix=Y; 
    var y; 
    id a; 
    by setnum; 
run;
proc ttest data=dst; 
    paired y0 * y1; 
run;
/****************************************************************
* Regression models: 
*   GLM (via printmle) 
*   GLM w/robust SEs (subject-level) 
 ****************************************************************/ 
proc genmod data=ds; 
    class idx; 
    model y = a ; 
    weight w1; 
    repeated subject=idx / printmle; 
run;
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/****************************************************************
* Regression model: GLM w/robust SEs (cluster-level) 
 ****************************************************************/ 
proc genmod data=ds; 
    class site; 
    model y = a ; 
    weight w1; 
    repeated subject=site / type=ind; 
run;
/****************************************************************
* Regression model: GEE w/cluster-level exchangeable correrlation 
 ****************************************************************/ 
proc genmod data=ds; 
    class site; 
    model y = a ; 
    weight w1; 
    repeated subject=site / type=exch; 
run;
/****************************************************************
* Regression models: ETT-weighted GLM w/robust SEs (matched-set) 
*    (SETNUM output by matching macros) 
 ****************************************************************/ 
proc genmod data=ds; 
    class setnum; 
    model y = a ; 
    weight setwt; 
    repeated subject=setnum / type=ind; 
run;
/****************************************************************
* Regression model: GEE w/matched-set-level exchangeable
*    correlation (SETNUM output by matching macros) 
 ****************************************************************/ 
proc genmod data=ds; 
    class setnum; 
    model y = a ; 
    repeated subject=setnum / type=exch; 
run;
/****************************************************************
* Lunceford estimator + standard error (using IPTW weights); 
 ****************************************************************/ 
proc sql noprint; 
    select 
        sum(y * a0 / (1 - e1)) / sum(a0 / (1 - e1)) as mu0, 
        sum(y * a1 / e1) / sum(a1 / e1) as mu1, 
        count(*) as nall 
    into 
        :mu0, :mu1, :nall 
    from ds; 
quit;
135
* If using a cluster-specific weight (W2 or W3), need to create individual 
* indicator variables for each cluster.  There are multiple ways to do this,
* below is one for a dataset with 50 sites where the sites are numbered 1 to 
* 50.  If using pooled weight (W1), can ignore this data step. 
;
data ds; 
    set ds; 
    array allsites(50) site1 - site50; 
    %do i = 1 %to 50; 
        allsites(&i) = 0; 
    %end; 
    allsites(site) = 1; 
run;
proc iml; 
    use ds; 
    read all var {x1 x2 x3 x4} into xraw; 
    ebbsum = j(4, 4, 0); 
    m2sum = j(4, 4, 0); 
    vsum1 = j(4, 1, 0); 
    vsum0 = j(4, 1, 0); 
    * If using a cluster-specific weight, need to replace the read 
    * and init code above to incorporate the cluster indicators like: 
    * 
    *    read all var { 
    *        %do s = 1 %to 50; 
    *            site&s 
    *        %end; 
    *        x1 x2 x3 x4} into xraw; 
    *    ebbsum = j(54, 54, 0); 
    *    m2sum = j(54, 54, 0); 
    *    vsum1 = j(54, 1, 0); 
    *    vsum0 = j(54, 1, 0); 
    * 
    ; 
    read all var {y} into y; 
    read all var {a} into a; 
    read all var {a0} into a0; 
    read all var {a1} into a1; 
    read all var {e1} into e; 
    x = xraw`; 
    isum = 0; 
    diff = &mu1 - &mu0; 
    v1 = (y - &mu1) # a1 / e; 
    v2 = (y - &mu0) # a0 / (1 - e); 
    v3pre = (a - e); 
    do i = 1 to &nall; 
        xxt = x[,i] * x[,i]`; 
        ebbsum = ebbsum + e[i] # (1 - e[i]) # xxt; 
        vsum1 = vsum1 + x[,i] # (y[i] - &mu1) # a1[i] # (1 - e[i]) / e[i]; 
        vsum0 = vsum0 + x[,i] # (y[i] - &mu0) # a0[i] # e[i] / (1 - e[i]); 
    end; 
    ebb = ebbsum / &nall; 
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    hb2 = (vsum1 + vsum0) / &nall; 
    do i = 1 to &nall; 
        toadd = v1[i] - v2[i] - v3pre[i] # (hb2` * ebb * x[,i]); 
        isum = isum + toadd # toadd; 
    end; 
    estvar = isum / (&nall * &nall); 
    se = sqrt(estvar); 
    outdata = diff || se; 
    create lunceford from outdata [colname={"diff" "se"}]; 
    append from outdata; 
    close outdata; 
quit;
/****************************************************************
* Doubly robust estimators + standard error (using IPTW weights) 
* DR estimates based on both a pooled outcome model and a
* cluster-specific outcome model are produced.
 ****************************************************************/ 
data ds; 
    set ds; 
    if not a then do; 
        y_notrt = y; 
        y_trt = .; 
    end; 
    else do; 
        y_notrt = .; 
        y_trt = y; 
    end; 
run;
* GLM predictors for DR; 
proc genmod data=ds;
    model y_notrt = x1 x2 x3 x4; 
    output out=ds pred=m0_glm; 
run;
proc genmod data=ds;
    model y_trt = x1 x2 x3 x4; 
    output out=ds pred=m1_glm; 
run;
* Mixed predictors for DR; 
proc mixed data=ds;
    class site; 
    model y_notrt = x1 x2 x3 x4 / outpred=ds( 
        drop=alpha df lower resid stderrpred upper _level_: 
        rename=(pred = m0_mix) 
    ); 
    random intercept / subject=site; 
run;
proc mixed data=ds;
    class site; 
    model y_trt = x1 x2 x3 x4 / outpred=ds( 
        drop=alpha df lower resid stderrpred upper _level_: 
        rename=(pred = m1_mix) 
    ); 
    random intercept / subject=site; 
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run;
proc sql noprint; 
    select 
        sum(y * a0 / (1 - &e)) / count(*) as part2_1, 
        sum(y * a1 / &e) / count(*) as part1_1, 
        sum((a - &e) * m0_mix / (1 - &e)) / count(*) as part2_2_mix, 
        sum((a - &e) * m1_mix / &e) / count(*) as part1_2_mix, 
        sum((a - &e) * m0_glm / (1 - &e)) / count(*) as part2_2_glm, 
        sum((a - &e) * m1_glm / &e) / count(*) as part1_2_glm 
    into 
        :p2_1, :p1_1, :p2_2x, :p1_2x, :p2_2l, :p1_2l
    from ds; 
quit;
data dr; 
    set ds end=final; 
    retain var_gee 0 var_mix 0 var_glm 0; 
    tau_mix = &p1_1 - &p1_2x - &p2_1 - &p2_2x; 
    tau_glm = &p1_1 - &p1_2l - &p2_1 - &p2_2l; 
    piece_mix =
        (y * a1 / e1) - 
        ((a - e1) * m1_mix / e1) -
        (y * a0 / (1 - e1)) - 
        ((a - e1) * m0_mix / (1 - e1)) - 
        tau_mix 
    ; 
    piece_glm =
        (y * a1 / e1) - 
        ((a - e1) * m1_glm / e1) -
        (y * a0 / (1 - e1)) - 
        ((a - e1) * m0_glm / (1 - e1)) - 
        tau_glm 
    ; 
    var_mix = var_mix + (piece_mix * piece_mix); 
    var_glm = var_glm + (piece_glm * piece_glm); 
    if final then do; 
        var_mix = var_mix / (_n_ * _n_); 
        se_mix = sqrt(var_mix); 
        var_glm = var_glm / (_n_ * _n_); 
        se_glm = sqrt(var_glm); 
        output; 
    end; 
    keep tau: var_: se_:; 
run;
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APPENDIX 2 
SAS CODE FOR THE FULL MATCHING MACRO, FMATCH.SAS 
/***************************************************************************
| Program: FMATCH.SAS                                                       | 
| Purpose: Perform full matching or optimal matching on a single scalar     | 
|          variable between 2 study groups                                  | 
| Author:  Brad Hammill                                                     | 
| Date:    2015Jan01                                                        | 
| Output:  Two datasets named by the &OUTLINKS and &OUTDS macro variables   | 
|          that contain link-level results and record-level results         | 
|                                                                           | 
| Modifications:                                                            | 
 ***************************************************************************/ 
/***************************************************************************
| INDS           Input dataset *REQUIRED*, no default                       | 
| MATCHVAR       Matching variable *REQUIRED*, no default                   | 
|                  The variable on which to match members of Group 1 to     | 
|                  to Group 2 (see GROUPVAR)                                | 
| GROUPVAR       Group variable *REQUIRED*, no default                      | 
|                  This variable defines study groups                       | 
|                  Only 2 non-missing levels allowed                        | 
|                  The first level (sorted alphanumeric) of this variable   | 
|                  defines Group 1.  The second level defines Group 2.      | 
| IDVAR          Record-level ID variable *REQUIRED*, no default            | 
|                  This variable must be unique across records              | 
| STRATVAR       Stratification variable, default = NONE                    | 
|                  This variable defines the strata within which matching   | 
|                  occurs, if desired                                       |
| CALIPER        Caliper width, default = NONE                              | 
|                  This variable defines the maximum distance allowable for | 
|                  matching on MATCHVAR between groups. Assumed to be an    | 
|                  absolute value unless noted as a multiple of the observed| 
|                  SD in CALIPER_TYPE option below                          | 
| CALIPER_TYPE   Type of caliper to apply, ABS (default) | SD               | 
|                  ABSolute calipers match records within the distance noted| 
|                  by the CALIPER option.                                   | 
|                  SD calipers match records within a multiple (noted with  | 
|                  the CALIPER option) of the observed standard deviation   | 
|                  of the MATCHVAR.                                         | 
|                  Ex: To match within 0.2SD of the MATCHVAR, specify       | 
|                      CALIPER=0.2 and CALIPER_TYPE=SD                      | 
| RATIO_MIN      Thinning cap, if specified must be < 1                     | 
| RATIO_MAX      Thickening cap, if specified must be > 1                   | 
|                  Both are applied to the observed ratio of Group 1 to     | 
|                  to Group 2 records.  Constrains the matching ratio to be | 
|                  within some multiple of the observed ratio.              | 
|                  [See: Hansen, JASA 99:467 pp 609-618]                    | 
|                  Default is NONE, which leads to an uncontrained match.   | 
|                  To apply limits, specify both RATIO_MIN and RATIO_MAX    | 
|                  options and ensure that RATIO_MAX > 1 and RATIO_MIN < 1. | 
| MATCHTYPE      Type of match to make: FULL (default) or OPT               | 
|                  FULL matching ensures that all records in Group 1 are    | 
|                  matched to all records in Group 2 (within calipers, if   | 
|                  specified).  Matched set sizes can vary.                 | 
|                  OPTimal matching performs optimal 1:1 matching (within   | 
|                  calipers, if specified).                                 | 
| OUTLINKS       Output dataset for links, default = _OUTLINKS              | 
|                  This is a link-level dataset that includes record IDs    | 
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|                  matched from each group and distance between records.    | 
|                  Dataset variables:                                       | 
|                    GRP1 = Record ID for Group 1 record                    | 
|                    GRP2 = Record ID for Group 2 record                    | 
|                    [STRATVAR] = Strata, if specified for link             | 
|                    DIST = Distance between MATCHVAR values                | 
| OUTDS          Output dataset for records, default = _OUTMATCH            | 
|                  This is a record-level dataset that includes record ID,  | 
|                  matched set number, and weights for analysis.            | 
|                  Dataset variables:                                       | 
|                    [IDVAR] = Record ID                                    | 
|                    [GROUPVAR] = Group variable value                      | 
|                    [STRATVAR] = Strata, if specified for link             | 
|                    SETNUM = Matched set index                             | 
 ***************************************************************************/ 
%macro fmatch( 
    INDS          = , 
    MATCHVAR      = , 
    GROUPVAR      = ,
    IDVAR         = ,
    STRATVAR      = NONE, 
    CALIPER       = NONE, 
    CALIPER_TYPE  = ABS, 
    RATIO_MAX     = NONE, 
    RATIO_MIN     = NONE, 
    MATCHTYPE     = FULL, 
    OUTLINKS      = _OUTLINKS, 
    OUTDS         = _OUTMATCH 
);
    * Local macro variables; 
    %local BREAK INFINITY G1 G2 SOLVER_STATUS; 
    %let BREAK = 0; 
    %let INFINITY = 1E14; 
    * Input parameter checks; 
    data _check1; 
        MERGEVAR = 1; 
        SPEC_INDS = upcase("&inds"); 
        SPEC_MATCHVAR = upcase("&matchvar"); 
        SPEC_GROUPVAR = upcase("&groupvar"); 
        SPEC_IDVAR = upcase("&idvar"); 
        SPEC_STRATVAR = upcase("&stratvar"); 
        SPEC_CALIPER = upcase("&caliper"); 
        SPEC_CALIPER_TYPE = upcase("&caliper_type"); 
        SPEC_RATIO_MAX = upcase("&ratio_max"); 
        SPEC_RATIO_MIN = upcase("&ratio_min"); 
        SPEC_MATCHTYPE = upcase("&matchtype"); 
        SPEC_OUTLINKS = upcase("&outlinks"); 
        SPEC_OUTDS = upcase("&outds"); 
        ABORT1 = 0; 
        PARM_NOMATCH = 0; 
        PARM_NOGROUP = 0; 
        PARM_NOID = 0; 
        PARM_1RATIO = 0; 
        PARM_HILORATIO = 0; 
        PARM_NOINDS = 0; 
        PARM_BADINDS = 0; 
        PARM_BADMATCHVAR = 0; 
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        PARM_BADGROUPVAR = 0; 
        PARM_BADIDVAR = 0; 
        PARM_BADSTRATVAR = 0; 
        PARM_BADCALIPTYPE = 0; 
        PARM_BADMATCHTYPE = 0; 
        %if %length(&matchvar) = 0 %then %do ; 
            PARM_NOMATCH = 1; 
            ABORT1 = 1; 
            call symput("BREAK", 1);
        %end; 
        %if %length(&groupvar) = 0 %then %do ; 
            PARM_NOGROUP = 1; 
            ABORT1 = 1; 
            call symput("BREAK", 1);
        %end; 
        %if %length(&idvar) = 0 %then %do ; 
            PARM_NOID = 1; 
            ABORT1 = 1; 
            call symput("BREAK", 1);
        %end; 
        %if &ratio_max ^= NONE | &ratio_min ^= NONE %then %do ; 
            %if &ratio_min = NONE | &ratio_max = NONE %then %do; 
                PARM_1RATIO = 1; 
                ABORT1 = 1; 
                call symput("BREAK", 1);
            %end; 
            %else %do; 
                if  not (&ratio_min < 1  and &ratio_max > 1) then do;
                    PARM_HILORATIO = 1; 
                    ABORT1 = 1; 
                    call symput("BREAK", 1);
                end; 
            %end; 
        %end; 
        %if %length(&inds) = 0 %then %do ; 
            PARM_NOINDS = 1; 
            ABORT1 = 1; 
            call symput("BREAK", 1);
        %end; 
        %if %sysfunc(exist(&inds)) = 0 %then %do ; 
            PARM_BADINDS = 1; 
            ABORT1 = 1; 
            call symput("BREAK", 1);
        %end; 
        %else %do; 
            dsid = open("&inds"); 
            if varnum(dsid, "&matchvar") = 0 then do; 
                PARM_BADMATCHVAR = 1; 
                ABORT1 = 1; 
                call symput("BREAK", 1); 
            end; 
            if varnum(dsid, "&groupvar") = 0 then do; 
                PARM_BADGROUPVAR = 1; 
                ABORT1 = 1; 
                call symput("BREAK", 1); 
            end; 
            if varnum(dsid, "&idvar") = 0 then do; 
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                PARM_BADIDVAR = 1; 
                ABORT1 = 1; 
                call symput("BREAK", 1); 
            end; 
            if "&stratvar" ne "NONE" and varnum(dsid, "&stratvar") = 0 then do; 
                PARM_BADSTRATVAR = 1; 
                ABORT1 = 1; 
                call symput("BREAK", 1); 
            end; 
            rc = close(dsid); 
            drop dsid rc; 
        %end; 
        %if &caliper ^= NONE %then %do; 
            select(upcase(substr("&caliper_type", 1, 1))); 
                when ("S") call symput("caliper_type", "SD"); 
                when ("A") call symput("caliper_type", "ABS"); 
                otherwise do; 
                    PARM_BADCALIPTYPE = 1; 
                    ABORT1 = 1; 
                    call symput("BREAK", 1); 
                end; 
            end; 
        %end; 
        select(upcase(substr("&matchtype", 1, 1))); 
            when ("O") call symput("matchtype", "OPT"); 
            when ("F") call symput("matchtype", "FULL"); 
            otherwise do; 
                PARM_BADMATCHTYPE = 1; 
                ABORT1 = 1; 
                call symput("BREAK", 1); 
            end; 
        end; 
        if "&stratvar" = "NONE" then 
            call symput("stratvar", "_ONE_"); 
    run; 
    %if &BREAK = 0 %then %do; 
        * Make working copy of input data; 
        data _useds; 
            set &inds; 
            _ONE_ = 1; 
        run; 
        * Data checks and input record counts; 
        proc sql noprint; 
            * Counts from input DS, including how many missing key variables; 
            create table _check2 as 
            select
                1 as MERGEVAR, 
                count(*) as N_INPUT, 
                sum(missing(&matchvar)) as NMISS_MATCH, 
                sum(missing(&groupvar)) as NMISS_GRP, 
                sum(missing(&idvar)) as NMISS_ID, 
                sum(missing(&stratvar)) as NMISS_STRAT, 
                count(&idvar) as N_NOMISS_ID, 
                count(distinct &idvar) as N_ID, 
                count(distinct &stratvar) as N_STRATA, 
                count(distinct &groupvar) as GRP_LEVELS 
            from _useds 
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            ; 
        quit; 
        data _check2; 
            set _check2; 
            ABORT2 = 0; 
            INDATA_BADGRP = 0; 
            INDATA_BADIDS = 0; 
            if grp_levels ne 2 then do; 
                INDATA_BADGRP = 1; 
                ABORT2 = 1; 
                call symput("BREAK", 1); 
            end; 
            if n_id ne n_nomiss_id then do; 
                INDATA_BADIDS = 1; 
                ABORT2 = 1; 
                call symput("BREAK", 1); 
            end; 
        run; 
    %end; 
    %if &BREAK = 0 %then %do; 
        * Check input group counts; 
        proc sql noprint; 
            select distinct &groupvar into :G1 - :G2 
            from _useds; 
            create table _check3 as 
            select 
                1 as MERGEVAR, 
                sum(&groupvar = &g1) as N_G1, 
                sum(&groupvar = &g2) as N_G2 
            from _useds; 
        quit; 
        * Keep useable data, add numeric index, output crosswalk; 
        data
            _useds
            _xwalk(keep = _IDX &idvar &groupvar &stratvar) 
        ; 
            set _useds; 
            where 
                not missing(&matchvar) and 
                not missing(&groupvar) and 
                not missing(&idvar) and 
                not missing(&stratvar) 
            ; 
            _IDX = _n_; 
        run; 
        * Figure caliper width, if based on SD; 
        %if &caliper ^= NONE & %upcase(&caliper_type) = SD %then %do; 
            %if &stratvar = _ONE_ %then %do; 
                proc means data=_useds noprint; 
                    var &matchvar; 
                    output out=_sd STD=SD_MATCH; 
                run; 
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            %end; 
            %else %do; 
                proc means data=_useds noprint; 
                    var &matchvar; 
                    class &stratvar; 
                    output out=_rawsd std=sitesd; 
                run; 
                proc means data=_rawsd noprint; 
                    var sitesd; 
                    output out=_sd mean=SD_MATCH; 
                run; 
                proc delete data=_rawsd; 
                run; 
            %end; 
            data _null_; 
                set _sd; 
                call symput("caliper", &caliper * sd_match); 
            run; 
            proc delete data=_sd; 
            run; 
        %end; 
        %put INFO: Caliper width = &caliper ; 
        proc sql; 
            create table _links as 
            select 
                use1._idx as FROM, 
                use2._idx as TO, 
                use1.&stratvar as STRAT, 
                abs(use1.&matchvar - use2.&matchvar) as WEIGHT, 
                . as LOWER, 
                1 as UPPER 
            from
                _useds use1, 
                _useds use2 
            where 
                use1.&groupvar = &g1 and 
                use2.&groupvar = &g2 and 
                use1.&stratvar = use2.&stratvar 
                %if &caliper ^= NONE %then 
                    and abs(use1.&matchvar - use2.&matchvar) < &caliper 
                ; 
            ; 
        quit; 
        proc sql; 
            create table _check4 as 
            select 
                1 as MERGEVAR, 
                count(distinct from) as USE_G1, 
                count(distinct to) as USE_G2, 
                count(distinct from) + count(distinct to) as USE_LIMIT, 
                count(distinct STRAT) as USE_STRATA 
            from _links; 
        quit; 
        data _check4; 
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            set _check4; 
            ABORT3 = 0; 
            LINK_NODATA = 0; 
            if use_limit = 0 then do; 
                LINK_NODATA = 1; 
                ABORT3 = 1; 
                call symput("BREAK", 1); 
            end; 
        run; 
    %end; 
    %if &BREAK = 0 %then %do; 
        * Optimal matching without strata and without calipers can use the linear
        * assignment solver.  Otherwise, create the graph input manually for the
        * simplex solver. 
        ; 
        %if &caliper = NONE &
            &stratvar = _ONE_ &
            &matchtype = OPT %then %do; 
            proc optnet
                loglevel = moderate 
                graph_direction = directed 
                data_links = _links 
            ; 
                linear_assignment 
                    out = _mcf 
                ; 
            run; 
            data _null_; 
                STATUS = scan(substr("&_OROPTNET_LAP_", 8), 1); 
                call symput("SOLVER_STATUS", STATUS); 
            run; 
        %end; 
        %else %do; 
            proc sql; 
                create table _stratinfo as 
                select 
                    strat, 
                    count(distinct from) as N_G1, 
                    count(distinct to) as N_G2, 
                    count(distinct from) / count(distinct to) as OBSRATIO 
                from _links 
                group by strat 
                order by strat; 
            quit; 
            data _stratinfo; 
                set _stratinfo;
                %if &matchtype = FULL %then %do; 
                    REQFLOW = max(n_g1, n_g2); 
                    %if &ratio_max ^= NONE & &ratio_min ^= NONE %then %do; 
                        U_RATIO = obsratio * &ratio_max; 
                        L_RATIO = obsratio * &ratio_min; 
                        format u_ratio l_ratio best5.; 
                        if u_ratio > 1 then do; 
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                            TO_MAX = ceil(u_ratio); 
                            FROM_MIN = 1; 
                        end; 
                        else do; 
                            TO_MAX = 1; 
                            FROM_MIN = floor(1 / u_ratio); 
                        end; 
                        if l_ratio > 1 then do; 
                            TO_MIN = floor(l_ratio); 
                            FROM_MAX = 1; 
                        end; 
                        else do; 
                            TO_MIN = 1; 
                            FROM_MAX = ceil(1 / l_ratio); 
                        end; 
                    %end; 
                    %else %do; 
                        FROM_MIN = 1; 
                        FROM_MAX = &INFINITY; 
                        TO_MIN = 1; 
                        TO_MAX = &INFINITY; 
                    %end; 
                %end; 
                %else %do; 
                    REQFLOW = min(n_g1, n_g2); 
                    FROM_MAX = 1; 
                    TO_MAX = 1; 
                    if n_g1 <= n_g2 then do; 
                        FROM_MIN = 1; 
                        TO_MIN = 0; 
                        *TO_MIN = .; 
                    end; 
                    else do; 
                        FROM_MIN = 0; 
                        *FROM_MIN = .; 
                        TO_MIN = 1; 
                    end; 
                %end; 
                format obsratio best5.; 
            run; 
            proc sql; 
                create table _nodes as 
                select 
                    sum(reqflow) as REQFLOW 
                from _stratinfo; 
            quit; 
            data _nodes; 
                set _nodes; 
                * FROM / SUPPLY node; 
                NODE = -1; 
                WEIGHT = reqflow; 
                WEIGHT2 = &infinity; 
                output; 
                * TO / DEMAND node; 
                NODE = -2; 
146
                WEIGHT = -&infinity; 
                WEIGHT2 = 0; 
                output; 
            run; 
            proc sql; 
                create table _links2 as 
                select 
                    case FROM_IND 
                        when 1 then -1 
                        when 0 then NODE 
                    end as FROM, 
                    case FROM_IND 
                        when 1 then NODE 
                        when 0 then -2 
                    end as TO, 
                    case FROM_IND 
                        when 1 then FROM_MIN 
                        when 0 then TO_MIN 
                    end as LOWER, 
                    case FROM_IND 
                        when 1 then FROM_MAX 
                        when 0 then TO_MAX 
                    end as UPPER, 
                    0 as WEIGHT, 
                    s.STRAT 
                from 
                    _stratinfo s, 
                    (   select
                            1 as FROM_IND, 
                            FROM as NODE, 
                            STRAT
                        from _links 
                        UNION 
                        select
                            0 as FROM_IND, 
                            TO as NODE, 
                            STRAT
                        from _links 
                    ) l 
                where 
                    s.strat = l.strat 
                ; 
            quit; 
            %if &caliper ^= NONE &
                &matchtype = OPT %then %do; 
                * Set up excess node to prevent infeasibility; 
                data _links2; 
                    set _links2; 
                    output; 
                    if from = -1 then do; 
                        from = to; 
                        to = -9; 
                        weight = 10 * &caliper; 
                        lower = .; 
                        upper = 1; 
                        output; 
                    end; 
                    if to = -2 then do; 
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                        to = from; 
                        from = -9; 
                        weight = 10 * &caliper; 
                        lower = .; 
                        upper = 1; 
                        output; 
                    end; 
                run; 
            %end; 
            data _links; 
                set
                    _links 
                    _links2 
                ; 
            run; 
            proc optnet
                loglevel = moderate 
                graph_direction = directed 
                data_nodes = _nodes 
                data_links = _links 
                out_links = _mcf 
                internal_format = thin 
            ; 
                mincostflow 
                    logfreq = 1000 
                ; 
            run; 
            data _null_; 
                Status = scan(substr("&_OROPTNET_MCF_", 8), 1); 
                call symput("SOLVER_STATUS", Status); 
            run; 
            data _mcf; 
                set _mcf; 
                where 
                    mcf_flow and 
                    from not in (-1, -2, -9) and
                    to not in (-1, -2, -9) 
                ; 
            run; 
        %end; 
        proc optnet 
            data_links = _mcf 
            out_nodes = _connected 
        ; 
            concomp; 
        run; 
        proc sql; 
            create table &outlinks as 
            select 
                x1.&idvar as GRP1, 
                x2.&idvar as GRP2, 
                %if &stratvar ^= _ONE_ %then
                    x1.&stratvar,; 
                l.weight as DIST 
            from 
                _mcf l, 
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                _xwalk x1, 
                _xwalk x2 
            where 
                l.from = x1._idx and 
                l.to = x2._idx 
            ; 
            create table &outds as 
            select 
                x.&idvar, 
                x.&groupvar, 
                %if &stratvar ^= _ONE_ %then
                    x.&stratvar,; 
                c.concomp as SETNUM 
            from 
                _connected c, 
                _xwalk x 
            where 
                c.node = x._idx 
            order by 
                c.concomp, 
                x.&idvar, 
                x.&groupvar 
            ; 
            create table _stratwt as 
            select 
                setnum, 
                sum(&groupvar = &g1) as SET_N1, 
                sum(&groupvar = &g2) as SET_N2, 
                count(*) as SET_N 
            from &outds 
            group by setnum 
            order by setnum; 
        quit; 
        data &outds; 
            merge 
                &outds 
                _stratwt 
            ; 
            by setnum; 
        run; 
        proc sql; 
            create table _check5 as 
            select 
                1 as MERGEVAR, 
                count(distinct GRP1) as LINK_G1, 
                count(distinct GRP2) as LINK_G2, 
                count(distinct GRP1) + count(distinct GRP2) as LINK_N, 
                %if &stratvar ^= _ONE_ %then
                    count(distinct &stratvar) as LINK_STRATA, 
                ; 
                sum(DIST) as TOTAL_DIST 
            from &outlinks; 
        quit; 
    %end; 
    * Output specifications and status; 
    data _null_; 
        merge 
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            _check1 
            %if %sysfunc(exist(_check2)) %then 
                _check2 
            ; 
            %if %sysfunc(exist(_check3)) %then
                _check3 
            ; 
            %if %sysfunc(exist(_check4)) %then
                _check4 
            ; 
            %if %sysfunc(exist(_check5)) %then
                _check5 
            ; 
        ; 
        by mergevar; 
        * Macro info; 
        put "-----FMATCH macro called-----"; 
        put; 
        put "Macro parameters specified"; 
        put "  Input dataset:               " spec_inds; 
        put "  Matching variable:           " spec_matchvar; 
        put "  Group variable:              " spec_groupvar; 
        put "  ID variable:                 " spec_idvar; 
        put "  Stratification variable:     " spec_stratvar; 
        put "  Caliper width:               " spec_caliper; 
        if spec_caliper ne "NONE" then 
        put "  Caliper type:                " spec_caliper_type; 
        put "  Max ratio multiplier:        " spec_ratio_max; 
        put "  Min ratio multiplier:        " spec_ratio_min; 
        put "  Match type:                  " spec_matchtype; 
        put "  Link-level output dataset:   " spec_outlinks; 
        put "  Record-level output dataset: " spec_outds; 
        put; 
        * If aborted, indicate why 
        * Else, report results 
        ; 
        if abort1 then do; 
            put "ERROR: Macro aborted"; 
            if parm_nomatch then 
                put "ERROR: No matching variable specified"; 
            if parm_nogroup then 
                put "ERROR: No group variable specified"; 
            if parm_noid then 
                put "ERROR: No ID variable specified"; 
            if parm_1ratio then 
                put "ERROR: Both RATIO_MIN and RATIO_MAX need to be specified if
                     one is specified"; 
            if parm_hiloratio then 
                put "ERROR: RATIO_MIN must be < 1.0 and RATIO_MAX must be > 1.0"; 
            if parm_noinds then 
                put "ERROR: No input dataset specified"; 
            if parm_badinds then 
                put "ERROR: Input dataset does not exist"; 
            if parm_badmatchvar then 
                put "ERROR: Match variable does not exist"; 
            if parm_badgroupvar then 
                put "ERROR: Group variable does not exist"; 
            if parm_badidvar then 
                put "ERROR: ID variable does not exist"; 
            if parm_badstratvar then 
                put "ERROR: Stratification variable does not exist"; 
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            if parm_badcaliptype then 
                put "ERROR: Caliper type must be ABS or SD"; 
            if parm_badmatchtype then 
                put "ERROR: Match type must be OPT or FULL"; 
        end; 
        %if %sysfunc(exist(_check2)) %then %do; 
            else if abort2 then do; 
                put "ERROR: Macro aborted"; 
                if indata_badgrp then 
                    put "ERROR: Group variable has " grp_levels " levels -- 2 are
                         required"; 
                if indata_badids then 
                    put "ERROR: ID variable is not unique"; 
            end; 
        %end; 
        %if %sysfunc(exist(_check4)) %then %do; 
            else if abort3 then do; 
                put "ERROR: Macro aborted"; 
                if link_nodata then 
                    put "ERROR: No data to link after applying caliper (if 
                         specified) and after"; 
                    put "       removing records with missing data in key fields"; 
            end; 
        %end; 
        %if %sysfunc(exist(_check5)) %then %do; 
            else do; 
                USE_PCT = trim(left(put(link_n / n_input, percentn7.1))); 
                G1_PCT = trim(left(put(link_g1 / n_g1, percentn7.1))); 
                G2_PCT = trim(left(put(link_g2 / n_g2, percentn7.1))); 
                put "Matching completed"; 
                put "  " LINK_N "of " N_INPUT "(" USE_PCT +(-1) ") records used for
                     matching"; 
                if spec_caliper ne "NONE" and use_limit ne n_input then 
                put "    - Some records may have had no potential matches within
                     the caliper"; 
                if nmiss_match > 0 then 
                put "    - " nmiss_match "record(s) missing matching variable"; 
                if nmiss_grp > 0 then 
                put "    - " nmiss_grp "record(s) missing group variable"; 
                if nmiss_id > 0 then 
                put "    - " nmiss_id "record(s) missing ID variable"; 
                %if &stratvar ^= _ONE_ %then %do; 
                    STRAT_PCT = trim(left(put(link_strata / n_strata, 
                                percentn7.1))); 
                    put "  " LINK_STRATA "of " N_STRATA "(" STRAT_PCT +(-1) ")
                         strata used for matching"; 
                %end; 
                if nmiss_strat > 0 then 
                put "    - " nmiss_strat "record(s) missing stratification
                         variable"; 
                put "  Group 1 defined as %upcase(&groupvar) = &g1, " link_g1 "of "
                     n_g1 "(" g1_pct +(-1) ") used for matching"; 
                put "  Group 2 defined as %upcase(&groupvar) = &g2, " link_g2 "of "
                     n_g2 "(" g2_pct +(-1) ") used for matching"; 
                put "  Total distance between matched records is " total_dist; 
                put "  Solver status is %trim(&solver_status) (anything other than
                     OPTIMAL may indicate a problem)"; 
                put; 
            end; 
        %end; 
        put "------------------------------"; 
    run; 
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    proc datasets library=work nolist; 
        delete _check1; 
        %if %sysfunc(exist(_check2)) %then %do; delete _check2; %end; 
        %if %sysfunc(exist(_check3)) %then %do; delete _check3; %end; 
        %if %sysfunc(exist(_check4)) %then %do; delete _check4; %end; 
        %if %sysfunc(exist(_check5)) %then %do; delete _check5; %end; 
        %if %sysfunc(exist(_stratinfo)) %then %do; delete _stratinfo; %end; 
        %if %sysfunc(exist(_nodes)) %then %do; delete _nodes; %end; 
        %if %sysfunc(exist(_links)) %then %do; delete _links; %end; 
        %if %sysfunc(exist(_links2)) %then %do; delete _links2; %end; 
        %if %sysfunc(exist(_mcf)) %then %do; delete _mcf; %end; 
        %if %sysfunc(exist(_connected)) %then %do; delete _connected; %end; 
        %if %sysfunc(exist(_stratwt)) %then %do; delete _stratwt; %end; 
        %if %sysfunc(exist(_useds)) %then %do; delete _useds; %end; 
        %if %sysfunc(exist(_xwalk)) %then %do; delete _xwalk; %end; 
    run; 
%mend;
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